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Abstract 
Activation of the transforming growth factor-beta (TGFβ) and Wnt/β-catenin 
signalling pathways have been linked to the pathogenesis of tissue fibrosis 
in systemic sclerosis (SSc) and crosstalk between the pathways is 
considered to be significant. Indeed, TGFβ upregulated secreted frizzled-
related protein 4 (SFRP4), a putative Wnt signalling antagonist; however, 
rhSFRP4 had no regulatory effects upon Wnt/TGFβ signalling in dermal 
fibroblasts from healthy control (HC) or SSc patients. This was irrespective 
of caveolin-1 (CAV-1) expression, an important component of caveolae, 
which is known to selectively regulate receptor-mediated signalling potential. 
Primarily, SSc fibroblasts displayed an inherent increase in responsiveness 
to canonical Wnt activation compared to HC. Consistently, the basal 
expression of AXIN2, a primary target and critical regulator of the canonical 
Wnt signalling pathway, was reduced in SSc fibroblasts. TGFβ was able to 
induce a quantitatively similar reduction in AXIN2 expression in HC 
fibroblasts that was initially mediated by an increase in the rate of mRNA 
decay. Concurrently, decreased Axin-2 expression was also evident in the 
TβRIIΔk-fib transgenic mouse model, which has a constitutive and fibroblast-
specific activation of the TGFβ signalling pathway. Functional studies 
demonstrated that TGFβ-primed HC fibroblasts displayed an enhanced 
canonical Wnt signalling amplitude equivalent to that of SSc fibroblasts. 
Mechanistically, gain or loss of AXIN2 bioavailability suppressed or 
reproduced the TGFβ-mediated increase in canonical Wnt signalling 
amplitude, respectively. 
Overall, this study demonstrates that TGFβ signalling can sensitise 
- v - 
fibroblasts to canonical Wnt signalling through AXIN2 depletion and 
reproduce the activation observed in SSc fibroblasts. However, this did not 
lead to the profibrotic activation of fibroblasts in two independent models of 
canonical Wnt signalling hyperactivation. Therefore further evaluation of 
processes associated with fibrosis including proliferation, migration and cell 
survival, might resolve the anti-fibrotic outcomes observed for therapeutics 
targeting the Wnt/β-catenin pathway in models of experimental fibrosis. 
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1 Introduction 
1.1 Systemic sclerosis 
Systemic sclerosis (SSc) is a rare and highly heterogeneous disease that 
affects between 75,000–100,000 individuals in the United States (Varga & 
Abraham, 2007). The etiology of the disease includes autoimmunity, 
inflammation, vasculopathy (blood vessel damage and reduced capillary 
density that leads to decreased blood flow and impaired tissue oxygenation) 
and fibrosis through excessive synthesis and deposition of collagens and 
other extracellular matrix (ECM) proteins (Varga & Abraham, 2007; 
Katsumoto et al., 2011). 
A number of clinical disease classifications have been proposed to better 
define SSc patient subsets, including SSc sine scleroderma (no skin 
involvement), limited (skin tightness distal to metacarpophalangeal joints), 
intermediate (skin tightness affecting whole arm, but no involvement of the 
trunk) and diffuse (skin tightness involving both extremities and trunk) (van 
den Hoogen et al., 2013). A revised classification in 2013 was reached, 
through a collaborative effort by members of the ACR and EULAR, which 
included standardised criteria for disease classification such as skin 
thickening, fingertip lesions, telangiectasia, nailfold capillary abnormalities, 
Raynaud’s phenomenon, SSc-specific autoantibodies (anti-topoisomerase I, 
anti-centromere, anti-RNA polymerase III), interstitial lung disease and 
pulmonary arterial hyperptension (van den Hoogen et al., 2013). 
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1.2 SSc pathology 
1.2.1 Skin 
SSc patients are commonly divided into two key clinical subsets according to 
their level of skin involvement; the limited cutaneous subset (lcSSc) and the 
diffuse cutaneous subset (dcSSc) (LeRoy et al., 1988). The former is 
characterised by a skin involvement proximal to elbows and knees, affecting 
the trunk whereas the lcSSc subset has skin involvement that is limited to 
the distal extremities and face (Eisenberg et al., 2008). Additionally, the 
lcSSc subset is characterised by prominent vasculopathy whereas the 
dcSSc subset is associated with a higher risk of internal organ fibrosis. 
Indeed, the dcSSc subset is most active within the first 3 years from onset, 
and within this time severe complications in the lung, kidney and heart can 
develop (Quillinan & Denton, 2009). Skin thickening in this subset is often 
preceded by hyperpigmentation, giving a pathognomonic ‘salt and pepper’ 
appearance. During the fibrotic phase, the skin becomes more thickened, 
losing its elasticity, hair follicles and sweat glands. This stage can be 
followed by a clinical resolution as a result of skin atrophy, which typically 
softens the skin but does not completely recover its elasticity or lost annexes 
(Eisenberg et al., 2008). 
Clinically, skin involvement is readily detectable and quantified by physicians 
using the modified Rodnan skin score (mRSS). This method was first 
described in 1979, and takes into account 17 skin areas (Rodnan et al., 
1979). These areas are pinched between two fingers and scored from 0 (no 
thickening) to 3 (severe thickening) up to a maximum score of 51 (Rodnan et 
al., 1979). While this method suffers from a certain amount of inter-observer 
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variability, it is a sufficient reflection of diffuse cutaneous disease severity 
owing to the fact that patient survival has been directly correlated to the level 
of skin involvement (Steen & Medsger, 2001). Indeed, patients with a high 
first year mRSS (≥35) showing no improvement clinical improvement had an 
increased mortality compared to those with a low first year mRSS that 
showed improvement (Shand et al., 2007). Early lesional skin from SSc 
patients show inflammatory infiltrates that include T-cells B cells and 
monocytes, which indicates that both innate and adaptive immune cells 
could likely play a role in the establishment of fibrosis through cytokine, 
growth factor and autoantibody production (Gabrielli et al., 2009). 
Nonetheless, dermal fibroblasts are the key cellular elements responsible for 
the increased accumulation of the ECM, which can alter in composition over 
the course of the disease. Fibrillin is a matrix protein that is typically present 
in the early stages of disease, whereas collagen I, III, V and VII are 
observed in the reticular dermis of lesional skin in the later stages of disease 
(Wei et al., 2011). Ultimately, fibrosis of the internal organs can lead to loss 
of function and if not treated can be life threatening. Aside from mortality, the 
thickening and rigidity of the skin can be severely debilitating, particularly on 
the hands and over the joints. 
 
1.2.2 Raynaud’s phenomenon 
Raynaud's phenomenon is characterised by an excessive reduction in blood 
flow to the extremities due to vasospasms (Block & Sequeira, 2001). This is 
typically brought on by vasoconstriction, which can be triggered by the 
exposure to cold and stress. Primary Raynaud’s phenomenon presents in 
the absence of an underlying illness, whereas secondary Raynaud’s 
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phenomenon occurs in the context of an underlying condition like SSc. 
Raynaud's phenomenon is thought to occur in more than 90% of patients 
with SSc and can precede or coincide with other manifestations (Gabrielli et 
al., 2009). There is also a strong correlation with the presence of anti-
centromere antibodies (ACA) that could potentially be used to predict the 
onset of lcSSc (Gabrielli et al., 2009). 
 
1.2.3 Pulmonary 
Pulmonary manifestations of SSc include interstitial lung disease (ILD) and 
pulmonary arterial hypertension (PAH), which together account for 
approximately 50% of all SSc-related mortality (Williams et al., 2006); 
Winstone et al., 2014; Rubio-Rivas et al., 2014). Despite the prognosis of 
patients affected by PAH, it can presently be improved by mediators of 
vasodilation such as endothelin-1 antagonists and PDE5 inhibitors (Buckley 
et al., 2013). 
ILD is an umbrella term for several disease subtypes that affect normal lung 
function, which includes interstitial pneumonitis, interstitial pneumonitis and 
idiopathic pulmonary fibrosis. No treatment has yet been proven to be 
effective in modifying the course of ILD. In SSc, the pulmonary function tests 
can measure both a reduction in the lung capacity or a reduction in the % 
diffusing capacity for carbon monoxide (%DLCO) that can indicate the 
presence of ILD and PAH, respectively. ILD and the early inflammatory 
phase preceding it are commonly detected as a “ground-glass” appearance 
following high-resolution computed tomography (Williams et al., 2006). ACA 
can be detected in 70-80% of patients with lcSSc and is associated with a 
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high risk of PAH, whereas anti-RNA-POL II antibodies and anti-
topoisomerase antibodies are associated with increase risk of developing 
ILD (Gabrielli et al., 2009). Mortality is often associated with right-heart 




Scleroderma renal crisis (SRC) is characterised by hypertension, 
hyperreninemia, proteinuria and haematuria that occurs in an estimated 5-
10% of SSc patients. Of these, approximately 66% of SSc patients develop 
SRC within 1 year of diagnosis, rising to ~86% at 4 years and mortality at 5 
years is ~30–40% (Denton et al., 2009). In 60% of SCR patients there was a 
strong correlation with anti-nuclear antibody (ANA) positivity (Denton et al., 
2009). Indeed, patients with dcSSc and anti-RNA Pol II antibodies have the 
highest risk of developing SRC, whereas lcSSc patients may develop SRC 
later during the course of the disease (Penn et al., 2007). Between 40–66% 
of SRC patients may never recover normal renal function and some may 
require chronic dialysis in lieu of renal transplantation (Denton et al., 2009). 
Both anti-hypertensives and the aggressive use of angiotensin-converting 
enzyme (ACE) inhibitors to control blood pressure are effective treatments in 
the majority of cases if diagnosed early (Denton et al., 2009; Eisenberg et 
al., 2008).  
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1.2.5 Autoantibodies 
The role of ANA in SSc disease pathogenesis is unknown; however, they 
are key predictors of disease severity, organ involvement and survival in 
SSc patients, which are currently used as disease biomarkers. There are 
three major subclasses of specific antinuclear autoantibodies in SSc that 
have a high specificity compared to HC patients and other connective tissue 
diseases, which are anti-centromere antibodies, anti–topoisomerase 1 (Scl-
70) antibodies and anti–RNA polymerase III antibodies (anti-RNAP) 
(Nihtyanova & Denton, 2010). Anti-centromere antibodies (ACA) are 
observed in approximately 70% of lcSSc, while Scl-70 antibodies are 
observed in approximately 20% of dcSSc patients and anti–RNA polymerase 
III antibodies are also found in approximately 20% of dcSSc patients (Ho & 
Reveille, 2003; Katsumoto et al., 2011). The concurrent presence of both 
ACA and Scl-70 in patients is less than 0.5% and are therefore considered 
to be exclusive of lcSSc and dcSSc, respectively (Ho & Reveille., 2003). 
More recent reports have demonstrated that SSc patients with anti-RNAP 
antibodies were at a higher risk of developing malignancies (Moinzadeh et 
al., 2014; Joseph et al., 2014). In a subset of anti-RNAP positive patients, 
somatic mutations of the POLR3A locus might be responsible for the 
initiation of the immune response toward RNAP where the resultant 
antibodies fail to discriminate between mutant and WT proteins (Joseph et 
al., 2014). 
 
1.2.6 Genetic factors 
SSc is not inherited in a classical Mendelian pattern, although several 
studies have concluded that genetic risk factors could predispose individuals 
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to the onset of SSc. A large twin study evaluated 24 monozygotic (MZ) and 
18 dizygotic (DZ) twins and found a low concordance rate of 4.7% for SSc. 
The concordance rates were also found to be the same for both MZ (4.2%) 
and DZ pairs (5.6%) with a final heritability factor of 0.008 (Feghali-Bostwick 
et al., 2003). Risk factors include an enrichment of gene single nucleotide 
polymorphisms (SNPs) in SSc patients, which could confer a predisposition 
to autoimmunity as many of the identified SNPs are also present in other 
autoimmune diseases, particularly connective tissue diseases (Gregersen & 
Behrens., 2006). A large GWAS study in 2010 was used to investigate SSc 
susceptibility in a Caucasian population with a total of 2296 SSc patients and 
5171 controls, which confirmed previous reports identifying SNPs in major 
histocompatibility complex (MHC) (HLA*DQB1 highest hit rate), STAT4 and 
IRF5 genes as important predictors of SSc susceptibility (Radstake et al., 
2010). Indeed, the association of multiple genetic risk factors may play a role 
in the breakdown of auto-antigen tolerance and the onset of autoimmunity. 
 
1.2.7 Gene expression profiling 
Genome-wide gene expression profiling using DNA microarrays have 
provided additional insights into the differences between HC and dcSSc skin 
but might also have a utility in directing the treatment course (Whitfield et al., 
2003; Gilbane et al., 2013). Adding to the evidence for the role of TGFβ in 
SSc, a TGFβ-responsive gene signature can be found in skin biopsies from 
a subset of dcSSc patients (Sargent et al., 2009). Indeed, microarray 
analysis can now be used to identify distinct subsets patterns of gene 
expression and these signatures have been used to describe novel, process 
driven disease subsets in SSc (Milano et al., 2008). Indeed, on the basis of 
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proliferative, inflammatory and fibrotic gene expression signatures, three 
distinct subsets can be identified within dcSSc patients and two within lcSSc 
patients (Milano et al., 2008). Out of a group of 995 genes consistently 
expressed across different skin biopsies from SSc patients, 177 genes were 
found to be associated with the severity of skin disease and correlated with 
the mRSS in dcSSc patients. Of these genes, Wif-1 showed low expression 
while those with high expression included the cell cycle genes CENPE, 
CDC7 and CDT1, Fibroblast Growth Factor 5 (FGF5), Tumour Necrosis 
Factor Receptor Superfamily member 12A (TNFRSF12A) and TRAF 
interacting protein (TRIP). The use of gene expression profiling has already 
considerably expanded our understanding of the complexity of SSc and 
promises to remain a powerful research and diagnostic tool for the disease. 
 
1.2.8 Environmental factors 
Environmental challenges (e.g. viruses, drugs, vinyl chloride, epoxy resins, 
rapeseed oil, gadolinium-based contrast agent and silica) may be a 
predisposing factor in SSc disease pathogenesis. As an example, silica dust 
has been well described to be a risk factor for many systemic autoimmune 
diseases including rheumatoid arthritis, SSc and systemic lupus 
erythematosus (Gold et al., 2007). As far back as 1967, it was reported that 
occupational exposure to silica (mainly men) showed a higher than average 
prevalence of SSc, compared to the general population (Rodnan et al., 
1967). Although the exact mechanisms involved are not understood, silica 
exposure does initiate an inflammatory phenotype and leads to an increased 
ANA production in humans and in mice (Pfau et al., 2014). Indeed, these 
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changes increase the risk of autoimmune disease and in mice it was also 
shown to accelerate the course of systemic autoimmune disease in a lupus-
prone strain (Brown et al., 2003). More recently, environmental factors could 
play a role in the somatic mutation of the POLR3A locus, which was 
associated with the initiation of the immune response to RNAP (Joseph et 
al., 2014). Both prevalence studies and animal models suggest that the 




A widely accepted model of immune-mediated skin fibrosis is chronic 
sclerodermoid graft versus host disease (Scl-GVHD), a rare form of chronic 
GVHD that occurs in some patients following the rejection of allogenic bone 
marrow transplantation (Martires et al., 2011). Indeed, the Scl-GVHD model 
has been shown to recapitulate the histological and serological features of 
SSc including skin thickening, lung fibrosis and inflammatory infiltrates 
(Artlett et al., 1997; Beyer et al., 2010). Therefore it has been used as a 
model to study the immunopathogenesis of tissue fibrosis and help in the 
identification of genes common to SSc and scl-GVHD. Initiation of GVHD 
could be driven by michrochimerism, which is a process were genetically 
distinct foetal and maternal lymphocytes can cross the placenta during 
pregnancy (Endo et al., 2002). Interestingly, allogeneic cells in both 
peripheral-blood and skin-biopsies have been detected in patients with SSc 
(Artlett et al., 1998). Over time, these foreign cells may become activated by 
a second event and the hosts may mount a GVHD reaction. At present, the 
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Fibroproliferative vasculopathy is a key morbidity factor in SSc with diverse 
presentation including Raynaud’s phenomenon, cutaneous telangiectasia, 
nail fold capillary alterations, gastric antral vascular ectasia, pulmonary 
arterial hypertension and SRC. Paradoxically, several pro-angiogenic factors 
including PDGF, VEGF, ET-1 and TGFβ are upregulated in SSc (Abraham 
et al., 2009). Predominantly, vasculopathy occurs in the microvasculature; 
however, it can also manifest in the macrovasculature. Vessel rarefaction 
commonly affects the capillaries, whereas arterioles and small arteries may 
be involved in fibroproliferative intimal hyperplasia, which is a proliferation of 
myofibroblasts and vascular smooth muscle cells (VSMC) within the inner 
layer of the vessel (intima), usually comprised of one endothelial cell layer 
(Humbert et al., 2004). The combination of neointimal hyperplasia and 
capillary rarefaction is responsible for a reduced blood flow to organs, which 
can cause a chronic state of ischemia and likely contributes to fibrosis and 
progressive loss of organ function. Since vascular symptoms often precede 
the fibrotic manifestations, vascular injury is thought to precede the 
development of fibrosis and subsequently lead to the involvement of both 
autoimmune and proinflammatory processes (Varga & Abraham, 2007; Ho 
et al., 2014). 
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1.3 Fibrosis 
Fibrosis is the fundamental characteristic of dcSSc that can occur in multiple 
organs and manifests as skin fibrosis, loss of esophageal function, 
collagenous colitis, ILD and impaired cardiac function. The key cellular 
elements of tissue fibrosis are fibroblasts; mesenchymal cells, which display 
a spindle-shaped morphology and are instrumental in the development of 
fibrosis (Gilbane et al., 2013). Fibroblasts are responsible for the continued 
maintenance of tissue architecture though the secretion of ECM that acts as 
a global scaffold and thus they have a ubiquitous organ distribution. Fibrosis 
develops through sustained fibroblasts activation by factors including 
cytokines as well as growth and angiogenic factors present in the tissue 
microenvironment (Kim et al., 2011). The uncontrolled activation of 
fibroblasts can lead to the excessive accumulation of ECM, which can affect 
normal organ homeostasis through profound changes in the tissue 
architecture but can also in advanced stages lead to the loss of blood 
vessels thereby increasing the risk of ischaemic injury. Currently, ILD, which 
includes idiopathic pulmonary fibrosis, is the leading cause of mortality in 
SSc patients (Steen & Medsger, 2001; Wells & Denton, 2014). 
While therapies that target immunological, vascular and fibrotic processes 
are required for the effective treatment of SSc, the development of novel 
anti-fibrotic treatments may be considered a priority given the high risk of 
mortality associated with fibrosis through internal organ involvement. 
Although there are currently several clinical trials of targeted therapies 
underway, there are currently no treatments available that can lead to the 
remission of fibrosis (Ong & Denton, 2010). 
- 12 - 
1.3.1 Wound healing 
Fibrogenesis is a component of the wound healing response, which is a 
multi-stage process involving the orchestration of many cells and cellular 
factors that that can be simplified into the inflammatory, proliferative and re-
modelling phases. 
Briefly, tissue injury elicits a wound healing response by exposing the 
underlying collagen, which leads to the activation of the clotting cascade and 
this results in conversion of the fibrinogen precursor into a fibrin clot 
(Broughton et al., 2006). In turn, this initiates the recruitment of inflammatory 
cells, which prime the microenvironment by releasing cytokines and growth 
factors such as interleukin (IL-1), tumour necrosis factor (TNF) and TGFβ, 
which are then concentrated by the scaffold of the clot (Eming et al., 2007). 
Fibroblasts then migrate into the wound site where they are exposed to the 
primed microenvironment (Broughton et al., 2006). These fibroblasts are 
further activated to proliferate, secrete and deposit ECM and can also 
differentiate into highly contractile and secretory myofibroblasts. Further, 
activated fibroblasts are known to upregulate TGFβ expression, which is 
fundamental in reproducing the hallmarks of fibrosis. The resolution of the 
resulting scar tissue usually occurs through myofibroblast apoptosis and 
revision of proteins in the ECM, such as collagen type III to collagen type I 
conversion (Klingberg et al., 2013). 
In contrast with physiological wound healing, in which myofibroblasts are 
present only transiently, a key feature in fibrotic diseases is the persistence 
of myofibroblasts and subsequent fibrogenesis that occurs through ECM 
contraction, deposition and scarring (Gabbiani et al., 2003). 
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1.3.2 Extracellular matrix 
The ECM is important for the regulation of both cellular function and tissue 
homeostasis in addition to its structural role (Lu et al., 2011; Cox & Erler, 
2011). The ECM controls the distribution of cytokines, growth factors and 
angiogenic factors as well as providing biochemical and biomechanical cues 
to the cells it contacts (Kim et al., 2011). These cues have numerous cellular 
effects known to include cell proliferation, migration, survival and 
differentiation (Lukashev & Werb, 1998). Therefore, dysregulation of the 
ECM through mechanical stress, lysyl oxidase and matrix metalloproteinase 
expression can contribute toward the dysregulation of tissue homeostasis 
and be a causative factor in disease pathogenesis in fibrotic disorders, 
including SSc (Schaller, 2010). Indeed, fibrosis is characterised by the 
excessive deposition of secreted ECM components including collagens, 
elastins, hyaluronic acid, fibronectin, fibrillins and proteoglycans. Over time, 
these changes can lead to deleterious effects including matrix rigidity, 
hypoxia, oxidative stress and the following accumulation of damage 
associated molecular patterns (DAMPs) (Ho et al., 2014). As a 
consequence, the dysregulated remodelling of tissue architecture can lead 
to the loss of normal organ function. 
 
1.3.3 Myofibroblasts 
Myofibroblasts (Figure 1.1) are specialised cells that normally increase in 
number after tissue injury and are an essential component of wound healing 
owing to their highly contractile nature and increased capacity to secrete 
ECM (Hinz et al., 2001). The persistence of myofibroblasts in tissues is 
considered to be a characteristic of fibrotic disease pathology, including SSc 
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(Zhang & Phan, 1999). Indeed, myofibroblasts are consistently found in 
higher numbers in skin biopsies from SSc patients, particularly in the 
reticular dermis, and correlate directly with the mRSS (Farina et al., 2009). 
While it is known that myofibroblasts can be produced by the activation and 
the subsequent differentiation of resident fibroblasts, other potential sources 
include epithelial-to-mesenchymal transition, endothelial-to-mesenchymal 
transition, pericyte differentiation and the recruitment of circulating fibrocytes 
(Mori et al., 2005; Humphreys et al., 2010; Piera-Velazquez et al., 2011; 
LeBleu et al., 2013). 
Myofibroblasts highly express ECM proteins including collagen I (composed 
of two A1(I) and one A2(I) chains); the major component of ECM, collagen 
III, fibronectin and hyaluronic acid, which are essential for the formation of 
scar tissue (Frantz et al., 2010). The differentiation of myofibroblasts is 
dependent on the growth factors present in the microenvironment, which can 
include platelet-derived growth factor (PDGF), angiotensin II (AII), 
connective tissue growth factor (CTGF), endothelin-1 (ET-1) and TGFβ 
(Leask, 2010). For terminal myofibroblast differentiation, fibroblasts first have 
to pass through the protomyofibroblast stage, requiring mechanical tension 
from the ECM, increased expression of the extradomain A (ED-A) variant of 
fibronectin and the formation of stress fibres from β-actin and γ-actin 
isoforms (Gabbiani, 2003; Hinz, 2010). Under these conditions 
myofibroblasts become a major source of TGFβ, which is a potent activator 
for terminal myofibroblast differentiation, in part by SMAD dependent 
signalling (Desmoulière et al., 1993; Gabbiani, 2003; Ho et al., 2014). 
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The terminal differentiation of myofibroblasts is characterised by the neo-
expression of alpha smooth muscle actin (α-SMA), which is organised into 
highly contractile stress fibres that are essential for wound closure (Otranto 
et al., 2012). Hence, high α-SMA expression is routinely used as a marker 
for activated fibroblasts and the detection of differentiated myofibroblasts by 
either gene expression or stress fibre detection, respectively (Desmoulière et 
al., 1993; Hinz et al., 2007; Hinz, 2010). 
Myofibroblasts are central in the pathology of tissue fibrosis and a better 
understanding of the mechanisms of myofibroblast production, inhibition and 
clearance is an important step for the development of targeted treatment 
strategies for SSc and other fibrotic diseases. 
Figure 1.1. The myofibroblast 
Activation of fibroblasts by extracellular factors, including TGFβ, can lead to 
the differentiation of a subset of fibroblasts into myofibroblasts. 
Myofibroblasts are characterised by the neo-expression of α-smooth muscle 
actin (α-SMA), which is recruited into contractile stress fibres (green 
staining) and concomitantly these fibroblasts exhibit an increase in 
mechanical force generation. Indeed, myofibroblasts are thought to persist in 
fibrotic diseases, including SSc. Furthermore, Caveolin-1 (CAV-1) (red 
staining), a key component of the caveolae endocytic pathway described to 
negatively regulate TGFβ signalling activity, is negative in the myofibroblast 
population but present in the remaining total fibroblast population and 
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1.4 TGFβ superfamily 
The transforming growth factor-beta (TGFβ) superfamily includes more than 
30 members comprising TGFβ, bone morphogenetic proteins (BMPs), 
activin, inhibin and growth and differentiation factors (GDFs) (Akhurst & 
Hata, 2012). These factors are known to play key roles in development, 
tissue homeostasis, proliferation, differentiation, morphogenesis and wound 
healing (Beanes et al., 2003; Akhurst & Hata, 2012). Indeed, their roles can 
be opposed, for example TGFβ inhibits mesenchymal differentiation along 
the osteoblast, myoblast and adipocyte lineages, while BMPs are known to 
promote differentiation into adipocytes, osteoblasts and chondrocytes 
(Derynck & Akhurst, 2007). 
There are three known isoforms of TGFβ expressed in mammalian tissues; 
TGFβ1, TGFβ2 and TGFβ3, which are known to signal through the same 
receptor pathway but have divergent signalling potential (Roberts & Sporn, 
1992). TGFβ1, herein referred to as TGFβ, is the most characterised isoform 
and has a predominant role in mediating fibrosis (Yu et al., 2003; Ask et al., 
2008). Indeed, TGFβ has an almost ubiquitous expression and is the focus 
of the majority of studies. However, during wound healing there is a spatial 
and temporal restriction of TGFβ isoforms (1-3), which suggests they may 
play distinct roles during the repair process (Levine et al., 1993). 
Unfortunately, TGFβ isoforms in relation to the pathogenesis of SSc is poorly 
described and therefore unclear whether individual isoforms play a unique 
role during the disease process. 
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1.4.1 TGFβ 
TGFβ is synthesised as a precursor with an amino-terminal pro-domain 
termed latency associated peptide (LAP) and is required for both correct 
protein folding and subsequent homodimerisation. The TGFβ dimer is 
cleaved in the trans-Golgi apparatus by furin type enzymes, although the 
pro-peptide remains part of the complex through non-covalent interactions. A 
further large latent complex (LLC) is formed with latent TGFβ binding 
proteins (LTBP) that targets it to the ECM whereupon it is stored in this 
inactive state (Shi et al., 2011). The release of biologically active TGFβ 
requires dissociation of the LLC from the ECM and the proteolytic cleavage 
of LAP. This process can be carried out by matrix metaloproteinases 
(MMPs), pH, reactive oxygen species (ROS), thrombospondin-1 or 
mechanical stress mediated by the αVβ6 integrin (Massagué et al., 2005; 
Akhurst & Hata., 2012). 
 
1.4.1.1 TGFβ signalling 
The TGFβ signalling pathway is activated when extracellular TGFβ binds to 
the type II serine-threonine receptor kinase (TβRII), which heterodimerises 
with the type I receptor kinase (TβRI) and phosphorylates the TTSGSGSG 
motif within its juxtamembrane domain. Intracellular signalling is propagated 
via a number of intermediaries including SMADs, MAP Kinase Kinases 
(MKK), phosphoinositide 3-kinase (PI3K), AKT, c-Jun N-terminal kinase 
(JNK) and p38 mitogen-activated protein kinases (Huang & Chen, 2012). 
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Figure 1.2 The TGFβ signalling pathway 
Transforming growth factor-beta (TGFβ) signalling can play a critical role in 
the regulation of cell growth, differentiation, development and homeostasis. 
Activation of TGFβ signalling occurs upon engagement of the activated form 
of the TGFβ ligand with the type II serine-threonine receptor kinases (TβRII). 
This heterodimerises with the type I receptor kinase (TβRI), initiates TβRI 
phosphorylation and the subsequent recruitment and phosphorylation of the 
canonical TGFβ signalling mediators SMAD2 and SMAD3. These mediators 
can form a complex with SMAD4 and upon translocation to the nucleus 
transactivatory SMAD3/4 can interact with the SMAD binding elements 
(SBE) present in gene promoters and upregulate SMAD-responsive TGFβ 
targets. Alternatively, TGFβ signalling can activate a number of other 
signalling intermediaries including MAP Kinase Kinases (MKK), 
phosphoinositide 3-kinase (PI3K), AKT, ERK, JNK and p38 mitogen-
activated protein kinases, which direct the expression of SMAD-independent 
gene targets. 
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1.4.1.2 SMADS 
SMAD proteins can be categorised into three groups 1) Receptor-regulated 
SMADs (R-SMADs); SMAD1, SMAD2, SMAD3, SMAD5 and SMAD8 that 
interact with the TGFβ receptors (TβR) 2) inhibitory SMADs (I-SMADs); 
SMAD6 and SMAD7, which act either as decoys by interfering with either 
receptor:SMAD or SMAD:SMAD interactions and 3) the common-SMAD 
(Co-SMAD) SMAD4, which acts as a common binding partner for all R-
SMADs (Massagué et al., 2005). 
Activation of TβR leads to the recruitment and phosphorylation of the R-
SMAD proteins, which are SMAD2/3 for TGFβ and activin signalling or 
SMAD1, 5, 8 for BMP signalling. The R-SMADs can then bind the Co-
SMAD, SMAD4, and translocate to the nucleus. In the TGFβ signalling 
pathway both SMAD3 and SMAD4 can interact with the conserved SMAD 
binding element (SBE), a cis-acting DNA sequence (CAGAC), and 
upregulate TGFβ-inducible genes. 
R-SMADs and Co-SMAD contain a conserved MH1 domain (Mad-homology-
1) and C-terminal MH2 domain connected by a sequence divergent linker 
segment. Unlike R-SMADs, the I-SMADs lack an MH1, which is important for 
DNA-binding activity. The MH2 domain contains hydrophobic regions that 
facilitate the binding of DNA-binding co-factors and various cytoplasmic 
proteins, as well as the TGFβ receptors. I-SMADs regulate R-SMAD 
activation by binding to the TβRI via their MH2 domain, effectively taking part 
in competitive binding with R-SMADs and preventing the propagation of 
TGFβ signalling (Massagué et al., 2005a; Huang & Chen, 2012; Kubiczkova 
et al., 2012). Of the I-SMADs, SMAD6 appears to preferentially inhibit BMP 
signalling, whereas SMAD7 acts to inhibit the TβRI phosphorylation of 
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SMAD2/3. SMAD7 acts through direct competition with the receptor and 
facilitates TβR turnover through the recruitment of the E3 ubiquitin ligases 
Smurf1 and Smurf2 (Hayashi et al., 1997). 
 
While TGFβ signalling acts primarily thorough the canonical SMAD 
pathways, it is important to mention that TGFβ can also signal via several 
non-canonical or non-SMAD-mediated pathways. This includes the 
activation of tumour necrosis factor (TNF) receptor-associated factor 4 
(TRAF4), TRAF6, TGFβ-activated kinase 1 (TAK1), p38 mitogen-activated 
protein kinase (MAPK), RHO GTPase, phosphoinositide-3-kinase (PI3K), 
AKT, extracellular signal-regulated kinase (ERK), JUN N-terminal kinase 
(JNK) and nuclear factor-κB (NF-kB) (Akhurst & Hata, 2012). Indeed, the 
MAP/MEK/ERK cascade has been shown to modify SMAD activity and 
thereby modify TGFβ-responsive gene expression; however, this is likely 
context dependent (Hough et al., 2012). Indeed, in epithelial cells, mesangial 
cells and fibroblasts non-canonical activation has been shown to be required 
for the expression of a subset of genes, although in epithelial cells the 
overexpression of Ras/MEK/ERK can block SMAD nuclear translocation 
(Hayashida et al., 2003; Leask & Abraham, 2004). 
 
1.5 TGFβ signalling in fibrosis 
Dysregulation of the TGFβ pathway highlights its pivotal role in tissue 
homeostasis. TGFβ signalling has been implicated in the pathogenesis of 
haemorrhagic telangiectasia, Loeys–Dietz syndrome, pulmonary 
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hypertension, Marfan’s syndrome, cancer and fibrotic disorders. In SSc, 
TGFβ is though to be fundamental in the pathogenesis of tissue fibrosis and 
has been extensively used to study the fibrotic processes in vitro (Varga & 
Pasche., 2009). Historic data also suggests that there is an increase in 
TGFβ isoforms in SSc skin biopsies, although the reliability of many 
antibodies to discriminate between the different TGFβ isoforms is 
questionable (Gabrielli et al., 1993; Sfikakis et al., 1993). Also, the 
measurement of serum levels of TGFβ isoforms has been of limited potential 
due to the indiscriminate ability of these assays to detect both the latent and 
active forms of TGFβ. Indeed, the variable reliability of more specific assays 
and also the ex vivo release of TGFβ from platelets represent significant 
obstacles to precise quantification (Dziadzio et al., 2005). More recent data 
suggests that circulating levels of TGFβ are not increased and that 
fibroblasts do not have an increased sensitivity to TGFβ. Rather it is 
suggested that latent TGFβ is sequestered within the ECM of involved SSc 
skin and therefore has increased bioavailability (Leask et al., 2002; Dziadzio 
et al., 2005). In support of this, activators of latent TGFβ such as 
thrombospondin-1 and integrin αVβ5 (suggested to be similar to αVβ6 
integrin activity) have been shown to have an increased expression in SSc 
tissue and fibroblasts, respectively (Asano et al., 2005; Mimura et al., 2005). 
 
1.5.1 Animal models 
TGFβ signalling has been well described in the context of several animal 
models of SSc that include dermal, renal, hepatic, lung and GVHD variants. 
For example, bleomycin-induced models of lung and liver fibrosis showed an 
improvement upon the disruption of the TGFβ pathway by expression of a 
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chimeric receptor, consisting of the two extracellular domain fragments of 
the TβRII fused to an immunoglobulin Fc fragment heavy chain (George et 
al., 1999; Wang et al., 1999). Furthermore, increased TGFβ bioavailability is 
thought to be the mechanism behind the Tsk-1 mouse model, which develop 
fibrosis through an increased binding of latent TGFβ caused by an in-frame 
duplication of fibrillin-1. The TβRIIΔk-fib mouse model employs fibroblast-
specific expression of a kinase-deficient TβRII gene that leads to the 
activation of TGFβ signalling. This activation is thought to be as a result of 
Wild-type (WT) and mutant receptor complexes being less susceptible to 
degradation, increasing the cell surface expression of TβRI and thereby 
increasing TGFβ signalling potential. Indeed, this is a similar pathogenic 
mechanism to Loeys-Dietz syndrome and the mice do have an increased 
latent TGFβ presence in the ECM. Over time, these mice develop a dermal 
fibrosis and also display vasculopathy, similar to SSc. In 25% of TβRIIΔk-fib 
mice, bleomycin treatment leads to lung fibrosis. Furthermore, injury to their 
epithelium through treatment with bleomycin or saline solution induced a 
significant fibrotic response: increased fibroblast proliferation, myofibroblast 
presence, increased type II collagen and alveolar epithelial cell apoptosis 
(Derrett-Smith et al., 2013). In support of this, gene profiling between 
TβRIIΔk-fib mice and WT mice treated with recombinant TGFβ1 were found 
to be highly similar (Denton et al., 2003; Sonnylal et al., 2007). 
The CAV-1−/− model has also been used to study experimental fibrosis. 
Indeed, TβRs are known to be are endocytosed through two distinct 
pathways; clathrin-coated pits and CAV-1-associated lipid rafts (Guglielmo et 
al., 2003). The former pathway facilitates SMAD2 activation leading to the 
propagation of TGFβ signalling while the latter mediates receptor 
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degradation (Guglielmo et al., 2003). The first observations showed 
hyperproliferation of explanted mouse embryonic fibroblasts (MEFs) as well 
as vascular abnormalities, but no pulmonary fibrosis was evident after 4-5 
months (Razani et al., 2001). Subsequent studies in these mice 
demonstrated a further role for CAV-1 in cardiac hypertrophy, impaired 
angiogenesis, pulmonary hypertension and also pulmonary fibrosis after 12 
weeks (Park et al., 2003; Woodman et al., 2003; Hassan et al., 2006). In 
addition to pulmonary fibrosis, mice developed skin fibrosis with evidence of 
increased collagen deposition (Del Galdo et al., 2008). Adenoviral 
overexpression of CAV-1 in the bleomycin-induced model improved 
pulmonary fibrosis (Wang et al., 2006). Further, on administration of the 
caveolin scaffolding domain (CSD) within this model resulted in a distinct 
improvement in pulmonary fibrosis (Tourkina et al., 2008). Nevertheless, 
global knockout of CAV-1 lead to a plethora of signalling pathways being 
affected within several cell types and these mice also displayed several non-
SSc related pathologies (Beyer et al., 2010). 
 
1.5.2 Fibroblasts 
In dermal fibroblasts, the role of TGFβ/SMAD signalling has also been well 
established in the production of collagen type I, III and V synthesis as well as 
several other components of the ECM (Leask et al., 2002; Babak Razani et 
al., 2001; Wynn, 2008). Indeed, skin fibrosis is generally thought to be driven 
and or initiated by TGFβ-activated fibroblasts (Smith & LeRoy, 1990; Leask 
& Abraham, 2004; Wynn, 2008; Varga & Pasche, 2009). Additionally, gene 
profiling of TGFβ-treated dermal fibroblasts from healthy individuals and 
from SSc patients identified a TGFβ-responsive gene signature of 674 
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genes, which was highly represented in dcSSc patient skin (Milano et al., 
2008). In contrast, this signature was absent in both lcSSc skin and morphea 
skin biopsies. This suggests that a TGFβ driven mechanism is uniquely 
associated with the diffuse form of SSc. 
In support of a TGFβ-driven mechanism, SSc fibroblasts taken from involved 
tissue have been shown to have an increased cell surface expression of 
both TβRI and TβRII, which suggests these fibroblasts could be more 
responsive to TGFβ (Ihn et al., 2001; Kubo et al., 2002; Asano et al., 2011). 
Additionally, myofibroblasts are primed to differentiate in response to growth 
factors and mechanical stress and can produce TGFβ for autocrine 
signalling (Desmoulière et al., 1993; Gabbiani, 2003; Ho et al., 2014). 
 
1.5.3 SMAD3 
TGFβ signalling is mediated by both SMAD2 and SMAD3; however, there is 
evidence that SMAD3 may have a differential role. Transgenic mice that 
have a homozygous deletion of SMAD2 do not survive past the embryonic 
stage of development, whereas those with a SMAD3 homozygous deletion 
are viable (Leask & Abraham, 2004). This suggests that SMAD2 is essential 
for development but also highlights that the potential for differential activities. 
Using both DNA microarray and promoter analysis, several early-
intermediate genes including COL1A2, COL3A1, COL6A1, COL6A3, and 
tissue inhibitor of metalloproteinase-1 (TIMP-1) were identified as SMAD3 
dependent targets in human dermal fibroblasts validated using a SMAD3 
overexpression and SMAD3−/− mice (Verrecchia et al., 2001). Moreover, the 
differentiation of myofibroblasts has also been shown to be SMAD3 
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dependent; overexpression of SMAD3, in contrast to SMAD2, increased 
TGFβ-induced α-SMA expression in human lung fibroblasts (Gu et al., 
2007). Another study found that bleomycin treatment of SMAD3 deficient 
mice showed attenuated myofibroblast differentiation and activity compared 
to fibrotic development in WT littermates (Dobaczewski et al., 2010). 
Notably, the expression of α-SMA was found to be predominantly mediated 
by the binding of SMAD3 to SMAD binding elements (SBEs) in the α-SMA 
promoter (Hu et al., 2003; Uemura et al., 2005). 
In support of these findings, microarray analysis of fibroblasts from adult 
SMAD3−/− and SMAD3+/+ mice showed that SMAD3 directly activated 
immediate-early TGFβ-responsive genes through SMAD3/SMAD4 
recruitment to SBEs, which are characteristically found within the promoters 
of immediate-early target genes (Yang et al., 2003). Further, SMAD3 
deficiency showed a significant attenuation of TGFβ-responsive immediate-
early target genes that were hyperactivated in SMAD2 deficient murine 
fibroblasts (Kim et al., 2009; Yang et al., 2003). This suggests that SMAD2 
may have an inhibitory activity on TGFβ/SMAD3 signalling. 
When taken together these data suggest that SMAD3 is essential for TGFβ-
mediated fibrosis and is a potential therapeutic target. Aside from the role of 
SMAD3 in TGFβ signalling it may also be involved in crosstalk with the Wnt 
signalling pathway. Indeed, Wnt-3a-induced phosphorylation of SMAD3 has 
been described, although this activation was inhibited by pre-incubation of 
fibroblasts with a neutralising anti-TGFβ antibody (Wei et al., 2012). 
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1.5.4 Caveolin-1 
Caveolin-1 (CAV-1) is a 22 KDa integral membrane protein that forms a 
hairpin loop in the plasma membrane and is indispensible for the structure 
and function of caveolae. Caveolae are 50- to 100-nm flask-shaped 
invaginations of the plasma membrane, which represent a morphologically 
distinct subset of lipid rafts important in receptor-independent endocytosis 
and act as scaffolding proteins for the regulation of signal transduction 
(Carver & Schnitzer, 2003). CAV-1 is a member of a family of three 
membrane proteins; CAV-1, CAV-2 and CAV-3, that all form caveolae. CAV-
1 has two isoforms designated α and β, which share an overlapping cellular 
distribution and differ by a 31 amino acid N-terminus present in the α but not 
β isoform (Fujimoto et al., 2000). CAV-1 and CAV-3 have high sequence 
identity, whereas CAV-2 is the most divergent member of the family. Both 
CAV-1 and CAV-2 are expressed in fibroblasts, endothelial cells, adipocytes, 
whereas CAV-3 is restricted to muscle cells. Interestingly, smooth muscle 
cells are the only cell type in which all three proteins are co-expressed. In 
fibroblasts, studies tend to focus on CAV-1 expression, as CAV-2 is directly 
dependent on CAV-1 for its expression, membrane targeting and 
stabilisation (Schubert et al., 2007). 
 
Evidence suggests that CAV-1 plays a key role in the pathogenesis of tissue 
fibrosis through the regulation of TGFβ signalling. It has been shown that 
TβRI receptors are present in lipid raft and non–lipid raft domains and can 
be respectively internalised into CAV-1 and clathrin-dependent early 
endosome antigen 1 (EEA-1) endocytosis pathways (Guglielmo et al., 2003) 
(Figure 1.3). Further, it has been shown that non-lipid raft associated 
- 27 - 
internalisation can promote TGFβ signalling in a SMAD2/SARA dependent 
mechanism, whereas CAV-1-associated internalisation can downregulate 
TGFβ signalling through the increased proteasomal degradation of the TGFβ 
receptor in a SMAD7/Smurf-2 dependent manner (Guglielmo et al., 2003). 
In SSc, the expression of CAV-1 has been shown to be significantly 
decreased in dermal and lung fibroblasts, which exhibit a profibrotic 
phenotype (Del Galdo et al., 2008; Tourkina et al., 2008). Intracellular 
signalling can be regulated by a CAV-1 scaffolding domain (CSD) peptide, 
which is a 20-amino-acid region of CAV-1 (amino acid position 82–101) that 
interacts with the subdomain IX of many kinases including H-Ras and Src 
family tyrosine kinases (Li et al., 1996). Indeed, the profibrotic activation of 
SSc fibroblasts could be abrogated by the use of the CSD peptide both in 
vitro and in vivo (Tourkina et al., 2008) suggesting that decreased 
expression of CAV-1 played a key role in SSc fibroblast activation. Further, 
CAV-1-/- mice show both skin and lung fibrosis and explanted fibroblasts 
from these mice showed increased collagen production (Galdo et al., 2008). 
These data indicate that CAV-1 deficient fibroblasts may share overlapping 
characteristics with scleroderma fibroblasts and may be important for 
reproducing a profibrotic phenotype. 
Like TGFβ signalling, CAV-1 may also play a role in regulating the canonical 
Wnt signalling pathway by interacting with the low-density lipoprotein 
receptor-related protein-6 (LRP-6), which is a single span transmembrane 
receptor that has been shown to be required for canonical activation 
(Yamamoto et al., 2006). Indeed, CAV-1 has been shown to positively 
regulate signal transduction by facilitating the Wnt-3a-induced internalisation 
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of LRP-6, which correlated with β-catenin accumulation in HEK293 cells 
(Yamamoto et al., 2006). 
 
Figure 1.3 Receptor-mediated endocytosis of the TGFβ receptor 
complex 
TGFβ-mediated activation of the TGFβ receptor complex leads to the 
internalisation of the receptor complex by receptor-mediated endocytosis. 
This is facilitated by at least two distinct endoyctic pathways, which dictate 
whether TGFβ signalling is promoted or inhibited. Internalisation via the 
clathrin-mediated endocytotic pathway is known to propagate TGFβ 
signalling and is dependent on an association with both SMAD2 and SARA. 
Alternatively, internalisation complex via caveolae lipid rafts acts to inhibit 
TGFβ signalling through an association with the inhibitory proteins 
SMAD7/Smurf2, which facilitates the ubiquitin-mediated proteosomal 
degradation of the receptor complex. In this model, aberrant TGFβ signalling 
is though to drive fibrosis by mediating a shift toward clathrin-mediated 
TβRI/II complex internalisation that results in the upregulation of TGFβ-
responsive profibrotic gene targets and the downregulation of CAV-1, the 
major component of caveolae (Figure adapted from Guglielmo et al, 2003). 
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1.5.5 TGFβ-mediated post-transcriptional regulation 
Eukaryotic mRNAs are stabilised by two key features, the 5′ 7-
methylguanosine cap (m7G) and a 3′ poly(A) tail, which are both 
incorporated upon transcription. eIF4E and the poly(A)-binding protein 
(PABP) facilitate protection of the transcript from exonuclease activity, 
associating with the 5’ end at the 3’ end, respectively. Decay of the mRNA 
transcript can be initiated by the removal of the 5′ cap, known as decapping, 
which facilitates 5′-3′ exonuclease activity by XRN1. Alternatively, 
dissociation of the PABPs from the 3′ end can lead to 3′→5′ exonuclease 
activity or can initiate decapping. The consensus is that the majority of 
mRNAs are degraded though poly(A)-tail shortening and initiation of a 
deadenylation-dependent pathway such as the Ccr4/Caf1/Not deadenylation 
complex and subsequent recruitment of the RNA degrading exosome 
complex (Figure 1.4). Indeed, the post-transcriptional control of gene 
expression through mRNA stability and therefore translation allows for 
dynamic changes in mRNA levels. Dysregulation of this process can 
contribute to aberrant protein expression and disease (Eberhardt et al., 
2007). One well-described method of post-transcriptional regulation is 
through adenosine and uridine (AU)-rich elements (ARE) that can be 
harboured within the 3′ untranslated region (3′UTR) of many mRNAs. 
Generally, AREs are present in the mRNA as repeated AUUUA pentamer 
sequences, although variations are known to exist (Beisang and Bohjanen, 
2012). These sequences facilitate the binding of ARE proteins including 
human antigen R (HuR), AU-rich element RNA-binding protein 1 (AUF1) and 
tristetraprolin (TTP-1), which are known to regulate the decay of mRNAs in 
response to extracellular cues (Houseley & Tollervey, 2009; Schoenberg & 
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Maquat, 2012). Furthermore, TGFβ has been shown to upregulate the ARE 
binding protein TTP-1; also known as zinc finger protein 36 homolog 
(ZFP36), which is part of a family of tandem CCCH zinc-finger proteins that 
bind to ARE motifs and negatively regulate the stability and/or translational 
efficiency of target mRNAs (Figure 1.4) (Brooks & Blackshear, 2013). 
Indeed, the mRNA and protein expression of several ARE containing 
mRNAs including TNF, COX-2, c-MYC and CCND1 have previously been 
shown to be suppressed through TTP-1-meidated mRNA destabilisation 
(Ogawa et al., 2003; Marderosian et al., 2006; Kang et al., 2014; Blanco et 
al., 2014). 
 
Figure 1.4 mRNA decay: TTP-1 mediated mRNA destabilisation 
The majority of eukaryotic mRNAs are degraded though poly(A)-tail 
shortening. In this illustration, TTP-1 recruits the Ccr4/Caf1/Not 
deadenylation complex, which reciprocally recruits the RNA degrading 
exosome complex (yellow) resulting in RNA destabilisation through polyA tail 
shortening. Post-transcriptional regulation of TTP-1 activity can be achieved 
though the p38-dependent-MAPK-activated protein kinase 2 (MK2) pathway, 
which facilitates 14-3-3 adaptor protein binding (Chrestensen et al., 2004; 
Stoecklin et al., 2004; Sun et al., 2007). The complex of TTP-1 and 14-3-3 
proteins has been shown to prevent TTP-1-medaited TNF transcript 
destabilisation by protecting against serine-threonine phosphatase (PP2A) 
dephosporylation (Sun et al. 2007). More recently, p38 activation alone was 
found to be insufficient to inhibit TTP-1-mediated degradation of the TNF 
transcript, requiring the activation of both the ERK and p38; two downstream 
targets of the TGFβ signalling pathway (Deleault et al., 2008). 
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1.6 Wnt signalling 
The Wnt family consists of 19 cysteine-rich Wnt ligands that are 
approximately 350-400 amino acids in size and contain an N-terminal signal 
peptide important for their secretion. Their eventual secretion and activity 
requires both glycosylation and palmitoylation events, with the latter 
catalysed by Porcupine (PORCN) (Gao & Hannoush, 2014). Once secreted, 
Wnt ligands can then interact with glycosaminoglycans in the ECM, which 
modulate their distribution, diffusion and therefore their signal transduction 
potential (Logan & Nusse, 2004). 
Wnt ligands signal through the engagement of frizzled receptors (Fz), which 
are a family of seven-pass transmembrane receptors that contain an N-
terminal cysteine rich domain (CRD) that may facilitate Wnt:Fz receptor 
binding through homodimerisation. This is thought to occur in the presence 
of single-pass transmembrane protein co-receptors including the LRP-5/-6, 
receptor tyrosine kinase-like orphan receptor (ROR)-1/-2 and receptor 
tryrosine kinase (Ryk). Indeed, 10 Fz receptors and at least 5 co-receptors 
have been described to date. Signal regulation can also be regulated by 4 
distinct families of Wnt signalling antagonists; secreted frizzled-related 
proteins, Dickopff proteins (DKKs), R-spondins and Wnt inhibitory factor-1 
(WIF-1) (Kawano & Kypta, 2003). 
Wnt signalling has been traditionally categorised into two main pathways i) 
the canonical Wnt (β-catenin-dependent) pathway (Figure 1.5) and ii) the 
non-canonical (β-catenin-independent) pathways, which include the planar-
cell-polarity (PCP) (also known as the JNK) and the Ca2+ pathway (Figure 
1.6). Classically, Wnts have been divided into those that activate the 
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canonical pathways (Wnt-1, Wnt-3a and Wnt-8) and those that activate the 
non-canonical pathways (Wnt-4, Wnt-5a and Wnt-11). However, more recent 
evidence suggests that the Wnt signalling co-receptors may play an 
instrumental role in conferring the signalling pathways elicited. For example, 
the canonical Wnt-3a and non-canonical Wnt-5a ligands have been shown 
to be exclusively recruit LRP-5/-6 and Ror-1/-2, respectively (Grumolato et 
al., 2010). 
 
1.6.1 Canonical Wnt signalling 
The term canonical Wnt signalling is used to describe β-catenin dependent 
signalling (Figure 1.5). In resting cells β-catenin is inhibited by the 
destruction complex; comprised primarily of the scaffolding proteins AXIN, 
adenomatous polyposis coli (APC), casein kinase-1 (CK1) and glycogen 
synthase kinase-3β (GSK-3β) (Stamos & Weis, 2013). AXIN directly 
interacts with the Armadillo repeats 2–7 of β-catenin, where upon complexed 
GSK-3β and CK1 can both act to constitutively phosphorylate β-catenin at 
Ser33/Ser37/Ser45/Thr41 (Stamos & Weis, 2013). Phosphorylated β-catenin 
is recognised by the E3 ubiquitin ligase β-transducin repeat-containing 
protein (β-TrCP), which facilitates the subsequent ubiquitination and 
degradation of β-catenin via the proteosome pathway. 
Binding of ‘canonical Wnts' to the extracellular CRD domain of Fz 
receptors/LRP co-receptors results in the recruitment of dishevelled (Dvl) to 
the cytoplasmic C-terminal of the Fz receptor and the resultant complex 
(Wnt/Fz/Dvl) facilitates the recruitment of the destruction complex to the 
plasma membrane. Here, AXIN binds to the cytoplasmic tail of LRP5/6 and 
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becomes phosphorylated, lowering its β-catenin binding capacity and is 
subsequently targeted for proteasomal degradation. As a result of 
destruction complex inactivation, there is an accumulation of cytosolic 
stabilised/un-phosphorylated β-catenin, which can then translocate to the 
nucleus and bind to the TCF/LEF family of transcription factors, in 
association with the co-activators p300 and CREB-binding protein (CBP). 
These events lead to transcriptional initiation of canonical Wnt target genes 
known to be important in the control of processes including differentiation, 
proliferation, migration and more recently genes those involved in fibrosis. 
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Figure 1.5 Overview of the canonical Wnt signalling pathway 
Activation of canonical Wnt signalling occurs upon the binding of a Wnt 
ligands with a Frizzled receptor (Fz) protein complex containing a co-
receptor (LRP5/6). This complex can then recruit the adaptor protein 
dishevelled (Dvl) to the plasma membrane. Dvl then acts to recruit and 
inhibit the β-catenin destruction complex whose core components include 
GSK-3β, APC and AXIN, which are required for the ubiquitin-mediated 
targeting of β-catenin for proteasomal degradation. This results in the 
cytoplasmic accumulation of unphosphorylated/stabilised β-catenin, which 
can then be available for nucleus translocation. β-catenin can then bind to 
LEF and activate the TCF/LEF transcription factor family and upregulate 
canonical target genes. 
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1.6.2 Non-canonical Wnt signalling 
Although recent studies have shown that aberrant canonical signalling is 
potentially involved in fibroproliferative disorders, little is known about the 
role of non-canonical signalling and its contribution to the fibrotic phenotype. 
Non-canonical signalling is a collective term for those signalling pathways 
that are β-catenin independent, used to predominantly describe the JNK 
pathway (also termed the PCP-like pathway) and the Ca2+ pathway, which 
are associated with tissue polarity and cell migration and proliferation and 
cell migration, respectively (Figure 1.6) (Kawano & Kypta, 2003); Heisenberg 
et al., 2000). Wnt-induced stimulation of these pathways requires the Fz 
receptor family and was long believed to occur independently of co-
receptors. However, studies looking at the PCP non-canonical pathway in 
the alignment of sensory hair cells of the inner ear in mice found that and 
Ror2-/-, like Wnt-5a-/-, exhibit defects in the orientation of these hair cells, 
which suggest that both Fz and co-receptor binding may be required for non-
canonical signalling activation (Qian et al., 2007; Yamamoto et al., 2008). 
Induction of the Wnt/Ca2+ signalling pathway commences upon Wnt ligand 
binding with both Fz and co-receptor (Figure 1.6B), which induces 
intracellular signal transduction through activation of Dvl and membrane 
bound phospholipase-C (PLC), the later hydrolyses phospholipid 
phosphatidylinositol 4,5-bisphosphate to the second messengers inositol 
1,4,5-triphosphate (IP3) and 1,2-diacylglycerol (DAG). DAG can then 
activate protein kinase-C (PKC), whereas IP3 binds to the IP3 receptor 
calcium channel located on the endoplasmic reticulum (ER) to induce 
calcium flux (Luna-Ulloa et al., 2011). The consequence of elevated [Ca2+] in 
the cytosol is the activation of calcium-sensitive signalling mediators such as 
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calmodulin-dependent protein kinase II (CAMKII) and calcineurin (CN). 
Then, PKC and CN can act together to regulate the activity of nuclear factor 
of activated T cells (NFAT) transcription factors, whereas CaMKII and PKC 
can activate both the NF-kB and c-AMP-responsive element binding protein 
(CREB) transcription factors. 
In the Wnt/PCP pathway (Figure 1.6C), Wnt-induced activation of Fz 
receptors leads to the subsequent activation of Dvl, which in-turn mediates 
downstream activation of Rac, Rho and Rap small GTPases and JNK. The 
functions of the PCP pathway are not well understood but are known to be 
important in convergent extension during development, including the 
orientation of hair cells in the inner ear and neural tube closure (Yin et al., 
2009). The JNK family of stress-activated protein kinases has been shown to 
be involved in cell motility through cytoskeletal stabilisation of microtubules, 
and may also regulate gene expression through by phosphorylation of the 
transcription factor activator protein-1 (AP-1) subunit c-JUN transactivation 
domain at S63/S73 (Ciani & Salinas, 2007; Lapébie et al., 2011). 
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Figure 1.6 Overview of the non-canonical Wnt signalling pathway 
Activation of non-canonical Wnt signalling occurs upon the engagement of 
Wnt ligands with both Frizzled (Fz) and co-receptors (ROR2/RYK), which 
leads to the recruitment of Dvl to the plasa membrane where it can 
recruitment and activate small GTPases. This activation leads to the JNK-
mediated phosphorylation of c-Jun, an important component of the AP-1 
transcription factor leading to the regulation of AP-1-responsive gene 
targets. Alternatively, activation of Dvl can mediate phospholipase-C (PLC) 
activity, which hydrolyses phospholipid phosphatidylinositol 4,5-
bisphosphate to the second messengers inositol 1,4,5-triphosphate (IP3) 
and 1,2-diacylglycerol (DAG). DAG can then activate protein kinase-C 
(PKC), whereas IP3 binds to the IP3 receptor calcium channel located on 
the endoplasmic reticulum (ER) and both can lead to the induction of 
calcium flux (Luna-Ulloa et al., 2011). The consequence of elevated [Ca2+] in 
the cytosol is the activation of calcium-sensitive signalling mediators such as 
calmodulin-dependent protein kinase II (CAMKII) and calcineurin (CN). PKC 
and CN can act together to regulate the activity of nuclear factor of activated 
T cells (NFAT) transcription factors, whereas CaMKII and PKC can act 
together to activate the nuclear factor kappa-B (NF-κB) and c-AMP-
responsive element binding protein (CREB) transcription factors. 
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1.6.3 Antagonists of Wnt signalling 
Wnt antagonists can be divided into two functional classes; the SFRP and 
the DKK protein families. The SFRP class includes SFRP1-5, WIF-1 and 
Cerberus, which are generally thought to modulate Wnt signalling by direct 
binding of Wnts to prevent receptor engagement; however, different context-
dependent models of SFRP activity, both inhibitory and activatory, have 
been proposed (Figure 1.7). On the basis of sequence homology SFRP1, 
SFRP2 and SFRP5 have high sequence identity, as do SFRP3 and SFRP4, 
which share 92% sequence identity but are distantly related to SFRP1, 2 
and 5. SFRPs contain two conserved domains termed the cysteine-rich 
domain (CRD) and the netrin-like domains (NTR), which are separated by a 
linker region and are present at the N- and C-terminus, respectively. 
Interestingly, CRD that shares 30-50% homology with Fz receptor CRDs 
including 10 conserved cysteine residues, which might be of functional 
significance in the homodimerisation with CRDs present in Wnt/Fz receptors 
(Melkonyan et al., 1997). Whereas the function of the NTR, which contains 
only six conserved cysteines with several hydrophobic regions is not fully 
understood; however, these domains are also present in tissue inhibitors of 
metalloproteinases (TIMPs), type I procollagen C-proteinase enhancer 
proteins (PCOLCEs) and are thought to be important in the regulation of 
their activities (Bányai & Patthy, 1999). 
SFRPs are conventionally though of as inhibitors of Wnt signalling. The 
majority of studies have focused on the activities of SFRP1/2, but many 
have shown activities beyond putative inhibition of Wnt signalling. Indeed, 
the expression of SFRP1/2 has also been found to be decreased in 
proliferative keloid tumour tissue, which are benign tumours of the dermis 
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likely to be Wnt dependant (Russell et al., 2010). Furthermore, in Sfrp-1-/- 
and Sfrp-2-/- mice Wnt/β-catenin signalling was inhibited in the optic cup 
periphery (OCP) as shown by the lack of immunohistochemical staining for 
unphosphorylated β-catenin; however, these mice also showed an 
abrogation of Wnt-11 ligand diffusion across the OCP explants that could be 
restored upon SFRP1 co-treatment, which demonstrated that Wnt signalling 
activation can be regulated by SFRPs at the level of diffusion (Esteve et al., 
2011). Differential effects have also been shown to affect the self-renewal of 
haematopoietic stem cells, where both SFRP1/2 were able to stimulate the 
proliferation of haematopoietic progenitor cells; however, only SFRP2 
enhanced the differentiation potential of multipotent progenitors (Nakajima et 
al., 2009). 
The role of SFRPs in the regulation of dermal fibroblast biology, either direct 
or indirect, is currently unknown. Suggestively, SFRP4 was found to be 
significantly upregulated in the Tsk-1 mouse model of SSc by gene profiling 
studies and was also highly expressed in the deep dermis of SSc lesional 
skin in contrast to non-lesional and HC tissues (Bayle et al., 2008). 
Therefore, SFRP4 might be important in the development of fibrosis 
independently or in combination with Wnt signalling. 
 
- 40 - 
 
Figure 1.7 Functional models and putative activities for the Secreted 
Frizzled-Related Protein family 
A simplified summary of four independent models of SFRP-mediated Wnt 
signalling regulation. A) Formation of Wnt-SFRP can act to diffuse or shuttle 
Wnt to Fz and activate Wnt signalling activity. B) SFRPs may sequester Wnt 
ligands through direct binding to the netrin-related domain (NTR) and 
prevent Wnt signalling activity. C) SFRPs may directly bind to Fz, mediated 
by homodimerisation of their cysteine-rich domains (CRDs), and promote 
Wnt signalling activity. D) As C, but where SFRP4 binding competes with 
Wnt ligands to prevent Wnt signalling activity. 
 
1.7 Wnt signalling in fibrosis 
Canonical Wnt signalling is known to play a critical role in wound healing 
primarily through the co-ordination of wound closure. Indeed, β-catenin-
dependent transcriptional activity in fibroblasts is increased during the 
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proliferative phase of wound healing. Several studies have now shown that 
Wnt signalling may play an important role in the initiation/maintenance of 
fibrosis. A gene profiling study on NIH-3T3 fibroblasts treated with the 
canonical Wnt-3a agonist resulted in the upregulation of several key fibrotic 
mediators including Ctgf, Tgfβ and Et-1, while several genes involved in 
ECM degradation were supressed (Chen et al., 2007). Additionally, skin from 
the fibrotic Tsk-1 mouse model showed increased mRNA levels of several 
genes involved in Wnt signalling including Wnt-2, Wnt-9a, Wnt-10b and Wnt-
11; Dapper (Dact)-1 and Dact-2; Wnt-induced secreted protein 2; and Sfrp2 
and Sfrp4 (Bayle et al., 2008). Further studies confirmed that Wnt-10b 
mRNA was highly expressed in the bleomycin-induced fibrotic mouse and 
was differentially expresses in SSc compared to HC skin (Wei et al., 2011b; 
Beyer et al., 2012). Interestingly, the in vivo overexpression of Wnt-10b was 
sufficient to induce fibrosis: myofibroblast accumulation, progressive loss of 
subcutaneous adipose tissue, increased collagen deposition and 
consequent increase in dermal thickness (Wei et al., 2011). Explanted 
fibroblasts from the Wnt-10b model also showed increased collagen and α-
SMA expression (Wei et al., 2011). Consistent with these findings, the 
inhibition of GSK3-β (a component of the β-catenin destruction complex) 
was sufficient to induce fibrosis by activation of the canonical pathway and 
coincided an increase in the presence of dermal fibrosis in both the 
bleomycin/Tsk-1 mouse models of SSc (Bergmann et al., 2011). 
Furthermore, the overexpression of β-catenin in the mesenchymal cells of 
transgenic mice, show increased fibroblast proliferation, motility, 
invasiveness and also showed aggressive fibromatoses as well as 
hyperplastic wounding and tumour formation when grafted into nude mice 
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(Cheon et al., 2002). Two separate studies also showed that the inhibition of 
Wnt/β-catenin signalling could reduce pulmonary fibrosis in the bleomycin 
mouse model (Henderson et al., 2010; T. H. Kim et al., 2011). 
Interestingly, in β-catenin null fibroblasts TGFβ signalling was unable to 
induce a common proliferative response or upregulate MMP-3 and MMP-13 
(Cheon et al., 2006). This study suggests that β-catenin crosstalk might be 
involved in the regulation of TGFβ-induced gene expression. Such crosstalk 
could lead to the synergistic/inhibitory regulation of shared target genes or 
regulated through the interaction of signalling mediators from both pathways. 
Also, like TGFβ, the observation that CAV-1 expression can regulate 
canonical/β-catenin signalling may be a key link between both the Wnt and 
TGFβ signalling pathways. 
 
1.7.1 Non-canonical signalling in fibrosis 
The best characterised example of the Wnt/Ca2+ pathway induction is 
through Wnt-5a engagement of Fz2 in Xenopus and zebrafish embryos 
(Torres et al., 1996; Slusarski et al., 1997). The contribution of this pathway 
in different diseases may be context dependent given conflicting evidence. 
For example, the expression of Wnt-5a has been shown to be decreased in 
the majority of primary tumours from patients with pre-B cell acute 
lymphoblastic leukaemia (Liang et al., 2003). Consistently, Wnt-5a could 
function as a tumour suppressor in haematopoietic tissue, as CAMKII-
dependent induction of the Ca2+ pathway suppressed cyclin-D1 expression 
and inhibited B cell proliferation. However, in prostate cancer the expression 
of Wnt-5a correlated with malignancy where cell migration and invasiveness 
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were likely as a result of the non-canonical JNK pathway activation and 
upregulation of MMP-1 (Yamamoto et al., 2010). Other studies report similar 
oncogenic observations in melanoma and lung cancer (Weeraratna et al., 
2002; Huang, 2005). 
The contribution of the non-canonical pathway in fibroproliferative diseases 
and in SSc remains largely unstudied. An early study revealed that 
increased expression of Wnt-5a or Fz2, its receptor, in hepatic stellate cells 
lead to a significant increase in fibrosis both in vitro and in vivo (Jiang et al., 
2006). Also, in pulmonary tissue of patients with sarcoidosis, Wnt-5a 
expression was increased and was suggested to be a factor involved in the 
inflammatory or chronic fibrotic processes (Levänen et al., 2011). 
Interestingly, Wnt-5a was also shown to increase the proliferation, inhibit 
apoptosis and to induce fibronectin expression in normal lung-derived 
fibroblasts (Vuga et al., 2009). Wnt-5a might therefore be a useful agonist to 
study the effects of non-canonical signalling in fibroblasts. 
 
1.7.2 Canonical signalling in fibrosis 
1.7.2.1 β-catenin - a central mediator 
β-catenin was first identified as a cytoplasmic protein that linked the cadherin 
complex to the actin cytoskeleton (McCrea et al., 1991). β-catenin consists 
of 781 residues in humans and includes 12 Armadillo repeat domains and 
distinct intrinsically disordered N-terminal and C-terminal domains. Both the 
N-terminal and C-terminal domain are known be involved in protein:protein 
interactions; however, the C-terminal domain also houses a transactivatory 
motif that facilitates Wnt signalling (Valenta et al., 2012). Moreover, β-
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catenin can be divided into two spatial populations within a cell. The first is 
located at the plasma membrane and is bound to the cytoplasmic tails of 
cadherin and participates in cell adhesion, while the other pool plays a 
critical role in the TCF/LEF-mediated transcriptional activation (Luo and Lin, 
2004). 
Canonical Wnt signalling activation results in free cytosolic β-catenin that is 
then available to undergo nuclear translocation from the cytoplasm; 
however, β-catenin does not contain a nuclear localisation signal (NLS) and 
therefore its method of entry is as yet unclear. However, SMAD3 has been 
suggested to form a complex with β-catenin and play a role in shuttling it to 
the nucleus in chondrocytes and in the chondrogenic cell line RCJ3.1C5.18 
(Li et al., 2006; Zhang et al., 2010). 
The presence of nuclear β-catenin leads to the upregulation of Wnt target 
genes by activating any of the four mammalian TCF/LEF transcription 
factors (LEF-1, TCF-1, TCF-3 and TCF-4). These TCF/LEF transcription 
factors require β-catenin to mediate their transactivatory activity and act as 
repressors in its absence by forming a complex with the Groucho/TLE 
repressors. Nuclear β-catenin competes with and displaces the 
Groucho/TLE co-repressors and leads to the initiation of TCF/LEF driven 
canonical Wnt signalling (Roose et al., 1998; Daniels & Weis, 2005). 
 
1.7.2.1.1 β-catenin crosstalk 
β-catenin is also able to interact with other nuclear proteins, which suggests 
that it may have a more diverse signalling role. A genome-wide loss-of-
function screen was evaluated in 85 cancer cell lines, which found that the 
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survival and transformation of β-catenin-driven cell lines was dependent on 
β-catenin in complex with the transcriptional regulator YAP1 and the 
transcription factor TBX5 (Rosenbluh et al., 2012). 
Further, the hypoxia-mediated induction of Hypoxia Factor-1 (HIF-1) has 
been shown to compete with TCF-4 for β-catenin binding resulting in a 
reduction of TCF/β-catenin-mediated transcription and an increase in HIF-
1/β-catenin at the promoters of HIF-1 target genes: supporting cell survival 
(Kaidi et al., 2007). The function of the HIF-1/β-catenin seems to be context 
dependent. For example, in cancer cells the HIF-1 protein acts as a 
repressor of TCF/β-catenin signalling whereas in stem cells HIF-1 leads to 
activation of this pathway (Mazumdar et al., 2010). 
Also, the AP-1 complex has been observed to form a physical and functional 
co-operation with the TCF/LEF/β-catenin complex (Toualbi et al., 2007). In 
support of this, chromatin immunoprecipitation sequencing (ChIP-Seq) 
analysis in colon cancer cell line HCT116 showed that approximately a 
quarter of all β-catenin enriched regions harbour both TCF and AP-1 binding 
sites in close proximity in intestinal cancer cell lines (Bottomly et al., 2010). 
This study also observed that a subset of genes that contained both TCF-4 
and AP-1 binding sites were upregulated in response to mitogen and Wnt 
activation together, in contrast to independent treatments (Bottomly et al., 
2010). 
These data, when taken together, suggest that there is significant crosstalk 
at the level of β-catenin. Evidence shows that context is critical and that 
while this crosstalk can modulate β-catenin/TCF/LEF-mediated transcription, 
TCF/LEF-independent pathways are also likely to be important in regulating 
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gene expression. The traditional paradigm of increased β-catenin resulting in 
hyperactivation of canonical Wnt signalling may therefore in a fact be a 
misnomer. 
 
1.7.2.1.2 β-catenin in disease 
The role of β-catenin in carcinogenesis was first described in colorectal 
cancer, the majority of tumours had inactivating mutations in APC leading to 
the inappropriate stabilisation of β-catenin, while activating mutations in β-
catenin were present at a much lower frequency (Rubinfeld et al., 1997; 
Nishita et al., 2000; Wong & Pignatelli, 2002). Mutations in the β-catenin 
gene were frequently present within the N-terminal Ser/Thr destruction motif, 
which conferred resistance to APC-mediated regulation (Morin et al., 1997). 
In a subset of these patients mutations were also localised in the AXIN2 
gene and correlated with an increased nuclear accumulation of β-catenin 
within tumour cells (Morin et al., 1997). 
β-catenin has also been shown to have an important function in 
fibroproliferative diseases, which is unsurprising given its crucial role in 
during wound healing through the regulation of dermal fibroblast 
proliferation, motility and invasiveness (Cheon et al., 2002; Bowley et al., 
2007). Indeed, increased β-catenin expression/nuclear localisation was 
observed in Dupuytren’s disease: a superficial fibromatosis of the hand in 
which hyperproliferation leads to increased collagen deposition in the tissue 
(Varallo et al., 2003). Similar to the pathogenesis of some cancers, 
aggressive fibromatosis (desmoid tumours) have also exhibited increased 
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Wnt/β-catenin signalling associated with both activating mutations of β-
catenin or APC (Li et al., 1998; Tejpar et al., 1999). 
The induction of stabilised β-catenin in transgenic mice leads to the 
development of an aggressive fibromatoses and hyperplastic gastrointestinal 
polyps absent in WT mice and fibroblasts explanted from these β-catenin 
transgenic mice showed increased proliferation, motility, invasiveness and 
tumour growth when grafted into nude mice (Cheon et al., 2002). These data 
suggest that β-catenin is an important regulator of fibroblast phenotype.  
Specifically, the role of Wnt/β-catenin signalling is currently under 
investigation in SSc. Nuclear β-catenin accumulation has repeatedly been 
observed in the dermis SSc patients, co-localising with a fibroblast-specific 
marker, but absent in HC tissues (Beyer et al., 2012). In mice, the fibroblast-
specific stabilisation of β-catenin lead to fibrosis including dermal thickening, 
increased collagen expression and myofibroblast count (Beyer et al., 2012). 
Furthermore, the fibroblast-specific deletion of β-catenin was able to 
significantly reduce bleomycin-induced dermal fibrosis (Beyer et al., 2012). 
However, while increased nuclear β-catenin localisation was observed in 
lung fibroblasts from SSc patients with pulmonary fibrosis, rather than 
contributing to the fibrotic phenotype the overexpression of Wnt or β-catenin 
lead instead to increased migratory and proliferative activities (Lam et al., 
2011). Therefore the role of β-catenin in regulating the fibrotic activities in 
SSc fibroblasts remains to be clarified. 
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1.7.2.2 AXIN - a rate limiting control 
AXIN is a 832 or 868 amino acid protein identified through mutations of the 
mouse fused locus that encoded the Axin gene. This gene was shown to 
regulate embryonic axis formation through the inhibition of the Wnt signalling 
pathway (Zeng et al., 1997). Using a yeast two-hybrid screening approach, 
AXIN was shown to directly interact with β-catenin, GSK3-β and APC (Hart 
et al., 1998). AXIN has two main functional domains, the regulators of G-
protein signalling domain (RGS) domain at the N-terminus and the DIX 
domain at the C-terminus. APC binds to the RGS domain, while the DIX 
domain may have a role in signal transduction given its ability to interact with 
the Dvl through its own DIX domains (Cadigan & Nusse, 1997; Fagotto et 
al., 1999). Other, more central domains facilitate the binding of β-catenin and 
GSK3-β. In addition, AXIN has also been shown to bind to the C-terminal 
domain of the low-density LRP-5 and positively regulate signal activation 
(Luo & Lin, 2004). 
AXIN is essential for the formation of the β-catenin destruction complex and 
plays a critical in the efficient turnover of β-catenin, consistently 
demonstrated in Xenopus to mammalian systems (Hart et al., 1998; 
Sakanaka et al., 1998; Willert et al., 1999; Salic et al., 2000; Liu et al., 2002). 
In vertebrates, two AXIN genes are expressed and both act as negative 
regulators of Wnt signalling (Chia & Costantini, 2005). AXIN2 shares 44% 
sequence identity to AXIN1 and conserves multiple domains including the 
RGS and DIX domains as well as the β-catenin, GSK3-β, and SMAD3 
binding sites (Chia & Costantini, 2005). While AXIN1 is constitutively 
expressed, AXIN2 (also called Conductin or Axil) is a direct transcriptional 
target of the Wnt pathway, facilitated by TCF binding sites present within its 
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promoter and thereby acts to control Wnt signalling through negative 
feedback (Jho et al., 2002; Leung et al., 2002; Taniguchi et al., 2002). 
Axin1(-/-) transgenic mice are embryonically lethal, whereas Axin2(-/-) mice are 
viable and fertile but show osteogenic cranial abnormalities (Perry-III et al., 
1995; Behrens et al., 1998). Further, the delivery of Axin-2 cDNA can rescue 
the lethal phenotype in Axin-1(-/-) mice, which indicated that the two proteins 
share overlapping functional activity (Chia & Costantini, 2005). However, 
heterozygous AXIN2 germ line mutations can independently lead to familial 
tooth agenesis, which would indicate that the two proteins are not redundant 
and can have distinct roles in vivo (Lammi et al., 2004). 
Recently, a small molecule inhibitor of the Wnt/β-catenin pathway, XAV939, 
was discovered to significantly inhibit Wnt3a-induced TOPFlash luciferase 
reporter activity in HEK293 cells as part of a high-throughput screen (Huang 
et al., 2009). The decreased level of nuclear β-catenin following Wnt 
activation was mediated by increased AXIN expression. Mechanistically, the 
stability of AXIN was enhanced though the XAV939-mediated inhibition of 
PARsylation (addition of ADP-ribose polymers) by the poly(ADP-ribose) 
polymerase (PARP) enzymes, specifically though Tankyrases 1/2, which 
then facilitated the subsequent ubiquitin-mediated degradation of AXIN 
(Huang et al., 2009). In support of these observations, an AXIN:Tankyrase 
crystal structure was solved revealing the bivalent complex formation 
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1.7.2.2.1 AXIN Crosstalk 
AXIN, while crucial in Wnt/β-catenin signalling can also interact with proteins 
that are more representative of other signalling pathways, including those 
involved in TGFβ signalling. In HEK293 cells, activation of TGFβ signalling 
was facilitated by AXIN though its ability to bind SMAD7 and in parallel 
Arkadia; a ubiquitin E3 ligase that acts upon the inhibitory SMAD7 protein 
(Liu et al., 2006). Further, in resting HepG2 cells, both AXIN and SMAD3 
were observed to form a complex that was localised to the cytoplasm 
(Furuhashi et al., 2001). This interaction was also present in the COS7 
fibroblast cell line and was abolished upon the constitutive TβRI activation; 
additionally, the expression of an AXIN mutant was able to inhibit TGFβ 
signalling (Furuhashi et al., 2001). A further study showed that SMAD3 
stability was controlled by the expression of/interaction with AXIN and 
GSK3-β in HEK293 cells. The reduction of AXIN/GSK3-β expression lead to 
stabilisation of SMAD3 and therefore promoted TGFβ signalling (Guo et al., 
2008). Taking these data together, AXIN may facilitate the TGFβ–induced 
activation of SMAD3 or could be important in negatively regulating TGFβ 
signalling activation. 
 
1.7.2.2.2 AXIN in disease 
Unlike β-catenin, little is known about the role AXIN in fibrotic diseases but is 
considered to be a tumour suppressor given its role in the inhibition of β-
catenin signalling. Interestingly, AXIN mutations were found in colorectal 
cancer patients and correlated with nuclear β-catenin accumulation (Morin et 
al., 1997). Loss of heterozygosity or rearrangements in the genomic locus 
containing AXIN2 can contribute to tumour progression through Wnt/β-
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catenin signalling (Phelan et al., 1998). The gene itself has also been found 
to be mutated and can be functionally inactivated in hepatocellular, ovarian 
and colorectal carcinomas (Liu et al., 2000; Wu et al., 2001; Taniguchi et al., 
2002; Liu et al., 2002). Reduced AXIN expression has also been correlated 
with aggressiveness in both lung and oesophageal squamous cell 
carcinomas (Xu et al., 2006). Additionally, AXIN2 loss of function studies 
have shown its involvement in the pathogenesis of certain cancers and tooth 
agenesis (Lammi et al., 2004; Mazzoni & Fearon, 2014). 
Furthermore, in chondrocytes it was observed that TGFβ signalling inhibited 
the expression of both AXIN1 and AXIN2 in a SMAD3 dependent manner 
(Dao et al., 2007). Additionally, TGFβ signalling was enhanced by AXIN 
overexpression (Dao et al., 2007). As Wnt/β-catenin signalling is 
hyperactivated in SSc patient dermal fibroblasts (Beyer et al., 2010), their 
phenotype might also depend upon AXIN crosstalk with the TGFβ signalling 
pathway in parallel with its transitional role in the regulation of Wnt/β-catenin 
signalling. 
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1.8 Hypothesis and aims 
Activation of the TGFβ and Wnt/β-catenin signalling pathways have been 
linked to the pathogenesis of tissue fibrosis in SSc. In fibroblasts the 
mechanism behind Wnt/β-catenin signalling hyperactivation and the 
consequence of differential SFRP4 expression are largely unknown. 
Therefore the following questions were asked: 
 
1. Do SSc fibroblasts demonstrate differential Wnt/TGFβ signalling 
pathway activities compared to HC? 
I. Does this contribute to a fibrotic fibroblast phenotype? 
II. Does this correlate with an increased canonical Wnt signalling 
activity? 
 
2. Do fibroblasts contribute to the increased SFRP4 expression 
observed in SSc? And can recombinant SFRP4 treatment of 
fibroblasts regulate those activities observed in Q1? 
 
3. Is the expression of TGFβ-regulated CAV-1 expression important in 
reproducing the SSc fibroblast phenotype, independently or as a 
result of Wnt/TGFβ signalling, observed in Q1 & Q2? 
 
4. Is canonical Wnt signalling hyperactivation in fibroblasts regulated by 
crosstalk between the Wnt and TGFβ signalling pathways? 
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2 Methods 
2.1 Cell lines and culture 
Adult human dermal fibroblasts (Healthy Control, HC) (TCS Cellworks, 
Buckingham, UK; PromoCell GmbH, Heidelberg, Germany) were 
immortalised using the stable integration of a human telomerase reverse 
transcriptase (hTERT) vector that expressed the telomerase catalytic 
subunit, which maintains cell immortality through the addition of TTAGGG 
repeats to the telomere ends of the chromosome. These fibroblasts were 
used as a first screen and subsequent experiments were repeated in HC 
fibroblasts. Adult dermal fibroblasts were cultured in Dubecco’s Modified 
Eagle’s Medium (DMEM) (Sigma-Aldrich, Poole, UK) containing 10% fetal 
calf serum (Biosera, Ringer, UK). Small molecule inhibitors (Table 4) were 
introduced prior to stimulation with recombinant human TGFβ (Sigma), Wnt-
3a, Wnt-5a, Wnt-10b, Wnt-11a and SFRP4 (R&D systems, Abingdon, UK). 
 
2.2 Study subjects and controls 
Informed consent was obtained from all patients, and studies were granted 
approval by the Leeds Teaching Hospitals NHS Trust Medical Ethics 
Committee and the Ethical Committee of Verona University. All scleroderma 
patients fulfilled the American College of Rheumatology (ACR) classification 
criteria for SSc, classified as dcSSc according to skin involvement evaluated 
by the modified Rodnan total skin score (mRSS). Patient fibroblasts were 
taken under the CONVAS study, approved by the LTH REC approval 
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number 10/H1306/88. Animals used in this study were housed in a clean 
conventional colony, with access to food and water ad libitum. Strict 
adherence to institutional guidelines was practiced, and full local ethics 
committee and Home Office approvals were obtained prior to animal 
procedures. 
 
2.3 Statistical analysis 
Statistical analyses were performed using nonparametric Mann-Whitney U 
tests for unpaired samples, the Wilcoxon signed rank test for paired samples 
and the Spearman’s rank correlation test for correlations. Experimental data 
are presented as the mean ± standard error of the mean. A P-value <0.05 
was considered statistically significant. Statistical analysis was performed 
using GraphPad Prism software, version 5.0 (San Diego, CA, USA). 
 
2.4 SFRP4 ELISA 
The concentration of SFRP4 present in the sera of SSc patients was 
determined using a commercially available sandwich immunoassay (SFRP4 
ELISA, USCNK lLife Science Inc, Wuhan, China) as per the manufacturer’s 
instructions. In summary, a standard curve was prepared by serial dilution 
with a detection range between 15.6 pg/ml and 1000 pg/ml, using the 
supplied recombinant protein and standard diluent. Sera samples, diluted 
1:200 and protein standards were added to the pre-coated 96 well ELISA 
plate and incubated for 2 hr at 37oC. Detection reagent A was added for 1 hr 
at 37oC and the plate washed 3 times using the supplied wash buffer. 
- 55 - 
Detection reagent B was added for 30 min at 37oC and followed by wash 
buffer 3 times. Substrate solution was added and catalysis proceeded for a 
period of up to 5 min at room temperature. The reaction was stopped using 
stop solution and the absorbance of each well was read at 450 nm using an 
OpsysMR plate reader (Dynex Technologies). 
 
2.5 TβRIIΔk-fib transgenic mice 
The generation of TβRIIΔk-fib transgenic mice has been described 
previously (Denton et al., 2003). Constitutive activation of TGFβ signalling in 
transgenic mouse fibroblasts is driven through the fibroblast-specific 
expression of a kinase deficient TGFβ Receptor II gene, targeted using the 
specific pro-alpha2(I) collagen (Col1a2) gene enhancer and promoter 
(Denton et al. 2003). Mice were genotyped using PCR with primers specific 
to LacZ as an internal control. Dermal tissue was taken from these mice and 
each experiment was performed on at least 3 mice for each condition and 
compared to age-matched littermate controls and then performed at least in 
duplicate. Mice were aged 6-8 weeks for all experiments. 
 
2.6 Histology studies 
Formalin-fixed skin specimens from TβRIIΔk-fib transgenic mice were 
embedded in paraffin and sections were cut at 5 microns. Skin fibrosis was 
evaluated by dermal thickness between the dermal-epidermal boundaries to 
the dermal-subcutaneous fat boundary and further evaluated by Masson’s 
Trichrome blue staining of collagen. Antigen retrieval was carried out using 
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10 mM citrate buffer and sections were stained with isotype control antibody 
(Sigma) and anti-AXIN2 antibody (Sigma) followed by for 1 hour incubation 
at room temperature followed by StreptAB-Complex-HRP (Dako Cytomation, 
Glostrup, Denmark) for 30 minutes and visualised with 3,3′diamino-benzidine 
terahydrochloride (DAB; Vector Laboratories). A concentration matched and 
isotype matched antibody was used for controls. Microscopic analysis was 
performed using an Olympus BX50 with MicroFire (Optronics, USA) 
connected to a micro-bright field camera and images were captured using 
Stereo Investigator software at 10X-20X magnification. 
 
2.7 Short-hairpin RNA mediated gene silencing 
shRNAmir GIPZ lentiviral particles were used to transduce HC fibroblasts 
with either a non-targeting negative control (SCR) or CAV-1 shRNA as listed 
in Table 1 (Open Biosystems, Surrey, UK). Cells were seeded into a 6 well 
plate at 50-60% confluence. The medium was changed to 1 ml of serum and 
antibiotic free DMEM containing a 1:50 dilution of lentiviral particles, with an 
initial titer of 1 x 108 TU/ml, and. were incubated at 37oC for 6 hr, after which 
an additional 1 ml of DMEM/ 10% FCS was added and the fibroblasts were 
incubated for a further 72 hr. The efficiency of integration was determined for 
the shRNAmir-containing pGIPZ lentiviral vector microscopically on the basis 
of vector-driven green fluorescent protein (GFP) co-expression. Stably 
transduced fibroblasts were then selected in media containing 1.0 µg/ml 
puromycin (Life Technologies) for 10 days. 
 
- 57 - 
Table 1. Lentiviral particle technical data 
Catalogue 








100991154 V3LHS_312897 shCAV_97 2.38x10^8 CAV1 
V2LHS_150248-
98912154 V2LHS_150248 shCAV_48 2.95x10^8 CAV1 
V3LHS_312899-
100989763 V3LHS_312899 shCAV_99 2.96x10^8 CAV1 
RHS4348 





2.8 Small interfering RNA (siRNA) mediated gene silencing 
Cells were seeded to reach a confluence of 50-70% on the day of 
transfection in DMEM/ 10% FCS. N-TER transfection system (Sigma-
Aldrich) was used to transfect all siRNA oligos (Table 5) according to the 
manufacturer’s protocol for serum containing media. Transfection efficiency 
was determined by immunofluorescence using the Alexa Fluor-488 AllStars 
negative control (Qiagen) in the presence and absence of serum containing 
media. Briefly, 10 µM siRNA stock was diluted into siRNA dilution buffer, 
while the N-TER reagent was diluted into dH2O. Both were vortexed before 
being mixed together in a ratio of 1:1 and vortexed again. The transfection 
mix was incubated for 15 min to allow for complex formation, thereafter it 
was added to DMEM/ 10% FCS at a ratio of 1:10 to yield a final siRNA 
concentration of 20 nM. Medium was removed form the culture plate and 
changed in to the medium containing the transfection complexes. Gene 
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silencing was monitored between 24-96 hr post-transfection and confirmed 
by qRT-PCR and Western blot. Optimal siRNA delivery into HC fibroblasts 
cells was performed by first optimising transfection conditions. Serum 
compatibility was tested post-transfection complex formation, where these 
complexes were delivered to fibroblasts in serum containing or in serum 
absent media. This was carried out in parallel with varied molar 
concentrations of oligonucleotide across a range of 10nM, 20nM and 40nM, 
while the transfection reagent was kept constant across a 24 hr period. 
These oligonucleotides contained AlexaFlour-488, which enabled the 
visualization of transfection efficiency. Using Fluorescent microscopy in 
tandem with phase-contrast microscopy, two independent images from the 
same region were used to produce an overlaid image (Sup Figure 10.1). 
 
2.9 RNA extraction and purification 
Extraction and purification of total cellular RNA was performed using the 
RNeasy kit (Qiagen, Crawley, UK) and removal of any contaminating 
genomic DNA was achieved using on-column DNase I digestion (Qiagen) 
following the manufacturer’s protocol. Briefly, 350 µl RTL buffer was used to 
directly lyse fibroblasts in culture plate wells and lysates were transferred to 
microcentrifuge tubes, where an equal volume of 70% ethanol was then 
added to precipitate RNA and facilitate binding to the RNeasy spin column 
silica-based membrane. Columns were centrifuged 10,000 x g for 30 
seconds at room temperature and supernatant discarded. The columns were 
then washed with 350 µl RW1 buffer and centrifuged at 10,000 x g for 1 min. 
On-column DNase I digestion was performed (1:8; DNase I:RDD buffer) for 
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15 min at room temperature to degrade genomic DNA, then the samples 
were centrifuged. Columns were washed with RW1 buffer and centrifuged. 
Next, the columns were washed with RPE buffer and centrifuged at 10,000 x 
g for 1 min. Columns were centrifuged empty for 2 min in clean collection 
tubes to remove all traces of carryover RPE. RNA was then eluted from the 
column using 30 µl of nuclease free water, added directly to the column 
membrane and centrifuged at 10,000 x g for 1 min into nuclease free 
microcentrifuge tubes. 
 
2.10   cDNA preparation 
cDNA was prepared from RNA samples was prepared using a first-strand 
cDNA synthesis kit (Life Technologies), following the manufacturers’ 
protocol, to produces a 1:1 conversion of RNA to cDNA. For first stage of 
synthesis reaction up to 2 µg RNA, 100 ng random primers and 10 mM 
dNTPs were added to an RNase free thin-walled PCR tube to a total volume 
of 13 µl and incubated at 65oC for 5 min followed by 1 min incubation on ice 
to allow primer to anneal to the RNA template. 1x First-strand buffer, 10 mM 
DTT, 40 units RNaseOUT and 200 units of SuperScript II reverse 
transcriptase were then added to each reaction to a total volume of 20 µl. 
The thermal cycler was set to 25oC for 5 min, 50oC 1 hr, 70oC for 15 min. 
Samples were stored long term at -20oC. 
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2.11   Measuring RNA and DNA concentrations 
DNA and RNA concentrations were determined using the NanoDrop 
(Thermo-Fischer), which measured the absorbance of the sample at 260 nm 
and normalised it to the absorbance at 340 nm. 
𝑐!"# = 𝐴!"# − 𝐴!"#  
𝑐!"# = 𝐴!"# − 𝐴!"#  
Further, the ratio between the 260 nm and 280 nm absorbance 
measurements was used to evaluate purity. All samples tested reached 






2.12   Primer design 
Primers used in qRT-PCR (Table 7) were designed using Primer Express 
3.0 software (Applied Biosystems) and were commercially synthesised and 
quality controlled (MWG Eurofins, Germany). Primers evaluating spliced 
transcripts of specific genes were designed to lie within exons boundaries. 
Exclusively, analysis of the AXIN2 primary transcript utilised primers 
spanning intron-exon junctions specifically limiting amplification to 
unprocessed RNA. 
Figure 2.1. Schematic representation and location of primers spanning 
intron-exon junction of exon 3 in the AXIN2 reference sequence. 
- 61 - 
2.13   Quantitative real-time PCR 
SYBR green technology was used to measure the expression of mRNA. 2x 
Power SybrGreen Master Mix (Applied Biosystems), containing SYBR green 
and ROX dyes, was mixed with 10-50 ng cDNA and 50 nM forward and 
reverse primers up to a total volume of 25 µl in MicroAmp Optical 96 reaction 
plates (Applied Biosystems, UK). All reactions were carried out in triplicate. 
The plates were sealed using MicroAmp Optical adhesive film (Applied 
Biosystems) and run on an ABI 7900 Real-time PCR system using the 
program listed in Table 2. qRT-PCR thermocycler program. The 
amplification in step 2 was followed by a melting curve analysis in step 3 to 
ensure the amplification specificity for a given primer set. Only samples that 
displayed one peak, with high amplitude and a defined melting temperature 
were included in the analysis. Initial analysis was carried out using SDS v2.3 
software (Applied Biosystems). Post-analysis was performed in Excel to 
determine the normalised gene target amplification using the efficiency-
corrected ΔΔCt method. 
Table 2. qRT-PCR thermocycler program 
Stage Temp (oC) Cycles Time (sec) 
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2.14   Cell lysate preparation 
Cells were incubated on ice and washed twice in ice-cold phosphate 
buffered saline (PBS) prior to the addition of RIPA cell lysis buffer (Sigma), 
supplemented with complete protease and phosphatase inhibitor cocktails to 
the recommended concentration (Roche). Cells were lysed in 6 well plates 
with 100 µl of lysis buffer, and further disruption was achieved using a cell 
scraper. Cell lysates were collected into a 1.5 ml microfuge tube and 
incubated on a rotating mixer for 15 min. Cell debris was pelleted by 
centrifugation at 16,000 x g at 4oC for 10 min and lysates were collected 
into new microfuge tubes and the protein concentrations quantified. 
 
2.15   Cytosolic / Nuclear preparation 
Cell supernatants were removed and fibroblasts were lysed in 0.5% Triton X-
100 lysis buffer (50 mM Tris-HCL (pH 7.5), 0.5% Triton X-100, 137.5 mM 
NaCl, 10% Glycerol, 5 mM EDTA, protease inhibitor cocktail (Roche)) and 
further disrupted with a cell scraper. Lysed fibroblasts were centrifuged at 
16,000 x g for 10 min at 4oC. The supernatant / cytosolic fraction was 
transferred to a microcentrifuge tube and the nuclei resuspended 1 ml lysis 
buffer to wash the pellet and centrifuged at 16,000 x g for 15 min at 4oC. The 
supernatant was removed and a volume of 1x LDS sample buffer and 1x 
Reducing agent was added to both the nuclear and cytosolic fractions and 
reduced at 70oC for 10 min. Samples were run on PAGE gels, Western 
blotted and developed as previously described. Fractionation was checked 
using Histone H3 antibody for nuclear purity and hypoxanthine 
phosphoribosyltransferase 1 (HPRT1) for cytosolic purity. 
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2.16   Protein quantification 
The protein concentration in whole cell lysates was quantified using the 
bicinchoninic acid (BCA) colorimetric protein assay kit (Thermo-Fisher, UK) 
as per manufacturer’s protocol. Briefly, a standard curve was generated 
using bovine serum albumin (BSA) sequentially diluted in PBS 1:2 over a 
range of 0 to 2 mg/ml. Lysates were generally diluted 1:3 and 10 µl of cell 
lysate and BSA standard were transferred in duplicate into a 96 well plate. 
BCA reagent A was added 1:50 parts into reagent B, and 200 µl were added 
to each sample well. The plate was then incubated at 37oC for 30 min to 
facilitate the colorimetric change. The difference in absorbance was 
measured at 570 nm using an OpsysMR plate reader (Dynex Technologies, 
West Sussex, UK) and the protein concentrations in the assay were 
calculated by generating a standard curve of the known concentration of 
BSA. 
 
2.17   Western blotting 
A volume of cell lysate with a protein concentration of 20-30 µg was added 
to 1x NuPage lithium dodecyl sulfate (LDS) sample buffer pH 8.0 (Life 
Technologies) and 1x NuPage reducing agent (Life Technologies) to a total 
of 45 µl. These protein samples were then incubated at 70oC for 10 min. 
Reduced samples or 3 µl of a protein ladder 7.5-250 KDa (LI-COR, 
Cambridge, UK) were then loaded into a NuPAGE® Novex 8-12% Bis-Tris 
sodium dodecyl sulphate polyacrylamide gel electrophoresis (SDS-PAGE) 
cassette (Life Technologies) housed in the XCell4 surelock midi cell 
apparatus, containing 1x SDS MES running buffer (Life Technologies) and 
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1x antioxidant (Life Technologies) and run at 200 volts for 1 hr. Proteins 
were transferred from the gel to polyvinylidene difluoride membrane (PVDF) 
(Amersham, UK) using a midi-transfer apparatus (Bio-Rad, Hertforshire, UK) 
with 1x NuPage transfer buffer and run at 100 volts for 1 hr at 4oC. 
PVDF membrane was blocked in 1x Tris-buffered saline (TBS) pH 7.4 plus 
milk or BSA for 1 hr at room temperature. Immunodetection was performed 
using primary antibodies diluted in 1x TBS and incubated with the 
membrane for 1 hr at room temperature on a roller. Membranes were 
washed three times in 1x TBS + 0.1% Tween-20 (TBST) for 10 min each. 
Secondary antibodies that were conjugated to horseradish peroxidase 
enzyme (HRP) and directed against the primary antibody species, were 
diluted in 1x TBS and incubated for 1 hr at room temperature. Membranes 
were then washed for five time 1x TBST for 10 min each. Protein detection 
was visualised on the membranes by incubation with SuperSignal Pico 
chemiluminescent substrate (Thermo-Fisher, UK), diluted in a 1:1 ratio of 
reagent A to reagent B, for 5 min at room temperature. Excess substrate 
was blotted off the membrane, which was then sealed in plastic wrap and 
exposed to photographic film. The exposure was then developed in a dark 
room, using an SRX-101A developer (Konica). 
 
2.18   AXIN2 mRNA and protein stability 
The half-life of AXIN2 mRNA was determined using actinomycin D. Briefly, 
fibroblasts were serum starved in DMEM/ 0.5% FCS for 24 hours followed 
by incubation in complete media alone or with 5 ng/ml of TGFβ. 0 to 120 min 
after the addition of 5 µg/ml of actinomycin D (Sigma-Aldrich), fibroblasts 
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were harvested and total cellular RNA was isolated. AXIN2 mRNA was 
quantified by quantitative real-time PCR (qRT-PCR). Cycloheximide was 
used to evaluate the protein stability of AXIN2. Fibroblasts were starved in 
DMEM/ 0.5% FCS for 24 hours prior to treatment with 30µg/ml 
cycloheximide (Sigma-Aldrich) or media alone and in the presence or 
absence of TGFβ for 2-6 hr. Cells were lysed, total protein was extracted 
and normalised for protein concentration as previously described. AXIN2 
expression was visualised by Western blot. 
 
2.19   AXIN2 3’UTR analysis 
Bioinformatics analysis was performed on AXIN2 mRNA by consulting the 
online database AREsite (http://rna.tbi.univie.ac.at/cgi-bin/AREsite.cgi) and 
was found to contain three pentamer motifs in the 3’UTR. 
 
2.20   Plasmid preparation 
Competent E. coli strain DH5alpha (New England Biolabs) were thawed on 
ice for 10 minutes. 1 ng of plasmid was triturated and incubated on ice for 30 
min. The E.coli and plasmid were then heat shocked at 42oC for 0.5 min and 
cooled on ice for 5 min. Then, 950 µl of room temperature SOC medium was 
added and was incubated with shaking at 250 rpm, 37oC for 1 hr. 100 µl was 
then spread on agar plates containing 100 µg/ml ampicillin and incubated at 
overnight at 37oC. Single colonies from these plates were inoculated into 40 
ml LB broth containing 100 µg/ml ampicillin and cultured at 37°C, shaking at 
250 rpm for 16 hr. The next day, 3 ml of the suspension was transferred into 
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a new tube and centrifuged at 10,000 x g for 10 min. The pellet was 
resuspended in fresh LB broth and mixed 1:1 with 80% glycerol and stored 
at -80oC as a stock. The plasmid from the remaining 37 ml was harvested 
using a plasmid plus Midiprep kit (Qiagen), according to the manufacturers 
instructions. Briefly, the 37 ml were centrifuged at 10,000 x g for 10 min and 
resuspended in 2 ml Buffer P1, followed by 2 ml P2 and the tube was 
inverted 6 times and incubated for 3 min at room temperature. Then 2 ml of 
buffer S3 was added and the tube inverted 6 times. The lysate was 
transferred to a QIAfilter and incubated for 10 min at room temperature. The 
lysate was separated from the cell membrane debris by plunger. 2 ml of 
buffer BB was added to the cleared lysate and inverted 6 times. This was 
transferred to a Midi spin column with a tube extender and the solution 
drawn thought as -300 mbar on a vacuum manifold. The midi spin column 
and captured DNA were washed with 700 µl of buffer ETR followed by 700 
µl buffer PE using the vacuum manifold. Residual buffer was removed by 
placing the midi column in a microcentrifuge tube and centrifuging at 10,000 
x g for 1 min. The midi column was then placed in a clean microcentrifuge 
tube, 200 µl of Buffer EB added and the DNA eluted by centrifugation at 
10,000 x g. The DNA concentration was measured and the plasmid used for 
transfection experiments. 
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2.21   Plasmid DNA transfection efficiency 
Similar to the method employed for siRNA, delivery of plasmid DNA 
into HC fibroblasts was optimised. Plasmid DNA has a higher barrier 
of entry into the cell, particularly of primary origin, and therefore a 
transfection method that captured a significantly cross-section of the 
cell population would be sought. An IRES-GFP plasmid was used to 
visualise transfection efficiency by immunofluorescence (Sup Figure 
10.2 & Sup Figure 10.3). Given the total length of the reporter 
constructs that were used in this study (<5Kb), the transfection of the 
pIRES-GFP (5.2Kb) would be considered equivalent. The pIRES-GFP 
and Lipofectamine 2000 transfection reagent (TR) were ratios 
evaluated are noted in Table 3. 
. 
Table 3. DNA:transfection reagent optimisation 
TR (µl) pIRES-GFP (µg/µl) Total volume (µl) Ratio 
1 1 1000 1:1 
1 2 1000 1:2 
2 1 1000 2:1 
2 2 1000 2:2 
3 1 1000 3:1 
3 2 1000 3:2 
4 1 1000 4:1 
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2.22   TOPFlash reporter assay 
Fibroblasts were transfected with either the TOPFlash TCF/LEF–firefly 
luciferase reporter vector that contains two sets of 3 copies of the wild-type 
TCF/LEF consensus sequence (AGATCAAAGGgggta), one of which is in 
the reverse orientation, or the FOPFlash luciferase reporter vector 
containing the same sequences but harboring mutations within the 
consensus sequence that affect DNA:protein binding (gift of R. Moon, 
University of Washington, Seattle, WA). pCMV-Renilla luciferase vector was 
co-transfected and this was used as a transfection control. Briefly, in 1 well 
of a 12 well plate, 1 µg of TOPFlash or FOPFlash vector and 0.1 µg pCMV-
Renilla vector were added into 100 µl of Optimem containing 2 µl of 
Lipofectamine 2000 transfection reagent (Life Technologies) and incubated 
at room temperature for 15 min. This complex mix was then added drop wise 
onto fibroblasts cultured in 1 ml DMEM/ 10% FCS in a 12 well plate. The 
transfection complexes were removed after 2 hr to avoid unnecessary cell 
death and fibroblasts were washed with PBS and fresh DMEM/ 10% FCS 
added for 24 hr at 37°C, 5% CO2. These fibroblasts were then starved for 24 
hr prior to stimulation. Stimulations were carried out in DMEM/ 0.5% FCS 
medium for 2-72 hr with TGFβ the medium removed and stimulated with 
Wnt-3a in DMEM/ 0.5% FCS for 24 hr. Cells were then harvested and 
luciferase activity was measured using the dual luciferase reporter assay 
reagents (Promega), as per the standard protocol, and detected using a 
luminometer (Berthold Mithras). To account for transfection efficiency, the 
Firefly luciferase activity was normalised to Renilla luciferase activity and 
expressed as the percentage change compared to control. 
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2.23   TGFβ reporter assay 
TGFβ activity was measured with both the p3TP-lux construct and the 
SBE4-Luc luciferase reporter constructs. p3TP-lux contains a 3TP promoter, 
three consecutive TPA response elements (TGAG/CTCA) and part of the 
plasminogen activator inhibitor 1 (PAI-1) promoter region cloned into pGL2-
Luc. SBE4-Luc contains a Smad3 specific reporter for TGFβ activity, 
containing four copies of the SBE (GTCTAGAC) cloned into pBV-Luc. 0.75 
µg of the p3TP-lux or 1 µg pSBE-luc reporter was transfected along with 
0.075 µg or 0.1 µg of pCMV-Renilla luciferase vector, respectively, in 100 µl 
of Optimem containing 2.5 µl of Lipofectamine 2000 transfection reagent 
(Life Technologies) according to the manufacturer’s instructions. This 
complex mix was then added drop-wise onto fibroblasts cultured in 1 ml 
DMEM/ 10% FCS in a 12 well plate. The transfection complexes were 
removed after 2 hr to avoid unnecessary cell death and fibroblasts were 
washed with PBS and fresh DMEM/ 10% FCS added for 24 hr at 37°C, 5% 
CO2. These fibroblasts were then starved for 24 hr prior to stimulation. 
Luciferase activity was measured using the dual luciferase reporter assay 
reagents (Promega) as per the standard protocol and detected using a 
luminometer (Berthold Mithras). Transfection efficiency was evaluated by 
normalising Firefly luciferase activity to the Renilla luciferase activity. 
 
2.24   Immunofluorescence 
Paraffin embedded tissue biopsies (5µm thick) were deparaffinised by 
incubation with xylene (Sigma) for 10 min two times and 100% ethanol for 10 
min twice. Antigen retrieval was carried out using 10 mM citrate buffer for 20 
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min. For in vitro studies, the fibroblasts were plated in 4-well Falcon culture 
slides (Becton Dickinson) and initially cultured in 500 µl of DMEM/ 10% FCS 
per well. Stimulations were performed in DMEM/ 0.5% FCS. The fibroblasts 
were then washed twice with 1 ml of PBS. Cell monolayers were then fixed 
in 4% paraformaldehyde (Sigma) for 10 min at room temperature, washed 
twice with 1 ml of PBS and this was followed by incubation in cell 
permeablisation buffer (PBS + 0.1% Trition-X100 + 0.2% BSA) for 20 min 
room temperature. 
Sections from both methods were blocked with 2% bovine serum albumin 
(BSA) for 1 hr at room temperature, prior to incubation with primary 
antibodies (Table 6) diluted in PBS pH7.4 overnight at 4oC. Sections were 
then washed three times in PBS before incubation with fluorophore-
conjugated secondary antibodies, either sheep anti-rabbit-CY3, anti-mouse-
FITC (Table 6) for 1 hr at room temperature. Vector shield mounting medium 
(Vector, Peterborough, UK) containing 4', 6-diamidino-2-phenylindole (DAPI) 
was used to stain cell nuclei and to fix the coverslip onto the slide. 
 
2.25   Confocal laser scanning microscopy 
Confocal images were acquired using an Olympus BX61 upright 
fluorescence microscope with 20x dry and 40x oil immersion objectives. 
Images were captures using EZ-C1 3.80 software (Nikon). DAPI 
fluorescence was measured using the 405 nm laser with excitation and 
emissions wavelengths of 345/455 nm, CY3 fluorescence was measured 
using the TRITC filter with a 543 nm laser (Ex/Em 577/590) and FITC 
fluorescence was measured using the with a 488 nm laser (Ex/Em 488/507 
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nm). Widefield fluorescent images were acquired using an Olympus BX61 
upright fluorescence microscope with a 20x and 40x objectives. 
 
2.26   Myofibroblast counts 
ImageJ software was used to take measurements from two separate 
fluorescent channels. Under the same conditions, data from the blue 
channel was captured as a function of the fluorescent DAPI stained nuclei 
and the red channel captured fluorescent data from the anti-mouse-CY3 
used to detect the α-SMA antibody stained stress fibres. The integrated 
density of florescence (IDF) was taken from both channels and the IDF for 
each was used to calculate the α-SMA positive fluorescence with respect to 
nuclei fluorescence in each image. Three separate images were taken per 
well and all treatments were normalised on either HC fibroblasts or SCR 
transfected fibroblasts under basal conditions and represented as fold 
change. This method was validated using individual counts of negative and 
α-SMA positive nuclei, which exhibited similar results when the data was 
represented as fold change in positive cells over total cell count. 
 
2.27   Collagen gel contraction assays 
Collagen gel contraction assays were prepared from a standard kit (Cell 
Biolabs). Briefly, one part of fibroblasts were mixed with four parts of 
collagen gel preparation, added to a 12 well plate and incubated for 1 hr at 
37°C for gel polymerisation. Following this incubation, 1 ml of DMEM was 
added and the plate was incubated for a further day. Next, the gels were 
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released from the sides of wells, treated or left untreated and 24-72 hr later 
the images were taken at various time points with a Gel Doc (BioRad). 
Treatment related mechanical force generation was evaluated as the 
percentage change in gel area relative to that of untreated controls as 
determined by ImageJ software. 
 
2.28   Cell viability 
The MTT (3-(4,5-Dimethylthiazol-2-yl)-2,5-Diphenyltetrazolium Bromide) 
assay (Sigma-Aldrich) measures mitochondrial integrity, which can be used 
as a measure of cell viability and cytotoxicity. Briefly, 1 x 104 fibroblasts were 
plated in 100 µl DMEM/ 10% FCS in a 96 well plate. The medium was 
removed the next day an the fibroblasts were then starved in DMEM/ 0.5% 
FCS for 24 hr. Cell treatments were carried out in the presence of the 
inhibitor or DMSO in a total volume of 200 µl. After which, 20 µl of 5 mg/ml 
fresh MTT reagent was then added to the plate and incubated for 6 hr at 
37oC and 5% CO2. 180 µl medium was removed, the fibroblasts lysed and 
the formazan crystals solubilised in 130 µl of DMSO by trituration and left for 
10 min. The color change of the yellow MTT to the purple formazan was 
then measured using a spectrophotometer set to a wavelength of 540 nM. 
Viability was measured as the percetage change in treated samples 
compared to DMSO treated controls. 
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Table 4. Small molecule inhibitor inventory 
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JNK Inhibitor Anthra[1,9-cd]pyrazol-6(2H)-one, 
1,9-pyrazoloanthrone 
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Table 5. siRNA oligonucleotide inventory 
Oligo name Oligo type Oligo code Supplier 
Caveolin-1 FlexiTube siRNA Hs_CAV1_7 Qiagen 
Caveolin-1 FlexiTube siRNA Hs_CAV1_10 Qiagen 
AllStars 
Negative Control 
FlexiTube siRNA SI03650318 Qiagen 
Negative Control 
No.1 
Silencer Select 4390843 Life Technologies 
AXIN1 Silencer Select s15814 Life Technologies 
AXIN2 Silencer Select s15818 Life Technologies 
SMAD3 Silencer Select s8400 Life Technologies 
β-Catenin Silencer Select s436 Life Technologies 
TTP-1 Silencer Select s14978 Life Technologies 
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β-Catenin 92 Rabbit 8480 WB, IF Cell Signalling 
Technology 
AXIN2 95, 98 Rabbit 2151 WB Cell Signalling 
Technology 




37 Mouse ab7817 WB, IF Abcam 
GAPDH 40 Mouse ab8245 WB GeneTech 
TTP-1 42 Mouse SAB42005
65 
WB Sigma-Aldrich 
DKK1 45 Rabbit SAB42005
65 
WB Sigma-Aldrich 
Caveolin-1 22 Rabbit sc-894 WB, IF Santa Cruz 
Phospho-
Smad3 




48 Rabbit D47G9 WB Cell Signalling 
Technology 
SFRP4 50 Rabbit ab32784 WB Abcam 
β-Actin 42 Mouse AC-74 WB Sigma-Aldrich 
Anti-Rabbit NA Sheep C2306 IF Sigma-Aldrich 




NA Sheep C2306 IF Sigma-Aldrich 
Anti-Mouse 
IgG-CY3 
NA Sheep C2181 IF Sigma-Aldrich 
Anti-Mouse 
IgG–HRP 
NA Sheep A6782 WB Sigma-Aldrich 
Anti-Rabbit 
IgG-HRP 
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Table 7. qRT-PCR primer pair inventory 
Primer Name Sequence 5’ - 3’ 
COX2_F GTT CCA CCC GCA GTA CAG AA 
COX2_R AGG GCT TCA GCA TAA AGC GT 
V-MYC_F TGT CAA GAG GCG AAC ACA CA 
V-MYC_R ACC TTG GGG GCC TTT TCA TT 
CDKN2A_F TTC GCT AAG TGC TCG GAG TT 
CDKN2A_R GGA CCG CGG TAT CTT TCC AG 
TTP_F TGC CAA ACC CCA CCC ATA AA 
TTP_R TAC AAG GGA AGC AGA CGA CC 
HUR_F TGG TAG TTA GAC CCC AGG CA 
HUR_R TGC GGC TTG GCA AAT TAC AC 
DKK-1_F GAC TGT GCC TCA GGA TTG TGT 
DKK-1_R CAG ATC TTG GAC CAG AAG TGT CT 
SMAD3_F ATG TCG TCC ATC CTG CCT TT 
SMAD3_R CGT TCT GCT CGC CCT TCT TC 
COL1A2_F GAT GTT GAA CTT GTT GCT GAG G 
COL1A2_R TCT TTC CCC ATT CAT TTG TCT T 
CTGF_F GTG TGC ACT GCC AAA GAT GGT 
CTGF_R TTG GAA GGA CTC ACC GCT G 
AXIN2_F CGG GAG CCA CAC CCT TC 
AXIN2_R TGG ACA CCT GCC AGT TTC TTT 
COL1A1_F CCT CCA GGG CTC CAA CGA G 
COL1A1_R TCA ATC ACT GTC TTG CCC CA 
- 78 - 
AXIN1_F GTG GAG AAG GTG GAC TGA TAG G 
AXIN1_R GCT CCT GAG TAC GAG GTC ATC T 
CTNNB1_F AAG GCT ACT GTT GGA TTG ATT CG 
CTNNB1 _R CCC TGC TCA CGC AAA GGT 
CAV1_F TCC CTT CTG GTT CTG TCA 
CAV1_R TCC CTT CTG GTT CTG CA 
α-SMA_F TGT ATG TGG CTA TCC AGG CG 
α-SMA_R AGA GTC CAG CAC GAT GCC AG 
Ribo16S_F GTA ACC CGT TGA ACC CCA TT 
Ribo16S_R CCA TVV AAT CGG TAG TAG CG 
SFRP4_F TGT CTA TGA CCG TGG CGT GT 
SFRP4_R TCC ACT TAA CAT CCT CCG GG 
PT9-1_AXIN2_F TGA TGC GCT GAC GGA TGA TT 
PT9-1_AXIN2_R ATC CAC TCC CAA GCA AGC C 
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3 Evaluation of SFRP4 expression in SSc 
patient sera and fibroblasts 
Differential gene expression analysis was used to determine highly 
expressed genes in SSc skin that were similarly expressed in Scl-GVHD 
skin, the fibrotic variant of GVHD, but not in GVHD or HC skin biopsies 
(Gillespie et al., 2011). Indeed, any identified genes could be of potential 
importance in regulating fibrosis or potentially act as biomarkers during 
fibrosis. The analysis revealed that SFRP4, a putative inhibitor of the 
canonical Wnt signalling pathway, was significantly upregulated in both SSc 
and Scl-GVHD but not in cGVHD skin biopsies (Gillespie et al., 2011). On 
this basis, the ex vivo expression and in vitro expression and function of 
SFRP4 were investigated to identify a possible association with fibrosis. 
 
3.1 SFRP4 might reflect fibrotic activity in dcSSc patients 
As SFRP4 is secreted, the protein concentration was determined in sera 
from 77 SSc patients and subsequently stratified against SSc disease index 
criteria. Of the 77 patients’ sera tested, 39 were from lcSSc patients, and all 
were anti-centromere antibody (ACA) positive, while the remaining 38 sera 
were from dcSSc patients, of which 30 were positive Scl-70 antibody (also 
known as anti-topoisomerase I). Indeed, these two autoantibodies are 
typically used as clinical biomarkers in SSc disease classification and 
typically correlate with lcSSc and dcSSc subsets, respectively. 
It was observed that those sera that were ACA negative had a higher mean 
SFRP4 concentration compared to those that were positive, 36.55 ng/ml ± 
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2.1 and 27.7 ng/ml ± 1.45, respectively (P<0.001) (Figure 3.1A). Conversely, 
patients negative for Scl-70 had a lower mean concentration of SFRP4 than 
those that were positive for the autoantibody, 28.71 ng/ml ± 1.67 compared 
to 36.19 ng/ml ± 2.51, respectively (P<0.05) (Figure 3.1A). Univariate 
analysis showed that the SFRP4 concentration did not correlate with the 
mRSS in the overall population (Figure 3.1B). However, SFRP4 
concentrations inversely correlated with a reduced pulmonary function, as 
indicated by a reduction in the percentage diffusing lung capacity for carbon 
monoxide (%DLCO) (Figure 3.1C). 
However, this might be as a result of the presence of idiopathic lung disease 
(IDL), pulmonary arterial hypertension (PAH) or, indirectly due to lung 
fibrosis. Therefore, the mRSS in patients with a normal-like lung function, 
DLCO ≥ 70.0%, was stratified against SFRP4 concentration and a direct 
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Figure 3.1 Increased SFRP4 concentration could reflect fibrotic activity 
in dcSSc patients. 
Stratification of SFRP4 concentration against disease index criteria included 
A) ACA and Scl-70 autoantibody presence B) % diffusion lung capacity of 
carbon monoxide (%DLCO) C) mRSS and D) mRSS in patients with 
%DLCO of >70% (normal-like). Data shown as mean, n=77; Mann-Whitney 
test for unpaired, Wilcoxon test for paired samples and correlations were 
calculated using Spearman’s rank correlation test, *P=0.05, ***P = 0.001. 
 
 
3.2 SFRP4 expression is increased in SSc fibroblasts and 
regulated by canonical Wnt and TGFβ signalling 
The mean concentration of SFRP4 in patient sera was higher in those 
positive for Scl-70, a biomarker typically associated with the fibrotic dcSSc 
subset. Taking this, together with the observation by Bayle et al., who 
showed that expression was increased in fibroblast-like cells resident in the 
deep dermis of lesional dcSSc skin (Bayle et al., 2008), fibroblasts were 
- 82 - 
likely to contribute to the increased expression of SFRP4 in dcSSc tissues. 
Therefore, SFRP4 expression was quantified in fibroblasts from HC and SSc 
patients and also the factors involved in eliciting this expression were also 
investigated. 
Indeed, the expression of SFRP4 was increased by 364% (P<0.0001) in SSc 
compared to HC fibroblasts at basal level, and this observation was further 
confirmed at protein level (Figure 3.2A). Next, the factors involved in the 
regulation of SFRP4 expression were explored. As unconfirmed reports 
have described SFRP4 as a putative Wnt antagonist, both canonical (β-
catenin-dependent) and non-canonical Wnt signalling pathway activation 
were investigated, using Wnt-3a (canonical ligand) and Wnt-5a (non-
canonical ligand) agonist treatments, respectively. In addition, TGFβ 
signalling was also evaluated due to its fundamental role in reproduction of 
the fibrotic SSc phenotype. 
Following treatment with Wnt-3a, SFRP4 expression was induced by 
144.0% (P<0.0001) in HC fibroblasts, while Wnt-5a treatment showed no 
significant effect on SFRP4 expression. Interestingly, TGFβ treatment 
induced a 362.0% (P<0.05) increase in SFRP4 expression in HC fibroblasts 
(Figure 3.2B). Next, SSc fibroblasts were treated under the same conditions; 
like HC fibroblasts, Wnt-3a induced SFRP4 expression by 206.1% 
(P<0.0001), and Wnt-5a treatment again showed no effect, while TGFβ 
treatment induced expression by 365.6% (Figure 3.2B). Indeed, for each 
treatment condition the induction of SFRP4 expression was similar between 
HC and SSc fibroblasts (Figure 3.2B). At protein level however, SFRP4 
expression was unchanged following both Wnt-3a and Wnt-5a treatment 
- 83 - 
although TGFβ treatment could still be observed to induce SFRP4 
expression in both HC and SSc fibroblasts (Figure 3.2B). 
As TGFβ induced the greatest change in expression of SFRP4, irrespective 
of fibroblast type, the mechanism of TGFβ-induced SFRP4 expression was 
evaluated in HC fibroblasts. TGFβ treatment mediated a dose-dependent 
increase in SFRP4 expression following treatment at a concentration of 1.0 
and 5.0 ng/ml (maximal effect) expressed by 138.4 and 198.0%, respectively 
(Figure 3.2C). Interestingly, at a concentration of 10 ng/ml SFRP4 
expression was significantly downregulated to 64.5% (Figure 3.2C). 
Treatment of HC with 5 ng/ml TGFβ showed a time-dependent increase in 
SFRP4 expression by 170.9%, to 348.2% at 48 and 72 hr, respectively 
(P<0.05) (Figure 3.2D). This time-dependent increase in expression was 
also evident at protein level and coincided with increased expression of α-
SMA, a fibroblast activation marker, and also showed an expected inverse 
relationship with CAV-1 expression at both 48 and 72 hr. 
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Figure 3.2 SFRP4 expression is increased in SSc fibroblasts and 
regulated by canonical Wnt and TGFβ signalling 
SFRP4 expression was determined in HC and SSc fibroblasts at A) basal 
level or B) following 24 hr treatment with Wnt-3a (100 ng/ml), Wnt5a (100 
ng/ml) or TGFβ (5 ng/ml) and quantified by qRT-PCR. Protein expression of 
SFRP4 and GAPDH (loading control) were determined by Western blot at C) 
basal level or D) following 72 hr treatments described in B. Following TGFβ 
treatment both C) dose (1.0, 5.0, 10.0 ng/ml) and D) time (24, 48, 72 hr) 
dependent effects upon SFRP4 expression were quantified by qRT-PCR. E) 
Protein expression of SFRP4, α-SMA, CAV-1 and GAPDH (loading control) 
were determined following 72 hr TGFβ treatment (5 ng/ml) by Western blot. 
Data shown as mean ± SEM, n=4; Mann-Whitney test for unpaired samples, 
*P=0.05, **P=0.05, ****P = 0.0001. 
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3.3 SFRP4 does not regulate canonical Wnt signalling 
activity or augment fibroblast activation 
As SFRP4 is described as a putative inhibitor of the canonical Wnt signalling 
pathway its role in the regulation of canonical Wnt signalling was 
investigated in HC fibroblasts. Canonical/β-catenin-mediated signalling was 
determined by TOPFlash reporter activity, driven by the TCF/LEF 
transcription factor activation. Following treatment of HC fibroblasts with the 
canonical Wnt-3a agonist, TOPFlash activity was induced by 5.3-fold and 
Wnt-3a co-treatment with SFRP4 at either 100 or 1000 ng/ml showed a 
weak tend toward the inhibition of TOPFlash activity, reduced to 4.5-fold and 
4.4-fold, respectively. Despite this reduction, no dose-dependent effect on 
the amplitude of TOPFlash activity was observed (Figure 3.3A). 
Next, as SFRP4 was significantly induced by TGFβ it was therefore 
considered to have a potential role in the regulation of TGFβ-induced 
profibrotic activity. To investigate this further, rhSFRP4 was used to treat HC 
and SSc fibroblasts over a dose series of 100-1000 ng/ml and the effect on 
fibroblast activation determined through the expression of α-SMA, a known 
fibroblast activation marker. While TGFβ induced a significant upregulation, 
a trend toward a reduction in α-SMA expression was observed following 
independent SFRP4 treatment in both HC and SSc fibroblasts (Figure 3.3B). 
However, this was not found to be a dose-dependent effect and fibroblasts 
were affected similarly over the SFRP4 concentration series (Figure 3.3B). 
Further, SFRP4 at 100 and 1000 ng/ml showed no effect on myofibroblast 
presence in contrast to the significant increase induced by TGFβ treatment 
in both HC and SSc fibroblasts (Figure 3.3C). 
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Figure 3.3 SFRP4 does not regulate canonical Wnt signalling activity or 
augment fibroblast activation 
A) HC fibroblasts were treated with Wnt-3a (100ng/ml) in the presence and 
absence of SFRP4 for 24 hr and canonical signalling activity was determined 
by TOPFlash luciferase activity. Next, HC and SSc fibroblasts were treated 
with rhSFRP4 (100, 500, 1000 ng/ml) or TGFβ for 72 hr to evaluate any 
profibrotic activation through α-SMA and GAPDH (loading control) protein 
expression, determined by Western blot or D) myofibroblast differentiation 
was determined by α-SMA stress fibril formation by confocal microscopy 
using a CY3-conjugated secondary (red) directed against anti-α-SMA 
antibody, nuceli were stained with DAPI (blue) (magnification 20x). Data 
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3.4 DISCUSSION: Evaluation of SFRP4 expression in SSc 
patient Sera and fibroblasts 
Differential gene expression analysis revealed that SFRP4, a putative 
inhibitor of the canonical Wnt signalling pathway, was highly upregulated in 
SSc skin comparable to Scl-GVHD, the fibrotic variant of GVHD, but not in 
GVHD or HC skin biopsies (Gillespie et al., 2011). It is notable that other 
reports have suggested that components of the Wnt signalling pathway are 
highly represented in models of experimental fibrosis by tissue and 
microarray studies and therefore SFRP4 could be of potential importance in 
regulating fibrosis (Bayle et al., 2007; Beyer et al., 2012; Wei et al., 2012). 
Since SFRP4 is a soluble protein, the concentrations present in SSc patient 
sera were determined to evaluate whether these might reflect the degree of 
fibrotic activity in SSc patients either directly or indirectly, and might also 
indicate its utility as a potential biomarker. Indeed, the mean SFRP4 
concentration was higher in Scl-70 positive and lower in ACA positive 
patients; two SSc specific autoantibodies linked to the diffuse (dcSSc) and 
limited (lcSSc) subsets, respectively (Figure 3.1A). These data suggested 
that the increased concentrations of SFRP4 might be associated with the 
dcSSc subset, which was further supported by reciprocal tests for negative 
and positive autoantibody presence for either Scl-70 or ACA, respectively 
(Figure 3.1A). Despite an association with the dcSSc subset, no correlation 
was observed with the mRSS, a measure of fibrotic skin involvement. In 
addition, while there was no correlation with the forced vital capacity (FVC) 
an inverse correlation was identified with the %DLCO, where lower %DLCO 
can indicate a worsening lung function (Figure 3.1C). Indeed, a reduced 
%DLCO may be more representative of patients presenting with PAH and 
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ILD (Hudson et al., 2013; Sivova et al., 2013). Therefore, patients that had a 
normal %DLCO (>70%) were selected and, on analysis, those showed a 
direct relationship between SFRP4 concentration and mRSS (Figure 3.1D). 
These data supported the hypothesis that SFRP4 might reflect the degree of 
fibrotic activity in dcSSc patients; however, the plotted data presented do not 
show clearly defined relationships by linear regression. In order to be 
conclusive, these correlations should not be dependent on outliers and 
therefore by increasing the number of patients tested these correlations 
could be confirmed or disproved. Despite this limitation, the expression and 
potential function of SFRP4 were investigated further, in vitro, to identify any 
possible association with fibrotic activity. 
Indeed, fibrobalsts are the key cellular mediators of fibrosis, and Bayle et al., 
have previously shown that SFRP4 expression is increased in vivo in cells 
resident in the deep dermis of lesional dcSSc skin that were thought to be 
morphologically similar to fibroblasts (Bayle et al., 2008). This was supported 
by the mean concentration of SFRP4, which was higher in Scl-70 positive 
patients, a marker typically associated with the fibrotic dcSSc. Together, 
these data suggested that fibroblasts likely contributed to the increased 
expression of SFRP4 observed in patient sera. In support of this hypothesis, 
a comparative analysis of HC and SSc fibroblasts showed that SFRP4 
expression, at both mRNA and protein level, was distinctly upregulated in 
dcSSc fibroblasts (Figure 3.2A). These data suggested that the increased 
SFRP4 observed could in fact be attributable to the fibroblast lineage. 
As a putative Wnt antagonist, SFRP4 was likely to be regulated by canonical 
(β-catenin-dependent) and/or non-canonical (β-catenin-independent) Wnt 
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signalling pathway activation. In addition, TGFβ signalling was also 
evaluated due to its fundamental role in reproduction of the fibrotic 
phenotype in vitro (Varga & Pasche, 2009). Accordingly, a comparative 
analysis between HC and SSc fibroblasts revealed that both canonical Wnt 
signalling and TGFβ signalling could upregulate the expression of SFRP4; 
however, only TGFβ treatment upregulated SFRP4 expression at protein 
level (Figure 3.2B). On this basis, further experiments determined the dose- 
and time-dependent nature of TGFβ signalling in HC fibroblasts (Figure 
3.2C-E). As SFRP4 expression was not evident following Wnt agonist 
treatment, this could be an effect of recombinant protein activity or its 
expression might be deficient as a result of indirect regulation by the 
canonical Wnt signalling pathway. Whether TGFβ induced SFRP4 
expression was direct or indirect was not determined. 
These data suggest that both canonical Wnt signalling and TGFβ crosstalk 
might act in parallel might act to negatively regulate canonical Wnt signalling 
through the upregulation of the putative inhibitor of Wnt signalling, SFRP4, 
Indeed, the Tsk-1 model of experimental fibrosis revealed that several 
components of the Wnt signalling pathways are upregulated, including Wnt-
2, Wnt-9a, Wnt-10b and Wnt-11; Dapper (Dact)-1 and Dact-2; Wnt-induced 
secreted protein 2; Sfrp2, Sfrp4, which suggest that the control of Wnt 
signalling might be important in resolving fibrosis (Bayle et al., 2008). 
While SFRP4 is putatively involved in the regulation of the Wnt signalling 
pathway, the possibility remained that SFRP4 might be also be involved in 
the regulation of the TGFβ signalling pathway and therefore preliminary 
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experiments to test these hypotheses were the subsequent considerations of 
this study. 
 
Canonical Wnt-3a agonist treatment of HC fibroblasts showed a clear 
activation of canonical Wnt signalling determined by TOPFlash reporter 
activity, a reporter driven by β-catenin-mediated activation of the TCF/LEF 
transcription factors (Figure 3A). 
rhSFRP4 co-treatments were used to evaluate the putative inhibitory 
function of SFRP4 upon Wnt-3a-induced canonical Wnt signalling activation. 
Higher SFRP4 concentrations were used than those found in SSc patient 
sera. This was deemed necessary, as the local concentration of SFRP4 in 
tissues might be higher and, irrespective of cell-type, previous studies used 
SFRP4 at concentration that ranged between 125 pg/ml-400 ng/ml (Carmon 
& Loose, 2008; Muley et al., 2010). Therefore 100 ng/ml was decided to be 
an adequate starting concentration and 500 ng/ml was also included incase 
the activity of the recombinant protein was modest. 
However, SFRP4 proved to be ineffective as a canonical Wnt signalling 
inhibitor, despite moderate to high doses SFRP4 co-treatment, which failed 
to reduce Wnt-3a-induced canonical signalling activity by any significant 
margin (Figure 3.3A). This data corroborates a previous study that found that 
while SFRP4 formed a complex with Wnt-3a (0-140nM), detected by surface 
plasmon resonance, in contrast to SFRP1/ SFRP2 (0-16nM) the Wnt-3a-
induced expression of total β-catenin was unaffected (Wawrzak et al., 2007). 
These data suggest that SFRP4 might act to titrate the inhibitory activities of 
other SFRPs and preserve Wnt agonist activatory activity. Supporting this 
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hypothesis, SFRP1/2 were both found to be expressed simultaneously in 
haematopoietic stem cells and while both contributed to proliferation they 
had opposing effects upon self-renewal, which in essence provides evidence 
that the concentration balance between SFRPs can have a profound 
consequence on cellular function (Nakajima et al., 2009). 
Of note was the ability of SFRPs to form complexes with Fz receptors 
facilitated via CRD:CRD interaction and that this interaction alone may be 
sufficient to activate Fz receptors signal transduction (Uren et al., 2000). In 
addition to Fz receptors, SFRP2 was able to participate in a complex with 
α5β1 integrin, in association with fibronectin, which mediated the protection 
of human mammary cancer cells from apoptosis (Lee et al., 2004). 
Therefore, SFRPs might independently activate receptor-mediated signal 
transduction independently of Wnt and might directly regulate fibroblast 
biology. Consequently, independent SFRP4 treatment was investigated for 
any agonistic effects on fibroblast activation and preliminary results indicated 
that, across a dose range of 100-1000 ng/ml, there was no increase in α-
SMA expression or myofibroblast presence in both HC and SSc fibroblasts 
(Figure 3.3B, C). Far from activating fibroblasts, SFRP4 appeared to reduce 
the baseline expression of α-SMA. In light of these data and despite the 
absence of a dose effect, the possibility remained that SFRP4 might act to 
limit fibroblast activation though the regulation of Wnt/TGFβ signalling, which 
were subsequently explored in combinational co-treatment experiments, 
discussed in the next chapter. 
Overall, these data suggested that the increased SFRP4 observed could in 
fact be attributable to the fibroblast lineage and also might be indicative of an 
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increased canonical Wnt or TGFβ signalling activity. Despite indications that 
the mean concentration of SFRP4 might be associated with dcSSc patients, 
an increased sample size is required. Further, rhSFRP4 did not appear to 
lead to profibrotic fibroblast activation nor did it limit canonical Wnt-induced 
activation of the canonical Wnt signalling pathway, despite its putative 
function as a Wnt antagonist. 
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4 Comparative analysis of Wnt/TGFβ 
signalling pathway activation and profibrotic 
gene expression in SSc and HC fibroblasts 
Comparable to TGFβ signalling, activation of the Wnt/β-catenin signalling 
pathway has more recently been linked to the fibroblast-mediated 
pathogenesis of tissue fibrosis though tissue expression studies and models 
of experimental fibrosis (Beyer et al., 2012; Wei et al., 2012). Interestingly, 
both pathways contribute to the upregulation of SFRP4 expression, which is 
increased in the Tsk-1 mouse model of fibrosis, correlated with mRSS in a 
subset of patients sera and was also increased in SSc fibroblasts (Figure 
3.1D; Figure 3.2A) (Bayle et al., 2008). Therefore, it was determined, 
irrespective of the microenvironment, whether SSc fibroblasts in comparison 
to HC fibroblasts could demonstrate a differential response to Wnt/TGFβ 
signalling, whether this contributed to downstream fibrotic activities and 
whether SFRP4 expression might regulate these activities. 
 
4.1 Canonical and non-canonical ligands have respective 
similarity based on sequence homology and phylogeny 
In SSc both Wnt-10b (canonical agonist) and Wnt-11a (non-canonical 
agonist) have been shown to be highly differentially expressed in the Tsk-1 
mouse model of experimental fibrosis and more recently Wnt-10b in SSc 
skin biopsies (Bayle et al., 2007; Beyer et al., 2012). Furthermore, Wei et al., 
have shown that fibroblasts explanted from Wnt-10b transgenic mice have 
increased canonical Wnt signalling and that this correlated this with an 
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increase in both Type-1 collagen and α-SMA gene expression. Since they 
were more relevant in SSc, canonical Wnt-10b and non-canonical Wnt-11a 
agonists were to be included as part the in-vitro studies with SFRP4. 
However, in HC fibroblasts treatment with either Wnt-10b or Wnt-11a did not 
induce AXIN2 expression, a direct target of canonical Wnt signalling 
pathway, in contrast to the 342.2% (P<0.01) increase following Wnt-3a 
treatment in HC fibroblasts (Figure 4.1A). This was subsequently confirmed 
by TOPFlash reporter activity, which was unchanged following Wnt-10b or 
Wnt-11a treatment but induced by 3.8-fold (P<0.05) following Wnt-3a 
treatment (Figure 4.1B). In a panel of genes, comprised of COL1A1, α-SMA 
and CTGF, only Wnt-3a treatment marginally induced COL1A1 expression 
by 133.8% otherwise genes expression was unchanged (Figure 4.1C, E). 
Recombinant human Wnt-10b and Wnt-11a were not commonly cited in 
publications at this time and therefore the activities quoted by the supplier 
were unsupported. However, both Wnt-3a and Wnt-5a were more described 
in the literature to elicit canonical and non-canonical activities, respectively. 
Therefore a phylogenetic analysis was performed, using full-length protein 
reference sequences from Wnt-3a, Wnt-5a, Wnt-11a and Wnt-10b as a 
validation for the inclusion of both Wnt-3a and Wnt-5a recombinant human 
proteins in place of Wnt-10 and Wnt-11a for this study. Phylogenetic 
alignment was based on protein structure similarity using Wnt-2 as a 
putative backbone due to its activity being associated with both canonical 
and non-canonical signalling activation. Indeed, on analysis of branching 
from an unrooted tree, similarities between Wnt-3a / Wnt-10b and Wnt-5a / 
Wnt-11a were observed following divergence from Wnt-2 protein sequence, 
which may also confer similar functional activities (Figure 4.1F, G). 
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Figure 4.1 Canonical and non-canonical ligands have respective 
similarities based on sequence homology and phylogeny 
HC fibroblasts were treated with Wnt-10b (200 ng/ml), Wnt-11a (200 ng/ml) 
or Wnt-3a (100 ng/ml) for 24 hr. Canonical Wnt signalling pathway activation 
of was evaluated through A) AXIN2 gene expression, quantified by qRT-
PCR or B) TOPFlash reporter activity, determined by luciferase activity. The 
effect upon profibrotic gene expression was also determined for C) COL1A1 
D) α-SMA and E) CTGF, quantified by qRT-PCR. Finally, protein similarity 
between canonical Wnt-3a, Wnt10b and non-canonical Wnt-11a and Wnt-5a 
were compared, using a bidirectional Wnt-2 as a backbone, through F) 
phylogenic analysis and G) multiple sequence alignment as determined by 
the ClustalX bioinformatics. Data shown as mean ± SEM, n=4; Mann-
Whitney test for unpaired samples, *P=0.05, **P=0.01. 
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4.2 SSc fibroblasts have an increased response to canonical 
Wnt signalling that is unaffected by rhSFRP4 treatment 
In an experimental model of SSc, activation of the canonical Wnt signalling 
pathway has been shown to promote a Wnt-induced fibrosis that 
characteristically involves fibroblast activation, myofibroblast accumulation 
and increased collagen deposition (Wei et al. 2011). Consequently, the 
increased expression of SFRP4 in SSc may be as a result of persistent 
activation of the Wnt signalling pathway. Therefore, following Wnt-3a 
treatment a comparative analysis between HC and SSc fibroblasts was used 
to evaluate i) any differential regulation of profibrotic gene expression 
(COL1A1 and α-SMA) and ii) any differential canonical Wnt signalling 
activity. The effect of independent or Wnt-3a co-treatment with SFRP4 was 
also investigated for modulatory effects on both profibrotic gene expression 
and canonical signalling activity. 
 
First, profibrotic gene expression was determined. At basal level, COL1A1 
showed no significant difference in expression between HC and SSc 
fibroblasts (Figure 4.2A). Following Wnt-3a treatment, COL1A1 gene 
expression was increased by 118.2% (P<0.05) in HC and 155.1% (P<0.001) 
in SSc fibroblasts, which was a significant increase in SSc compared to HC 
fibroblasts (P<0.01) (Figure 4.2A). Independent SFRP4 treatment showed 
no significant change in COL1A1 expression in HC fibroblasts, in contrast to 
the 137.3% increase (P<0.01) in SSc fibroblasts (Figure 4.2A). When Wnt-
3a was co-treated with SFRP4 no further effects were observed in both HC 
and SSc fibroblasts (Figure 4.2A). 
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Similarly, at basal level α-SMA showed no significant difference in 
expression between HC and SSc fibroblasts (Figure 4.2B). Following Wnt-3a 
treatment α-SMA expression was increased by 173.0% (P<0.0001) in HC 
and 352.2% (P<0.0001) in SSc fibroblasts, which was a significant increase 
in response by SSc fibroblasts (P<0.001) (Figure 4.2B). Independent SFRP4 
treatment showed no significant change in α-SMA expression in HC 
fibroblasts although expression was increased to 167.1% in SSc fibroblasts 
and this was found to be significantly different from HC levels (P<0.05) 
(Figure 4.2B). When Wnt-3a was co-treated with SFRP4 there was no 
significant effect on Wnt-3a-induced α-SMA upregulation in either HC or SSc 
fibroblasts (Figure 4.2B). Despite being increased at mRNA level, α-SMA 
protein expression was not induced by Wnt-3a treatment, and independent 
or Wnt-3a co-treatment with SFRP4 showed no significant effect on 
expression in both HC and SSc fibroblasts (Figure 4.2C). 
 
Next, these conditions were evaluated for an effect on the activation of the 
canonical Wnt signalling pathway determined by quantification of a direct 
Wnt-induced target of canonical Wnt signalling pathway, AXIN2. 
Interestingly, SSc fibroblasts showed a significant reduction in the 
expression of AXIN2 expressed at basal level, which was reduced to 51% of 
HC levels (Figure 4.2D). Following Wnt-3a treatment AXIN2 expression was 
induced by 190.0% (P<0.0001) in HC and 253.8% (P<0.0001) in SSc 
fibroblasts, which was a significant increase in response in SSc compared to 
HC fibroblasts (P<0.01) (Figure 4.2D). Independent or Wnt-3a co-treatment 
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with SFRP4 both showed no significant effect on AXIN2 expression in both 
HC and SSc fibroblasts (Figure 4.2D). 
Validation of the AXIN2 expression data was performed using TOPFlash 
activity under the same conditions. Consistently, basal TOPFlash activity 
showed no significant difference in activation between HC and SSc 
fibroblasts (Figure 4.2E). Wnt-3a Treatment induced TOPFlash activity by 
3.7-fold (P<0.05) in HC and 12.0-fold (P<0.05) in SSc fibroblasts, which was 
a significant increase in response in SSc compared to HC fibroblasts 
(P<0.05) (Figure 4.2E). Independent or Wnt-3a co-treatment with SFRP4 
showed no significant effect on the expression of AXIN2 in either HC or SSc 
fibroblasts (Figure 4.2E). 
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Figure 4.2 SSc fibroblasts have an increased response to canonical 
Wnt signalling that is unaffected by rhSFRP4 treatment 
Differential profibrotic gene expression and canonical Wnt singalling 
activation were compared between HC and SSc fibroblasts treated with 
canonical agonist Wnt-3a (100 ng/ml) in the presence and absence of 
putative Wnt inhibitor SFRP4 (70 ng/ml). The effect on profibrotic genes A) 
COL1A1 and B) α-SMA were determined following 24 hr treatment and 
quantified by qRT-PCR. C) Following 72 hr treatment, protein expression of 
α-SMA and GAPDH (loading control) were used as a confirmation of 
profibrotic activity, determined by Western blot. Canonical Wnt signalling 
activation was evaluated following 24 hr treatment by D) AXIN2 expression, 
a canonical Wnt target gene, quantified by qRT-PCR and by E) TOPFlash 
reporter activity, quantified by luciferase activity. All quantitative data were 
normalised on basal HC levels. Data shown as mean ± SEM, n=4; Mann-
Whitney test for unpaired samples, *P=0.05, **P = 0.01, ***P=0.001, ****P = 
0.0001. 
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4.3 Non-canonical treatment showed no profibrotic or 
canonical Wnt signalling activity and SFRP4 had no 
modulatory activity 
In contrast to canonical Wnt signalling, the role of the non-canonical Wnt 
signalling pathway in fibrosis is not well described, particularly with regard to 
SSc. Like canonical Wnt signalling, the non-canonical pathway may be 
involved in the activation of fibroblasts (Jiang et al., 2006; Levänen et al., 
2011; Vuga et al., 2009). Therefore following treatment with a classical non-
canonical agonist, Wnt-5a, a comparative analysis between HC and SSc 
fibroblasts was used to evaluate i) any differential regulation of profibrotic 
gene expression and ii) any crosstalk and in-turn differential canonical Wnt 
signalling activation. The effect of independent or Wnt-5a co-treatment with 
SFRP4 was also investigated for any modulation of non-canonical signalling 
effects on both profibrotic gene expression and canonical signalling activity. 
First, Wnt-5a-induced profibrotic gene expression was determined alongside 
Wnt-5a co-treatment with SFRP4. Wnt-5a treatment showed no effect on 
COL1A1 expression in HC fibroblasts in contrast to the 135.3% (P<0.0001) 
induction in SSc fibroblasts (Figure 4.3A). Wnt-5a co-treatment with SFRP4 
did not show any further effect upon the Wnt-5a-induced effects on of 
COL1A1 expression in HC or SSc fibroblasts (Figure 4.3A). 
Next, Wnt-5a increased α-SMA expression by 122.0% and 133.3% in HC 
and SSc fibroblasts, respectively (Figure 4.2B). However, Wnt-5a co-
treatment with SFRP4 showed no further in both HC and SSc fibroblasts 
(Figure 4.3B). At protein level however, α-SMA expression was not induced 
by Wnt-5a or affected by Wnt-5a co-treatment with SFRP4 in both HC and 
SSc fibroblasts (Figure 4.3C). 
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Despite Wnt-5a being classified as a non-canonical agonist, the effect on 
canonical Wnt signalling was evaluated to exclude the possibility that any 
observed effects could be mediated via activation of this pathway. Indeed, 
AXIN2 expression was not induced by Wnt-5a or by Wnt-5a co-treatment 
with SFRP4 in both HC and SSc fibroblasts (Figure 4.3D). Similarly, 
TOPFlash activity was not induced by Wnt-5a treatment Figure 4.3E). 
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Figure 4.3 Non-canonical treatment showed no profibrotic or canonical 
Wnt signalling activity and SFRP4 had no modulatory activity 
Differential profibrotic gene expression and canonical Wnt singalling 
activation were compared between HC and SSc fibroblasts treated with non-
canonical agonist Wnt-5a (100 ng/ml) in the presence and absence of 
putative Wnt inhibitor SFRP4 (70 ng/ml). The effect on profibrotic genes A) 
COL1A1 and B) α-SMA were determined following 24 hr treatment and 
quantified by qRT-PCR. C) Following 72 hr treatment, protein expression of 
α-SMA and GAPDH (loading control) were used as a confirmation of 
profibrotic activity, determined by Western blot. Canonical Wnt signalling 
activation was evaluated following 24 hr treatment by D) AXIN2 expression, 
a canonical Wnt target gene, quantified by qRT-PCR and by E) TOPFlash 
reporter activity, quantified by luciferase activity. All quantitative data were 
normalised on basal HC levels. Data shown as mean ± SEM, n=4; Mann-
Whitney test for unpaired samples, **P = 0.01, ****P = 0.0001. 
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4.4 TGFβ-mediated profibrotic and canonical Wnt signalling 
activities are not regulated by SFRP4 
While SFPR4 showed no significant regulatory effects independently or in 
tandem with Wnt agonist treatments (Figure 4.2 & Figure 4.3), the fact 
remained that TGFβ signalling was able to significantly upregulate SFRP4 
expression in fibroblasts (Figure 3.2B). Accordingly, SFPR4 could play a 
potential role in the regulation of TGFβ signalling. Therefore a comparative 
analysis between HC and SSc fibroblasts was used following TGFβ 
treatment to evaluate i) the known effect on profibrotic gene expression and 
ii) whether TGFβ regulated canonical Wnt signalling activity. The effects of 
independent or TGFβ co-treatment with SFRP4 were also investigated for 
any modulation of effects elicited by TGFβ signalling on both profibrotic gene 
expression and canonical signalling activity. 
First, TGFβ-induced profibrotic gene expression was determined alongside 
independent and co-treatment with SFRP4. TGFβ induced COL1A1 
expression by 229.0% (p<0.0001) and 206.0% (p<0.0001) in HC and SSc 
fibroblasts, respectively (Figure 4.4A). TGFβ co-treatment with SFRP4 did 
not affect COL1A1 expression in HC fibroblasts and in SSc fibroblasts co-
treatment showed a trend toward inhibition of COL1A1 expression, which 
was decreased to 163.3% but this was not found to be statistically significant 
(Figure 4.4A). 
Next, TGFβ induced α-SMA expression by 116.3% (P<0.01) and 142.5% 
(P<0.01) in HC and SSc fibroblasts, respectively. Interestingly, TGFβ co-
treatment with SFRP4 increased α-SMA expression by 205.0% (P<0.05) in 
HC fibroblasts but had no significant effect on expression in SSc fibroblasts 
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when compared to TGFβ treatment alone (Figure 4.4B). At protein level, 
TGFβ treatment also showed a significant induction of α-SMA expression, 
however, TGFβ co-treatment with SFRP4 showed no further effects (Figure 
4.4C). 
Next, these treatments were evaluated in 3D collagen gels seeded with HC 
or SSc fibroblasts. Fibroblast-induced contraction 3D collagen gel has been 
utilised as a comparable measure of fibroblast-induced contraction of tissues 
characteristic during fibrosis. The consequence of increased α-SMA 
expression is the increased potential for fibroblast to myofibroblast 
differentiation, where α-SMA stress fibrils polymerisation is characteristic, 
and the functional consequence is the generation of increased contractile 
force on the ECM. At basal level, there was no spontaneous contraction of 
SSc compared to HC fibroblasts (Figure 4.4D). Also there was no significant 
difference in TGFβ-induced 3D collagen gel contraction between HC and 
SSc fibroblasts, which were contracted to 51.5% and 56.8% of controls, 
respectively (Figure 4.4D). Interestingly, SFRP4 treatment increased the 
collagen gel area in both HC and SSc fibroblasts by 13.4% (Figure 4.4C). 
However, TGFβ co-treatment with SFRP4 did not greatly affect the TGFβ-
induced gel contraction, which contracted to 57.2% and 67.9% in HC and 
SSc fibroblasts, respectively (Figure 4.4D). 
Finally, canonical Wnt signalling activation was evaluated. TGFβ reduced 
the expression of AXIN2 to 50.0% (P<0.0001) and 16.0% (P<0.0001) in HC 
and SSc fibroblasts, respectively (Figure 4.4E). TGFβ co-treatment with 
SFRP4 had no effect on the TGFβ-induced downregulation of AXIN2 in 
either HC or SSc fibroblasts (Figure 4.4E). 
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These data were then validated by TOPFlash activity. TGFβ to inhibited 
TOPFlash activity to 59.6% (P<0.05) in HC fibroblasts but showed no 
significant effect on SSc fibroblasts (Figure 4.4F). SFRP4 treatment showed 
no significant effect on TOPFlash activity in HC fibroblasts but showed a 
trend a trend toward increased activity in SSc fibroblasts, induced by 1.3-fold 
(Figure 4.4F). TGFβ co-treatment with SFRP4 did not affect TOPFlash 
activity in HC fibroblasts but showed a trend a trend toward increased 
activity in SSc fibroblasts by 1.6-fold (Figure 4.4F). 
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Figure 4.4 TGFβ-mediated profibrotic and canonical Wnt signalling 
activities are not regulated by SFRP4 
Differential profibrotic gene expression and canonical Wnt singalling 
activation were compared between HC and SSc fibroblasts treated with 
TGFβ (5 ng/ml) in the presence and absence of putative Wnt inhibitor 
SFRP4 (70 ng/ml). The effect on profibrotic genes A) COL1A1 and B) α-
SMA were determined following 24 hr treatment and quantified by qRT-PCR. 
C) Following 72 hr treatment, protein expression of α-SMA and GAPDH 
(loading control) were used as a confirmation of profibrotic activity, 
determined by Western blot. Canonical Wnt signalling activation was 
evaluated following 24 hr treatment by E) AXIN2 expression, a canonical 
Wnt target gene, quantified by qRT-PCR and by F) TOPFlash reporter 
activity, quantified by luciferase activity. All quantitative data were 
normalised on basal HC levels. Data shown as mean ± SEM, n=4; Mann-
Whitney test for unpaired samples, *P=0.05, **P = 0.01, ****P = 0.0001. 
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4.5 DISCUSSION: Comparative analysis of Wnt/TGFβ 
signalling pathway activation and profibrotic gene 
expression in SSc and HC fibroblasts 
The Wnt-10b (canonical) and Wnt-11a (non-canonical) agonists display high 
differential expression in the dermis of the Tsk-1 mouse model of 
experimental fibrosis, and Wnt-10b more recently in SSc skin biopsies 
(Bayle et al., 2007; Beyer et al., 2012). Furthermore, Wei et al., have shown 
that fibroblasts explanted from Wnt-10b transgenic mice have increased 
canonical Wnt signalling, which correlated this with an increase in both 
Type-1 collagen and α-SMA gene expression (Wei et al., 2012). Although 
Wnt-11a activity has not been directly studied in relation to fibrosis, 
upregulation of Wnt-11a by TGFβ in renal epithelial cells has been shown to 
promote non-canonical signalling-mediated mesenchymal gene expression, 
including α-SMA (Zhang et al., 2012). Therefore Wnt-10b and Wnt-11a 
agonists were to be investigated as part of this study due to their biological 
relevance in the disease state. A limitation of this study was the absence of 
a reliable assay to evaluate non-canonical signalling. In contrast to Wnt-10b, 
Wnt-11a is described as a non-canonical agonist and therefore its activity 
would generally be thought to be β-catenin-independent. However, non-
canonical agonists have been observed to activate canonical signalling in 
various bilological contexts (Kikuchi et al., 2009). In vitro analysis of Wnt-10b 
and Wnt-11a, in contrast to Wnt-3a, demonstrated a failure to activate two 
determinants of canonical Wnt signalling, AXIN2 mRNA expression, a direct 
Wnt-induced target, and TOPFlash activity (Figure 4.1A, B). This was 
despite Wnt-3a concentration (100 ng/ml) being half that of the other 
agonists. All Wnt agonists initially showed no effect on genes associated 
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with profibrotic activity; however, Wnt-3a treatment did show a trend toward 
increased COL1A1 expression (Figure 4.1C-E). Accordingly, due to 
inactivity, Wnt-10b and Wnt-11a were excluded from the study. While the 
activity of Wnt-11a might demonstrate non-canonical activities, like Wnt-10b, 
the recombinant protein was not commonly cited in publications at this time 
and therefore the activities quoted by the supplier were unsupported by 
independent studies. Widely cited in the literature, Wnt-3a (canonical) and 
Wnt-5a (non-canonical) agonists had consistently been shown to activate 
canonical and non-canonical signalling, respectively. Indeed, Wnt-3a 
canonical signalling activity was already validated by gene expression and 
reporter activation (Figure 4.1A, B). Therefore these widely cited agonists 
were putative surrogates for Wnt-10b and Wnt-11a activity. 
As a secondary confirmation for the inclusion of Wnt-3a/Wnt-5a as 
surrogates of Wnt-10b/Wnt-11a, a phylogenetic analysis was performed 
based of protein structure similarity. This used the full-length protein 
reference sequences for Wnt-3a, Wnt-5a, Wnt-11a Wnt-10b and Wnt-2, 
where Wnt-2a, which was associated with both canonical and non-canonical 
signalling activation, acted as a backbone. On branch analysis of a derived 
unrooted tree, Wnt-3a and Wnt-10b were found to be closely related as were 
Wnt-5a and Wnt-11a based on divergence from Wnt-2 protein sequence 
(Figure 4.1F, G). These similarities may confer similar functional activities 
already demonstrated in the literature. Therefore these agonists were used 
as surrogates in place of Wnt-10b and Wnt-11a. 
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To determine whether canonical Wnt signalling was increased in SSc 
fibroblasts, comparative analyses were performed between explanted SSc 
patient and HC fibroblasts following canonical Wnt-3a treatment. SSc 
fibroblasts demonstrated an increased response to canonical Wnt signalling 
activation that was consistent between two gold standard measures of 
canonical Wnt signalling activity: AXIN2 mRNA expression and TOPFlash 
reporter activation. These in vitro analyses expand upon previous studies 
that have shown canonical Wnt signalling to be hyperactivated within SSc 
skin biopsies but related this to differential Wnt agonist expression (Beyer et 
al., 2012; Wei et al., 2011; Akhmetshina et al., 2012). Furthermore, no 
spontaneous activation of canonical Wnt signalling was observed in SSc 
fibroblasts, which would suggest that fibroblasts do not display an autocrine 
activation of canonical Wnt signalling and that this activity is likely caused by 
the production of Wnt agonists by other cell types present in the local 
microenvironment (Figure 4.2D, E). 
Prominently, AXIN2 expression was significantly downregulated in SSc 
compared to HC fibroblasts (Figure 4.2D). Downregulation of AXIN2, a key 
scaffold component of the β-catenin destruction complex, could explain the 
increased amplitude of canonical Wnt signalling, a subsequent evaluation 
discussed later in this report. 
This analysis also examined the ability of Wnt-3a-induced canonical 
signalling to upregulate the expression of two profibrotic genes, COL1A1 
and α-SMA. In SSc fibroblasts, Wnt-3a-induced profibrotic gene expression 
was more pronounced, which coincided with an increased canonical Wnt 
signalling activity (Figure 4.2A, B). However, despite changes at mRNA 
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level, α-SMA protein expression, a key marker of fibroblast activation, was 
unaffected by canonical Wnt signalling activation (Figure 4.2C). 
Unfortunately, collagen protein expression could not be included as part of 
this study due to the unreliability of several antibodies, which represents a 
study limitation. Overall, canonical Wnt signalling, while increased in SSc 
fibroblasts, had minimal effects on fibrotic activation. 
This adds to conflicting literature describing a role for Wnt-3a-induced 
canonical Wnt signalling in the regulation profibrotic gene expression. 
Studies in mouse fibroblasts have shown that mouse recombinant Wnt-3a 
treatment can induce myofibroblasts differentiation, visualised by α-SMA 
stress fibre formation (Carthy et al., 2011). Wei et al demonstrated that 
adenoviral overexpression of Wnt-3a in foreskin fibroblasts increased 
COL1A2 and α-SMA expression by 2.0-fold and 2.7-fold, respectively, 
following 6 days of culture (Wei et al., 2011). Despite the use of Wnt-3a 
overexpression only a 2.7-fold increase in α-SMA expression was achieved. 
In contrast, α-SMA expression in HC fibroblasts was induced by >100-fold 
following 1 day of TGFβ treatment, which would suggest that the relative role 
of Wnt in activating the profibrotic phenotype is insubstantial by comparison 
(Figure 4.4B). However, there are notable exceptions in the literature where 
no significant change in α-SMA expression is observed in response to Wnt-
3a treatment. Microarray analysis of NIH-3T3 mouse fibroblasts treated with 
Wnt-3a for 6 hr showed no substantial direct induction of profibrotic/matrix 
remodeling genes, including α-SMA (Chen et al., 2007). In a subsequent 
study, COL1A2 and α-SMA expression were not inducible by Wnt-3a 
overexpression in rat cardiac fibroblasts and could only be induced by 
overexpression of the Fz1 receptor (Laeremans et al., 2010). Several key 
- 111 - 
differences between these studies could explain the conflicting results. One 
possible explanation lies in species variation, where the biological relevance 
of a human condition is more suggestive from fibroblasts derived from 
human subjects, where the disease presents, than from our mammalian 
counterparts. Indeed, not all biological pathways are conserved between 
species and the regulation of those that are might diverge (Mestas & 
Hughes, 2004). Once species is considered, then the topographic location of 
the fibroblasts becomes important. For example, neonatal fibroblasts have 
differential gene expression compared to adult fibroblasts, which can explain 
functional differences between the two including migration, contracture and 
differentiation (Schor et al., 1985; Moulin et al., 2001). Furthermore, gene 
profiling studies have shown that there are distinct patterns of gene 
expression from fibroblasts derived from different anatomical regions (Castor 
et al., 1962; Chang et al., 2002). One consequence may extend to the ability 
of cells to respond to extracellular cues through the differential regulation of 
pathway components, which could include those associated with Wnt 
signalling. Comparatively, biopsies should be taken from patients at sites 
that have involved skin and analysed against matched regions from HC 
donors. In this study, it was difficult to source adult fibroblasts from the 
forearm and instead were sourced from the temple, abdomen and breast. 
 
The contribution of the non-canonical pathway in fibroproliferative diseases, 
including in SSc, remains largely unstudied. Despite this, limited reports 
indicate that non-canonical signalling may have fibrotic consequences. 
Therefore a comparative analysis between HC and SSc fibroblasts was used 
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to determine the effect on non-canonical agonist treatment on profibrotic 
gene expression and canonical Wnt signalling. SSc fibroblasts, in contrast to 
HC fibroblasts, showed an induction of COL1A1 expression in response to 
Wnt-5a, which could indicate that non-canonical signalling might be 
selectively utilised in SSc fibroblasts (Figure 4.3A). Similar expression levels 
were induced for α-SMA in both SSc and HC fibroblasts; however, protein 
expression of α-SMA confirmed that this level of expression at mRNA level 
was not translated to protein (Figure 4.3B, C). Therefore, the minimal 
induction of COL1A1 expression suggests that the aforementioned 
hypothesis is an unlikely outcome, although protein expression data are 
unavailable and cannot be used as a secondary confirmation. Like canonical 
signalling, these data suggest that non-canonical signalling is not a 
significant factor in profibrotic gene expression. This is in contrast to a report 
that showed that expression of Wnt-5a in hepatic stellate cells, or its 
receptor, Fz2, increased fibrosis both in vitro and in vivo (Jiang et al., 2006). 
However, in SSc fibroblasts no clear differential effect from HC fibroblasts 
was evident and therefore the expression of Fz receptor expression is likely 
not to be significantly different. A later report showed that Wnt-5a expression 
correlated with inflammatory or chronic fibrotic processes in pulmonary 
tissues from patients with sarcoidosis (Levänen et al., 2011). In contrast to 
fibrotic activity, Wnt-5a has also been shown to affect proliferation and 
apoptosis in lung-derived fibroblasts (Vuga et al., 2009). Therefore, Wnt-5a, 
rather that augmenting profibrotic gene expression might have more 
important functions in alternative biological processes. 
In addition, Wnt-5a showed no crosstalk with the canonical Wnt signalling 
pathway (Figure 4.3D, E). Unfortunately, no reliable non-canonical readouts 
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were available and therefore the ability of Wnt-5a to induce non-canonical 
Wnt signalling activity is unconfirmed, although might be indicated by Wnt-
5a-induced COL1A1 mRNA in SSc fibroblasts. 
 
As a putative Wnt signalling inhibitor, rhSFRP4 might be expected to 
function in the dampening of the agonist-induced canonical Wnt signalling 
response; however, several models of SFRP activity have been reported 
that support both additive or inhibitory functions. SFRP1 and SFRP3 can 
bind Wnt1 and XWnt8, through the NTR domain and antagonise canonical 
Wnt signalling activity in both Xenopus and medaka-fish embryos (Lopez-
Rios et al., 2008; Leyns et al., 1997; Wang et al., 1997). Furthermore, 
SFRP1/2 were found to bind to and antagonise Wnt-3a-induced β-catenin 
accumulation in L-cells (mouse fibroblasts) (Wawrzak et al., 2007). In 
contrast, another study described the promotion of Wnt:Fz complexes on 
addition of SFRP1 at concentrations between 20-200 ng/ml and therefore an 
additive effect could also be predicted (Uren et al., 2000). Respectively, 
these studies support a model where SFRPs sequester Wnt agonists and 
thereby prevent receptor activation or act to shuttle Wnt ligands to the 
frizzled receptor to elicit Wnt signalling activation. In this study, the co-
treatment of Wnt-3a or Wnt-5a with SFRP4 showed no effect on canonical 
Wnt signalling activity or profibrotic gene expression beyond those induced 
by independent Wnt-treatments and, in addition, no differential effects were 
observed between HC and SSc fibroblasts (Figure 4.2 Vs. Figure 4.3). 
Therefore, these results were not in agreement with either of the 
aforementioned standard models. Dicussed previously, Wawrzak et al. 
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demonstrated that SFRP4 could bind Wnt-3a but that this complex could not 
moderate Wnt-3a-induced β-catenin accumulation (Wawrzak et al., 2007). 
The authors suggested that these SFRPs might act as carrier proteins and 
facilitate the transport and diffusion of Wnt agonists in the tissue, which 
could explain the inactivity displayed by SFRP4 in co-treatment experiments; 
however, a complex set of experiments would need to be performed in order 
to confirm this diffusion hypothesis. 
 
In the literature, the contribution of TGFβ signalling towards profibrotic gene 
expression has already been well described. Therefore the TGFβ-induced 
upregulation of both COL1A1 and α-SMA in fibroblasts indicated the 
potential for the induction of these profibrotic genes, which demonstrated the 
low efficacy of canonical Wnt-3a-induced expression, discussed previously. 
SSc fibroblasts displayed increased basal α-SMA protein expression; 
however, protein expression was consistently unchanged compared to HC 
fibroblasts (Figure 4.4A-C). Following on from this, no spontaneous 
contraction was observed in 3D collagen gels in contrast to the contraction 
observed following TGFβ (Figure 4.4D), which suggested that increased α-
SMA expression in fibroblast does not necessarily correlate with contractile 
potential and therefore, indirectly, myofibroblast presence. More interesting 
was the observation that TGFβ treatment significantly downregulated AXIN2 
expression in both SSc and HC fibroblasts (Figure 4.4E). Contrary to 
previous reports, TGFβ did not induce canonical Wnt signalling as measured 
by TOPFlash activity (Figure 4.4F). These data indicated that TGFβ might 
crosstalk with the Wnt signalling pathway through the regulation of AXIN2 
- 115 - 
expression. On analysis of a gene profiling study evaluating of TGFβ 
responsive genes, as defined by the intrinsic dcSSc gene signature from 
Milano et al., a distinct Wnt signalling profile was not observed in dermal 
fibroblasts from dcSSc patients. However, on further inspection of the 
supplementary data, two important negative regulators of Wnt signalling 
were significantly downregulated, AXIN2 and DKK-1 (Milano et al., 2008; 
Sargent et al., 2009). This suggests that the TGFβ-mediated effects on 
canonical Wnt signalling might be as a result of crosstalk with these two 
proteins and AXIN2 expression was the subject of further investigation in this 
report. 
Previously observed, TGFβ signalling upregulated SFRP4 protein 
expression in preference to Wnt signalling and therefore SFRP4 could 
potentially be involved in the regulation of the TGFβ signalling pathway, 
independent of any effects on Wnt signalling (Figure 3.2B). In conflict with 
this hypothesis, TGFβ co-treatment with SFRP4 showed only a trend toward 
inhibition of COL1A1 expression in SSc fibroblasts and had no effect in HC 
fibroblasts; however, no protein data were available to support this 
observation (Figure 4.4A). The opposite effect was observed for α-SMA 
where TGFβ co-treatment with SFRP4 increased its expression in HC but 
not in SSc fibroblasts; however, protein expression data did not support this 
differential observation and showed no effect past that of independent TGFβ 
treatment (Figure 4.4B, C). In support of the α-SMA protein expression data, 
TGFβ co-treatment with SFRP4 showed no further contraction past that 
induced by independent TGFβ treatment in either HC or SSc fibroblasts 
(Figure 4.4D). 
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Similarly, TGFβ co-treatment with SFRP4 showed no effect upon canonical 
Wnt signalling activation beyond those observed following independent 
TGFβ treatment (Figure 4.4E, F). Therefore these data suggest that SFRP4 
does not regulate the TGFβ signalling pathway. As a further confirmation 
TGFβ signalling amplitude would need to be investigated. 
 
Finally, the independent effects of SFRP4 treatment on profibrotic gene 
expression and canonical Wnt signalling activity were evaluated in a 
comparative analysis between HC and SSc fibroblasts. Consistently, SFRP4 
treatment showed no ability to regulate canonical Wnt signalling activity, as 
measured by AXIN2 expression and TOPFlash activity (Figure 4.1D, E). 
However, the expression of COL1A1 and α-SMA profibrotic genes were 
increased by SFRP4 treatment but only in SSc fibroblasts, by 137.3% and 
167.1%, respectively (Figure 4.1A, B). This could suggest an agonistic role 
for SFRP4 in SSc fibroblasts, as has been observed for SFRP2, which was 
able to participate in a complex with fibronectin and α5β1 integrin to inhibit 
apoptotic events (Lee et al., 2004). Contrary to this prediction, the 
expression of α-SMA protein following independent SFRP4 treatment 
remained unchanged (Figure 4.1C). Taking this observation into account, 
those changes observed for COL1A1 at mRNA level, which were similar to 
those induced for α-SMA, were unlikely to be significant at protein level. 
Therefore these data do not support an agonistic role for SFRP4 in 
profibrotic gene expression. 
Overall, SSc fibroblasts displayed an increased response to canonical Wnt 
signalling activation and, at basal level, had a reduction in the expression of 
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AXIN2 compared to HC fibroblasts. In contrast to TGFβ, the canonical and 
non-canonical agonists, despite increased profibrotic gene expression, 
showed no profound increase in profibrotic fibroblast activation as 
determined by the expression of fibroblast activation marker α-SMA. In 
addition, rhSFRP4 co-treatment had no modulatory affect upon any agonist-
mediated activities and independent treatment was unable to demonstrate 
any agonistic activities. The absence of any profound effects by rhSFRP4 
could indirectly supported a model of activity whereby SFRPs might act as 
carrier proteins and facilitate the transport and diffusion of Wnt agonists in 
the tissue; however, a complex set of experiments would need to be 
performed in order to confirm this hypothesis. 
- 118 - 
5 CAV-1 expression in the reproduction of SSc 
fibroblast phenotype 
Myofibroblasts are known to be key mediators of fibrosis and are though to 
persist in fibrotic tissues, including in SSc, and cause both increased ECM 
protein deposition as well as increased contracture in tissues (Hinz et al., 
2001; Farina et al. 2009). Myofibroblasts and SSc fibroblasts have been 
described to have a reduced CAV-1 expression, a key component of the 
caveolae endocytic pathway described to negatively regulate TGFβ 
signalling activity (Guglielmo et al. 2003). As CAV-1 has been linked to the 
expression of profibrotic genes, this led to the hypothesis that CAV-1 
negative fibroblasts might reproduce the profibrotic or canonical Wnt 
signalling amplitude observed in SSc fibroblasts (Del Galdo et al., 2008; 
Tourkina et al., 2008). Determination of whether the increased canonical 
Wnt signalling in SSc fibroblasts was a consequence of CAV-1 depletion 
was primarily evaluated. 
 
5.1 Stable expression of shCAV-1 in HC fibroblasts 
In a resting population of HC fibroblasts, myofibroblasts were identified by 
immunofluorescence through the arrangement of α-SMA into stress fibers 
(green striations) (Figure 5.1A). Further, these myofibroblasts were observed 
to be CAV-1 negative in contrast to the majority of CAV-1 positive (stained 
red) undifferentiated fibroblasts (Figure 5.1A). However at basal level, SSc 
fibroblasts showed a wide variation in the level of CAV-1 expression with a 
mean reduction to 84.3% compared to HC fibroblasts (Figure 5.1B). Next, 
- 119 - 
the effect of Wnt-3a or Wnt-5a treatment on the expression of CAV-1 was 
evaluated and both ligands induced a marginal trend toward decreased 
CAV-1 expression, whereas TGFβ treatment significantly downregulated 
CAV-1 expression to 43.2% (P<0.05) or 50.4% in HC and SSc fibroblasts, 
respectively (Figure 5.1B). Consistent with this observation the protein 
expression of CAV-1 was not significantly reduced in SSc fibroblasts nor 
was there an increased expression of α-SMA when compared to HC 
fibroblasts (Figure 5.1C). 
In spite of the marginal reduction in CAV-1 expression in SSc fibroblasts, the 
hypothesis that CAV-1 negative fibroblasts may reproduce the profibrotic or 
canonical Wnt signalling amplitude observed in SSc fibroblasts was further 
investigated. HC fibroblasts were used to create stable cell lines with 
reduced CAV-1 expression. When transduced with the pGIPZ lentiviral 
vector, HC fibroblasts stably expressed either a non-targeting sequence 
(SCR) or an shRNA sequence targeted against CAV-1 (shCAV) (Figure 
5.1D). Following antibiotic selection the retention of the construct, 
expressing either the SCR or shCAV-1 sequence, within fibroblasts was 
evaluated by immunofluorescence, which showed that the construct was 
present and was integrated into all SCR / shCAV lines and all fibroblasts 
within these lines (Figure 5.1E). One SCR construct and three CAV-1 
shRNA constructs (shCAV_48, shCAV_97 and shCAV_99) were 
comparatively evaluated for an effect on CAV-1 expression. Indeed, at basal 
level CAV-1 expression was increased by 197.8% in shCAV_48 and 
reduced to 57.2% (P<0.01) and 28.7% (P<0.01) in shCAV_97 and 
shCAV_99, respectively (Figure 5.1F). 
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Similarly, the expression of CAV-1 protein was found to be significantly 
reduced in shCAV_97 and shCAV_99 constructs, but not shCAV_48, 
compared to SCR controls (Figure 5.1G). Also, the basal expression of α-
SMA and SFRP4 were assayed and were not found to be spontaneously 
affected by reduced CAV-1 expression (Figure 5.1G). Accordingly, both 
shCAV_97 and shCAV_99 constructs were utilised for further studies and 
were termed shCAV. 
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Figure 5.1 Stable expression of shCAV-1 in HC fibroblasts 
A) In resting HC fibroblasts, myofibroblasts were visualised by α-SMA stress 
fibril formation using confocal microscopy to detect fluorescence from a 
FITC-conjugated secondary antibody directed against the anti-α-SMA 
antibody (green stain), CAV-1 expression was also assessed by a CY3-
conjugated secondary targeted against the anti-CAV-1 antibody (red stain) 
and nuclei were stained with DAPI (blue stain). In both HC and SSc 
fibroblasts CAV-1 expression was determined by B) mRNA expression, 
quantified by qRT-PCR or C) protein expression determined by Western blot 
following 24 and 72 hr treatments, respectively. To determine whether 
depletion of CAV-1 could reproduce an SSc fibroblast-like phenotype, HC 
fibroblasts were transduced with D) pGIPZ lentiviral vector containing either 
a SCR or shCAV sequence. E) Stable transduction was determined 
following antibiotic selection by immunofluorescence using vector-driven 
GFP expression (green). Subsequently, CAV-1 expression was evaluated in 
fibroblasts expressing the distinct shCAV sequences (shCAV_48, shCAV_97 
or shCAV_99) through F) mRNA expression, quantified by qRT-PCR and by 
G) protein expression alongside SFRP4, α-SMA (fibroblast activation 
marker) and GAPDH (loading control), determined by Western blot. Data 
shown as mean ± SEM, n=3-4; Mann-Whitney test for unpaired samples, 
**P=0.01. 
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5.2 CAV-1 has no regulatory role in the increased SFRP4 
expression observed in SSc fibroblasts 
To determine whether depletion of CAV-1 could reproduce the increased 
SFRP4 expression observed in SSc fibroblasts either in the presence or 
absence of stimuli, stable shCAV expressing fibroblast lines were created. 
In shCAV compared to SCR fibroblasts, CAV-1 mRNA expression was 
silenced by 75.5% (P<0.0001), which was consistent with the substantial 
reduction in CAV-1 protein (Figure 5.2A, B). At basal levels, SFRP4 gene 
expression in shCAV fibroblasts was unchanged compared to SCR 
fibroblasts (Figure 5.2C). Following Wnt-3a treatment, SFRP4 expression 
was induced by 173.6% (P<0.001) and 180.3% (P<0.01) in SCR and shCAV 
fibroblasts, respectively (Figure 5.2C). Wnt-5a treatment showed no 
significant increase in SFRP4 expression, while TGFβ induced SFRP4 
expression by 207.9% (P<0.01) and 200.2% (P<0.05) in SCR and shCAV 
fibroblasts, respectively (Figure 5.2C). 
SFRP4 protein expression was unaffected by both Wnt-3a and Wnt-5a 
treatments, whereas TGFβ treatment increased SFRP4 expression in both 
SCR and shCAV fibroblasts (Figure 5.2D). No significant differences in 
SFRP4 expression could be observed at mRNA or protein level between 
SCR and shCAV fibroblasts following any treatment conditions (Figure 
5.2D). 
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Figure 5.2 CAV-1 has no regulatory role in the increased SFRP4 
expression observed in SSc fibroblasts 
SFRP4 expression was determined at basal level in SCR and shCAV 
fibroblasts by A) mRNA expression, quantified by qRT-PCR and B) protein 
expression, determined by Western blot. Fibroblasts were also treated with 
Wnt-3a (100 ng/ml), Wnt5a (100 ng/ml) or TGFβ (5 ng/ml) for 24 hr prior to 
determine any differential effects on C) SFRP4 mRNA expression following 
24 hr treatment, quantified by qRT-PCR. D) Protein expression of SFRP4 
and GAPDH (loading control) were also evaluated following 72 hr treatment, 
determined by Western blot. Data shown as mean ± SEM, n=4; Mann-
Whitney test for unpaired samples, *P=0.05, **P = 0.01, ***P=0.001, ****P = 
0.0001. 
 
5.3 CAV-1 does not augment canonical Wnt-induced 
profibrotic or canonical Wnt signalling activities 
observed in SSc fibroblasts irrespective of SFRP4 
treatment 
As CAV-1 expression in fibroblasts had been shown to negatively regulate 
profibrotic gene expression, it was determined whether in the absence of 
CAV-1 and following treatment with Wnt-3a there was i) any differential 
regulation of profibrotic gene expression and ii) any differential canonical 
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Wnt signalling activation. Also the effect of independent, or Wnt-3a co-
treatment, with SFRP4 was also investigated for modulatory effects on both 
profibrotic gene expression and canonical signalling activity. 
When profibrotic gene expression was examined, basal COL1A1 expression 
was not affected between SCR and shCAV fibroblasts. Following Wnt-3a 
treatment, COL1A1 gene expression was marginally increased by 126.9% 
(P<0.001) and 113.2% (P<0.001) in SCR and shCAV fibroblasts, 
respectively (Figure 5.3A). Wnt-3a co-treatment with SFRP4 showed no 
significant effect upon the Wnt-3a-induced increase in COL1A1 expression 
and independent SFRP4 treatment also showed no significant effect on 
expression (Figure 5.3A). 
Like COL1A1, α-SMA expression was unchanged at basal level between 
SCR and shCAV fibroblasts (Figure 5.3B). Wnt-3a treatment induced α-SMA 
expression in SCR and shCAV fibroblasts to similar levels, induced by 
187.2% (P<0.001) and 194.6% (P<0.01), respectively (Figure 5.3B). Wnt-3a 
co-treatment with SFRP4 showed no significant effect on the Wnt-3a-
induced increase in α-SMA expression in SCR fibroblasts but showed a 
trend toward increased expression in shCAV fibroblasts, 194.6%, although 
this was not found to be significant (Figure 5.3B). Independent SFRP4 
treatment also showed no effect on α-SMA expression in SCR or shCAV 
fibroblasts (Figure 5.3B). 
At protein level, CAV-1 was confirmed to be significantly downregulated in 
shCAV compared to SCR fibroblasts (Figure 5.3C). However, α-SMA 
expression, despite being increased at mRNA level, was unchanged 
- 125 - 
following Wnt-3a treatment, Wnt-3a co-treatment with SFRP4 and also 
following independent SFRP4 treatment (Figure 5.3C). 
Finally, the effect of CAV-1 expression on canonical Wnt signalling activity 
was determined and at basal level there was no change in AXIN2 
expression between SCR and shCAV fibroblasts (Figure 5.3D). Following 
Wnt-3a treatment, AXIN2 expression levels were similarly expressed by 
195.9% (P<0.0001) and 193.9% (P<0.0001) in SCR and shCAV fibroblasts, 
respectively (Figure 5.3D). Wnt-3a co-treatment with SFRP4 did not affect 
Wnt-3a-induced AXIN2 expression in either SCR or shCAV fibroblasts and 
independent SFRP4 treatment also showed no effect (Figure 5.3D). 
These data were then confirmed by TOPFlash activity. Indeed, at basal level 
there was no change in TOPFlash activity between SCR and shCAV 
fibroblasts (Figure 5.3E). Wnt-3a treatment induced TOPFlash activity by 
5.4-fold (P<0.001) in SCR and 4.5-fold (P<0.001) in shCAV fibroblasts, 
although the reduction in shCAV fibroblasts was not found to be significant 
(Figure 5.3E). Wnt-3a co-treatment with SFRP4 showed no effect on Wnt-
3a-induced TOPFlash activity and independent SFRP4 treatment also 
showed no effect in SCR or shCAV fibroblasts (Figure 5.3E). 
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Figure 5.3 CAV-1 does not augment canonical Wnt-induced profibrotic 
or canonical Wnt signalling activities observed in SSc fibroblasts 
irrespective of SFRP4 treatment 
Differential profibrotic gene expression and canonical Wnt singalling 
activation were compared between SCR and CAV-1 depleted shCAV 
fibroblasts treated with canonical agonist Wnt-3a (100 ng/ml) in the presence 
and absence of SFRP4 (70 ng/ml). The effect on profibrotic genes A) 
COL1A1 and B) α-SMA were determined following 24 hr treatment and 
quantified by qRT-PCR. C) Following 72 hr treatment, protein expression of 
α-SMA and GAPDH (loading control) were used as a confirmation of 
profibrotic activity, determined by Western blot. Canonical Wnt signalling 
activation was evaluated following 24 hr treatment by D) AXIN2 expression, 
a canonical Wnt target gene, quantified by qRT-PCR and by E) TOPFlash 
reporter activity, quantified by luciferase activity. All quantitative data were 
normalised on basal HC levels. Data shown as mean ± SEM, n=4; Mann-
Whitney test for unpaired samples, **P = 0.01, ***P=0.001, ****P = 0.0001. 
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5.4 CAV-1 does not augment non-canonical or SFRP4 
activities 
Next it was determined whether in the absence of CAV-1 i) there was an 
increased profibrotic response to non-canonical Wnt-5a treatment and ii) 
whether this could be due to crosstalk with the canonical signalling pathway. 
The effect of independent or Wnt-5a co-treatment with SFRP4 was also 
investigated for modulatory effects on both profibrotic gene expression and 
canonical signalling activity. 
When profibrotic gene expression was examined, Wnt-5a treatment and 
Wnt-5a co-treatment with SFRP4 showed no effect on COL1A1 expression 
in either SCR or shCAV fibroblasts (Figure 5.4A). In contrast, Wnt-5a 
induced α-SMA expression by 122.6% (P<0.001) in SCR and 141.0% 
(P<0.05) in shCAV fibroblasts, which was found to be significantly different 
between SCR and shCAV fibroblasts (P<0.05) (Figure 5.4A). 
Wnt-5a co-treatment with SFRP4 showed a trend toward increased α-SMA 
expression in SCR fibroblasts, increased to 139.0%, and in shCAV 
fibroblasts, increased to 168.3% (Figure 5.4B). The difference in α-SMA 
expression following Wnt-5a co-treatment with SFRP4 was found to be 
significantly increased in shCAV fibroblasts compared to SCR fibroblasts 
(Figure 5.4B). 
At protein level and consistent with mRNA data, α-SMA expression was 
unchanged at basal level (Figure 5.4C). However, Wnt-5a treatment or Wnt-
5a co-treatment with SFRP4, despite being increased at mRNA level, 
showed no effect on the expression of α-SMA in both SCR and shCAV 
fibroblasts (Figure 5.4C). 
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Next the effect of CAV-1 expression on canonical Wnt signalling activity was 
determined under the same conditions. AXIN2 expression was unaffected by 
Wnt-5a treatment in SCR fibroblasts, whereas expression was decreased to 
75.6% (P<0.01) in shCAV fibroblasts (Figure 5.4D). Wnt-5a co-treatment 
with SFRP4 reduced AXIN2 expression to 84.1% in HC fibroblasts but had 
no effect in shCAV fibroblasts compared to Wnt-5a treatment alone (Figure 
5.4D). However, no significant increase in TOPFlash activity was observed 
following Wnt-5a treatment in both SCR and shCAV fibroblasts (Figure 
5.4E). Furthermore, Wnt-5a co-treatment with SFRP4 also showed no effect 
on Wnt-5a-induced TOPFlash activity in HC fibroblasts but was increased by 
1.6-fold in shCAV fibroblasts, although this was not found to be significant 
(Figure 5.4E). 
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Figure 5.4 CAV-1 does not augment non-canonical or SFRP4 activities 
Differential profibrotic gene expression and canonical Wnt singalling 
activation were compared between SCR and CAV-1 depleted shCAV 
fibroblasts treated with non-canonical agonist Wnt-5a (100 ng/ml) in the 
presence and absence of SFRP4 (70 ng/ml). The effect on profibrotic genes 
A) COL1A1 and B) α-SMA were determined following 24 hr treatment and 
quantified by qRT-PCR. C) Following 72 hr treatment, protein expression of 
α-SMA and GAPDH (loading control) were used as a confirmation of 
profibrotic activity, determined by Western blot. Canonical Wnt signalling 
activation was evaluated following 24 hr treatment by D) AXIN2 expression, 
a canonical Wnt target gene, quantified by qRT-PCR and by E) TOPFlash 
reporter activity, quantified by luciferase activity. All quantitative data were 
normalised on basal HC levels. Data shown as mean ± SEM, n=4; Mann-
Whitney test for unpaired samples, *P=0.05, **P = 0.01, ***P=0.001, ****P = 
0.0001. 
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5.5 CAV-1 does not regulate TGFβ-mediated profibrotic 
gene expression or canonical Wnt signalling activity 
irrespective of SFRP4 treatment 
Next, it was determined whether TGFβ treatment in the absence of CAV-1 i) 
increased profibrotic gene expression and ii) modulated TGFβ-induced 
effects on canonical Wnt signalling activity. The effect of independent or 
TGFβ co-treatment with SFRP4 was also investigated for modulatory effects 
on both profibrotic gene expression and canonical signalling activity. 
TGFβ induced a similar increase in COL1A1 expression in SCR and shCAV 
fibroblasts by 230.3% (p<0.001) and 282.0% (p<0.01), respectively (Figure 
5.5A). TGFβ co-treatment with SFRP4 showed a trend toward a reduction in 
COL1A1 expression by 186.7% in SCR and 210.9% in shCAV fibroblasts 
(Figure 5.5A). α-SMA expression was also induced following TGFβ 
treatment by 1067.0% (P<0.0001) and 1646.6% (P<0.01) in SCR and 
shCAV fibroblasts, respectively (Figure 5.5B). TGFβ co-treatment with 
SFRP4 showed an increase in the expression of α-SMA by 2030.2% in SCR 
fibroblasts, which was not found to be statistically significant, and no 
additional induction was observed in shCAV fibroblasts (Figure 5.5B). 
Next, canonical Wnt signalling activity was determined in relation to CAV-1 
expression. At basal level, AXIN2 expression was unchanged between SCR 
and shCAV fibroblasts and following TGFβ treatment AXIN2 expression was 
reduced to 47.6% (P<0.0001) and 38.8% (P<0.0001) in SCR and shCAV 
fibroblasts, respectively (Figure 5.5C). TGFβ co-treatment with SFRP4 did 
not affect the TGFβ-induced downregulation of AXIN2 (Figure 5.5C). In 
support of these data, TOPFlash activity was not significantly induced by 
TGFβ or affected by TGFβ co-treatment with SFRP4 in both SCR and 
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shCAV fibroblasts (Figure 5.5D). 
 
Figure 5.5 CAV-1 does not regulate TGFβ-mediated profibrotic gene 
expression or canonical Wnt signalling activity irrespective of 
SFRP4 treatment 
Differential profibrotic gene expression and canonical Wnt singalling 
activation were compared between SCR and CAV-1 depleted shCAV 
fibroblasts treated with TGFβ (5 ng/ml) in the presence and absence of 
SFRP4 (70 ng/ml). The effect on profibrotic genes A) COL1A1 and B) α-
SMA were determined following 24 hr treatment and quantified by qRT-PCR. 
C) Following 72 hr treatment, protein expression of α-SMA and GAPDH 
(loading control) were used as a confirmation of profibrotic activity, 
determined by Western blot. Canonical Wnt signalling activation was 
evaluated following 24 hr treatment by D) AXIN2 expression, a canonical 
Wnt target gene, quantified by qRT-PCR and by E) TOPFlash reporter 
activity, quantified by luciferase activity. All quantitative data were 
normalised on basal HC levels. Data shown as mean ± SEM, n=4; Mann-
Whitney test for unpaired samples, **P = 0.01, ***P=0.001, ****P = 0.0001. 
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5.6 DISCUSSION: CAV-1 expression in the reproduction of 
SSc fibroblast phenotype 
CAV-1 is downregulated in SSc patient fibroblasts and its expression has 
been shown to be important in regulating profibrotic gene expression, 
including collagen and α-SMA, through the inhibition of caveolae-mediated 
negative regulation of TGFβ signalling (Guglielmo et al., 2003; Del Galdo et 
al., 2008; Tourkina et al., 2008). In this study, myofibroblasts were identified, 
by immunofluorescence, through their arrangement of α-SMA into stress 
fibers and were confirmed to have a low expression of CAV-1 in contrast to 
the majority of fibroblasts that were CAV-1 positive (Figure 5.1A). 
Myofibroblasts are known to be key mediators of fibrosis and are though to 
persist in fibrotic tissues, including in SSc, and cause both increased ECM 
protein deposition as well as increased contracture in tissues (Hinz et al., 
2001; Farina et al. 2009). Therefore, this led to the hypothesis that CAV-1 
negative fibroblasts might reproduce elements of the SSc fibroblast 
phenotype, which might overlap with the profibrotic myofibroblast phenotype. 
In this study, CAV-1 expression in SSc fibroblasts varied greatly, which 
could be due to dilution of myofibroblasts relative to the total SSc fibroblast 
population (Figure 5.1C). 
TGFβ-mediated a substantial decrease in the expression of CAV-1 in 
contrast to Wnt-3a treatment, which indicated that any differential effects 
mediated by CAV-1 expression would likely be as a result of TGFβ rather 
than canonical Wnt signalling (Figure 5.1B). 
To examine whether the increased SFRP4 expression, profibrotic gene 
expression and/or canonical Wnt signalling amplitude observed in SSc 
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fibroblasts could be regulated by CAV-1 expression, stable primary fibroblast 
lines were expressing either shRNA targeted against CAV-1 or a SCR 
sequence were created. Of the shCAV-1 expressing primary fibroblast lines, 
shCAV_97 and shCAV_99 showed a markedly reduced expression of CAV-
1 compared to SCR fibroblasts (Figure 5.1F, G). This observation was found 
to be greater several passages after successful transduction and can be 
observed at protein level in the successive data sets. 
 
First, the stable shCAV-1 expressing fibroblast lines were utilised to 
determine whether CAV-1 depleted fibroblasts could reproduce the 
increased expression of SFRP4 observed in SSc fibroblasts. Despite a 
profound reduction in CAV-1 protein expression, no spontaneous increase 
SFRP4 expression was observed nor was there any differential expression 
in response to Wnt-3a, Wnt-5a or TGFβ treatments compared to SCR 
fibroblasts. Therefore the increased expression of SFRP4 in both SSc and 
HC fibroblasts following TGFβ and canonical Wnt signalling was 
independent of CAV-1 regulation. 
 
Next, in the absence of CAV-1 the effects of Wnt-3a, Wnt-5a and TGFβ were 
readdressed to determine any similarity with the differential responses 
observed in SSc compared to HC fibroblasts. 
The first hypothesis investigated was whether CAV-1 negative fibroblasts 
might reproduce the Wnt-3a-induced increase in profibrotic gene expression 
and canonical Wnt signalling activation observed in SSc fibroblasts. In the 
absence of CAV-1, the Wnt-3a-induced effects on profibrotic gene 
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expression and canonical signalling activation were highly similar to those of 
SCR fibroblasts, which indicated that CAV-1 expression was not responsible 
for either the increased profibrotic gene expression or canonical signalling 
activation observed in SSc fibroblasts (Figure 4.1A-E Vs. Figure 5.3A-E). 
Furthermore, the reduced expression of AXIN2 in SSc fibroblasts was also 
found to be independent of CAV-1 expression (Figure 4.1D Vs. Figure 5.3D). 
These data were in contrast to a previous studies that showed that β-catenin 
was recruited to the cell membrane through the overexpression of CAV-1 
thereby preventing canonical signalling induced by either Wnt-1 or β-catenin 
overexpression in NIH-3T3 fibroblasts (Galbiati et al., 2000). Similarly, β-
catenin accumulation and Wnt signalling amplitude were positively regulated 
by the CAV-1-dependent internalisation of LRP6 in HEK293, HeLaS3 or 
CHO cells (Yamamoto et al., 2006).  
 
Similarly, non-canonical Wnt-5a-induced activities were evaluated for 
differential responses following CAV-1 depletion. In contrast to SSc 
fibroblasts, COL1A1 in was not induced by Wnt-5a or SFRP4, which initially 
suggested that CAV-1 was required for the elicited activity in SSc fibroblasts, 
although protein confirmation would be required (Figure 4.3A Vs. Figure 
5.4A). Also, the expression of α-SMA was marginally increased; however, no 
effect on protein expression was observed (Figure 5.4B, C). Therefore the 
lack of any effect on α-SMA protein expression likely reflects the magnitude 
of effect upon collagen protein expression. This would therefore support the 
inference that CAV-1 did not regulate a differential Wnt-5a-induced 
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profibrotic effect in agreement with the lack of a differential effect between 
SSc and HC fibroblasts (Figure 4.3A-C). 
Arguably, canonical Wnt signalling was also unaffected by Wnt-5a treatment 
in the absence of CAV-1 (Figure 5.4D, E). While AXIN2 expression was 
decreased by Wnt-5a treatment, the relatively small 24.4% reduction was 
unlikely to be observable at protein level (Figure 5.4D). Although unlikely, 
these data could suggest that in the absence of CAV-1, Wnt-5a-induced 
non-canonical signalling could partially reproduce the decreased AXIN2 
expression observed in SSc fibroblasts (Figure 4.2D Vs. Figure 5.4D). To 
test this hypothesis further, non-canonical pathway activation would first 
need to be confirmed. 
 
In addition to Wnt signalling, the effects of CAV-1 depletion upon TGFβ-
induced signalling activities were also evaluated. In the absence of CAV-1, 
TGFβ treatment showed no differential expression of both COL1A1 and α-
SMA profibrotic genes compared to SCR fibroblasts (Figure 5.5A, B). This 
was not in agreement with several reports using siRNA mediated down-
regulation of CAV-1, which have shown that the TGFβ-induced expression of 
α-SMA, collagen type I and fibronectin was enhanced in silenced cells 
(Wang et al., 2006; Del Galdo., 2008). Although siRNA technology has been 
considerably improved in recent years, the expression of these genes could 
be as a result of siRNA-mediated off-target effects. Further, these could lead 
to activation of as Toll-like receptors (TLR) 7/8, which recognise pathogen 
associated molecular proteins like single stranded RNA and lead to the 
upregulation of pro-inflammatory and interferon gene expression. By using 
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the endogenous cellular processing machinery, optimised shRNAmir 
constructs allow for sustainable gene silencing using low concentrations that 
have less chance of mediating off-target effects (Rao et al., 2009). One 
contrasting study, utilising an shRNA approach, showed that xenografts in 
nude mice, that were established by injection of either WT or shCAV1 
neonatal dermal fibroblasts along with B16F10 melanoma cells, showed that 
while there was an increased tumor growth in shCAV xenografts, the 
intratumoral collagen deposition was unchanged in B16F10/shCAV1 
compared to B16F10/WT tumors (Capozza et al., 2012). Although Del Galdo 
et al., showed that CAV-1 null fibroblasts explanted from mice showed 
increased COL1A1 and α-SMA production, this could be attributed to the 
global deletion of CAV-1 in all cell types and the resultant environment the 
fibroblasts are exposed to prior to in vitro culture (Del Galdo et al., 2008). 
 
Canonical signalling activity was subsequently evaluated following CAV-1 
depletion, which showed no effect on basal AXIN2 expression, in contrast to 
the reduction in SSc fibroblasts, or TOPFlash activity (Figure 5.5C, D). 
Therefore the TGFβ-induced downregulation of AXIN2 expression, observed 
in both HC and SSc fibroblasts, was independent of CAV-1 regulation, which 
is potently downregulated by TGFβ. Indeed, this reduced expression of 
AXIN2, a regulatory component of Wnt signalling, could be an important 
factor contributing toward the increased canonical Wnt signalling amplitude 
observed in SSc fibroblasts. 
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Next, CAV-1 regulatory effects upon Wnt/TGFβ co-treatment with SFRP4 
were evaluated for completeness to determine any differential activities. 
In the absence of CAV-1, co-treatment of Wnt-3a or Wnt-5a with SFRP4 
showed no further effect beyond that of HC fibroblasts for both profibrotic 
gene expression and canonical Wnt signalling activity under the same 
experimental conditions (Figure 4.2 Vs. Figure 5.3 & Figure 4.3 Vs. Figure 
5.4, respectively). Comparative analysis showed that TGFβ co-treatment 
with SFRP4 had no differential effect on COL1A1 expression in the absence 
of CAV-1, although protein data were unavailable to support this observation 
(Figure 5.5A). In the absence of CAV-1, the expression pattern for α-SMA 
was highly similar to that of SSc fibroblasts, which showed no increase in 
expression compared to HC fibroblasts; however, those data were also 
concluded to be inconsequential on analysis of protein expression (Figure 
4.4B Vs. Figure 5.5B). Finally, both measures of canonical Wnt signalling 
activation showed no further effect following co-treatment with SFRP4 
beyond that of independent TGFβ treatment (Figure 4.4E, F). These results 
suggest that CAV-1 does not differentially regulate rhSFRP4 activty to 
facilitate the increased profibrotic gene expression or increased canonical 
Wnt signalling activity observed in SSc fibroblasts following Wnt/TGFβ 
treatments. 
 
Finally, the independent effects of rhSFRP4 treatment on profibrotic gene 
expression and canonical Wnt signalling activity were evaluated in the 
presence and absence of CAV-1. In SSc fibroblasts, the increased 
expression of COL1A1 and α-SMA observed following SFRP4 treatment was 
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not observed in the absence of CAV-1, which could suggest that this is 
regulated independently of CAV-1 (Figure 4.2A, B Vs. Figure 5.3A, B); 
however, these increases at mRNA level were unlikely to influence protein 
expression as has been observed on several occasions with relation to α-
SMA expression. Finally, the absence of any SFRP4-induced effect on 
canonical Wnt signalling activity was maintained following the depletion of 
CAV-1 (Figure 4.2D, E Vs. Figure 5.3D, E). 
 
Overall, the prediction that CAV-1 expression might reproduce the increased 
canonical Wnt signalling response was not supported. Additionally, CAV-1 
showed no regulatory activity on profibrotic fibroblast activation, as 
determined by the expression of fibroblast activation marker α-SMA, or 
canonical signalling activity at both basal levels and in response to 
TGFβ/Wnt agonists. Similarly, rhSFRP4 co-treatments and independent 
rhSFRP4 treatments also showed no differential activities. The subsequent 
focus of this study was to determine the mechanism behind the increased 
canonical Wnt signalling response observed in SSc fibroblasts and to 
determine the consequence, if any, on profibrotic fibroblast activation.  
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6 Crosstalk between the TGFβ and Canonical 
Wnt signalling pathways 
As previously discussed, characteristically, fibrosis develops through the 
sustained activation of fibroblasts by factors including cytokines, growth 
factors and angiogenic factors present in the microenvironment (Varga & 
Pasche 2009; Kim et al., 2011). Activation of the TGFβ and Wnt/β-catenin 
signalling pathways have both been linked to the pathogenesis of tissue 
fibrosis in SSc (Beyer et al., 2012; Wei et al., 2011). While the level of 
crosstalk between the pathways is considered to be significant it is relatively 
under described. Principally, the increased canonical Wnt signalling 
response displayed by SSc fibroblasts might in fact be regulated by crosstalk 
between the TGFβ and Wnt and signalling pathways. 
 
6.1 SSc fibroblasts display increased canonical Wnt/β-
catenin signalling and a reduction in AXIN2 expression 
Characteristically, fibrosis develops through the sustained activation of 
fibroblasts and several studies have shown that β-catenin might be a central 
mediator shown in both SSc patients and experimental models of fibrosis 
(Beyer et al., 2012; Wei et al., 2012). One possibility was the potential for 
explanted SSc fibroblasts, from dcSSc patients, to self-activate through 
autocrine signalling and induce the canonical Wnt signalling pathway 
independent of the tissue microenvironment. In order to determine this, 
TOPFlash reporter activity was used to evaluate canonical β-catenin-
activated TCF/LEF transcription. When compared to HC fibroblasts, SSc 
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fibroblasts showed no significant difference in the basal level of TOPFlash 
activity (Figure 6.1A). Next, TOPFlash assays were performed to see 
whether SSc fibroblasts displayed an increased response to canonical Wnt 
activation compared to HC fibroblasts. SSc fibroblasts displayed an 
increased response to canonical Wnt activation compared to HC fibroblasts, 
displaying 9.8-fold increase in TOPFlash activity following stimulation with 
Wnt-3a, which was significantly higher than the 4.8-fold increase observed in 
HC fibroblasts (P<0.01) (Figure 6.1A). Consistent with this, Wnt-3a-induced 
a 5.0-fold increase in AXIN2 mRNA expression in SSc fibroblasts compared 
to the 1.8-fold increase in HC fibroblasts (P<0.001) (Figure 6.1B). 
Interestingly, the basal expression of AXIN2 expression in SSc fibroblasts 
was reduced to 52% of HC fibroblasts (P<0.01) (Figure 6.1B). Although SSc 
fibroblasts were unavailable for comparative analysis, HC fibroblasts showed 
a time-dependent increase in Wnt-3a-induced β-catenin nuclear localisation, 
most abundant at 240 and 360 min (Figure 6.1D). 
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Figure 6.1 SSc fibroblasts display increased canonical Wnt/β-catenin 
signalling and a reduction in AXIN2 expression 
Differential canonical Wnt signalling activity was determined in additional HC 
and SSc fibroblasts. A) Fibroblasts were transfected with the TOPFlash 
reporter and following 24 hr treatment with Wnt-3a (100ng/ml) canonical Wnt 
signalling activity was determined by luciferase activity. B) HC fibroblasts 
were treated with Wnt-3a (100ng/ml) for 24 hr or for 0-360 min and AXIN2 
expression determined, quantified by qRT-PCR or C) Wnt-induced β-catenin 
localisation was determined by immunofluorescence using a CY3-
conjugated secondary (grey) directed against anti-β-catenin antibody 
(magnification 200X). Data shown as mean ± SEM, n=3-5; Mann-Whitney 
test for unpaired samples, **P=0.01, ****P=0.0001. 
 
6.2 TGFβ signalling reproduces the reduced expression of 
AXIN2 observed in SSc fibroblasts 
TGFβ plays a pivotal role in tissue homeostasis and numerous studies have 
demonstrated the TGFβ-induced profibrotic effects of TGFβ both in vitro and 
in vivo, which reproduce many of the hallmarks of fibrosis observed in SSc 
(Leask & Abraham, 2004; Wynn, 2008; Varga & Pasche, 2009). Increased 
TGFβ signalling has been proposed in SSc fibroblasts and at the very least a 
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subset of SSc patients display a TGFβ-regulated gene expression signature 
(Asano et al., 2005; Mimura et al., 2005; Milano et al., 2008; Sargent et al., 
2009). Therefore to determine whether the observed reduction of AXIN2 in 
SSc fibroblasts was TGFβ-responsive, HC fibroblasts were treated with 
recombinant TGFβ and the effect upon AXIN2 expression and Wnt signalling 
activity were evaluated. 
TGFβ-stimulated HC fibroblasts showed a 51% reduction in the expression 
of AXIN2 expression at 24 hr (P<0.0001), which was equivalent to the basal 
level of AXIN2 expression in SSc fibroblasts, 52% of HC levels (Figure 
6.2A). Nevertheless these SSc fibroblasts showed a further reduction of 
AXIN2 expression to 20% of HC levels in the presence of TGFβ (P<0.01) 
(Figure 6.2A). Concordantly, AXIN2 protein expression in HC fibroblasts was 
significantly reduced following TGFβ treatment, which was again equivalent 
to the expression of AXIN2 in untreated SSc fibroblasts (Figure 6.2B). 
To check whether TGFβ could induce canonical activation the level of 
TOPFlash activity was determined. Interestingly, TGFβ reduced the basal 
level of TOPFlash activity in HC fibroblasts by 0.6-fold and this was similar to 
the 0.3-fold reduction in SSc fibroblasts (Figure 6.2C). 
As TGFβ was unable to induce TOPFlash activity, the nuclear localisation of 
β-catenin was evaluated following TGFβ or Wnt-3a treatment. Despite no 
meaningful depletion of β-catenin in the cytosolic fraction and in contrast to 
TOPFlash reporter data, TGFβ induced a notable increase in the nuclear 
fraction at 240 min and 360 min post-treatment, similar to the levels induced 
by Wnt-3a at 360 min, used as positive control (Figure 6.2D). The TGFβ-
induced nuclear localisation of β-catenin was validated by 
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immunofluorescence of HC fibroblasts. Similar to the nuclear/cytosolic 
fractionation data, β-catenin was clearly distributed around the nucleus at 
240 and 360 min following TGFβ treatment, although the majority of β-
catenin was still observed to be membrane associated (Figure 6.2E). 
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Figure 6.2 TGFβ signalling reproduces the reduced expression of 
AXIN2 observed in SSc fibroblasts 
Comparative analysis between HC and SSc fibroblasts was used to 
determine whether AXIN2 expression was TGFβ-responsive. A) AXIN2 
expression was evaluated after stimulation with TGFβ (5ng/ml) for 24 hr, 
quantified by qRT-PCR or B) AXIN2, α-SMA (+ve) and GAPDH (loading 
control) protein expression were determined in treated HC and in resting HC 
and SSc fibroblasts. C) HC and SSc fibroblasts were transfected with the 
TOPFlash reporter and canonical signalling activity quantified by luciferase 
activity under the same treatment conditions. D) In HC fibroblasts, 
cytosolic/nuclear β-catenin localisation was determined following TGFβ 
(5ng/ml) treatment for 0-360 min by Western blot or E) β-catenin localisation 
as determined by immunofluorescence using a CY3-conjugated secondary 
(grey) against anti-β-catenin (200X magnification). Data shown as mean ± 
SEM, n=3-5; Mann-Whitney test for unpaired samples, **P=0.01, 
****P=0.0001. 
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6.3 TβRIIΔk-fib transgenic mice exhibit fibrosis and a 
reduction in Axin-2 positive nuclei 
To evaluate in vivo, whether the downregulation of AXIN2 expression was a 
consequence of TGFβ signalling the TβRIIΔk-fib mouse mode was utilised, 
which demonstrate a ligand-independent and fibroblast-specific constitutive 
activation of the TGFβ signalling pathway that can ultimately lead to the 
development of fibrotic tissue involvement in a proportion of these mice. 
In fact, DNA microarray analysis between WT mice treated with TGFβ and 
the TβRIIΔk-fib mouse model were found to be highly similar (Denton et al. 
2003; Sonnylal et al. 2007). Consistent with previously published data, 6-8 
weeks old TβRIIΔk-fib mice showed a significant increase in dermal 
thickness and loss of subcutaneous fat compared to WT (Figure 6.3B). Also, 
Massons Trichrome staining of the tissues showed a significant increase in 
the amount of collagen deposited in the dermis in TβRIIΔk-fib mouse tissue 
(Figure 6.3C). Immunohistochemistry staining of the same biopsies showed 
a decreased number of Axin-2 positive nuclei present in the dermis of 
TβRIIΔk-fib tissue compared to WT (white arrows depicting negative nuclei), 
but this was not absolute (Figure 6.3D). Counts of Axin-2 positive nuclei 
revealed that TβRIIΔk-fib tissue showed a 28% reduction compared to WT 
tissues (Figure 6.3E). 
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Figure 6.3 TβRIIΔk-fib transgenic mice exhibit fibrosis and a reduction 
in Axin-2 positive nuclei 
Fibrosis and Axin-2 expression were compared between TβRIIΔk-fib 
transgenic mice, with fibroblast-specific constitutive activation of TGFβ 
signalling, and age-matched WT littermates. A) Schematic representation of 
the TβRII kinase-deficient transgene construct (TβRIIΔk-fib), regulated by a 
fragment of the Col1a2 enhancer (–19.5 to –13.5 kb) fused with a minimal 
Col1a2 promoter that also directs expression to the fibroblast lineage. B) 
Dermal fibrosis was evaluated by the distance between the muscle and 
epidermal boundary and by C) collagen deposition as determined by 
Masson’s trichrome staining. D) In the same skin biopsies from B and C, 
Axin-2 expression was evaluated by immunohistochemistry (stained brown), 
where positive and negative nuclei are highlighted with red and white 
arrows, respectively. E) Counts of Axin-2 positive nuclei were taken from the 
same biopsies as D. Original magnification 400X. Data shown as mean ± 
SEM, n=3. 
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6.4 TGFβ priming of fibroblasts reproduces the increased 
canonical Wnt signalling response observed in SSc 
fibroblasts independent of Wnt secretion 
One possible consequence of the decreased AXIN2 expression observed in 
SSc fibroblasts, which was also observed following TGFβ stimulation of HC 
fibroblasts, would be a reduced ability to negatively regulate β-catenin-
mediated activity. Therefore, to determine whether the TGFβ-mediated 
downregulation of AXIN2 expression was responsible for the increased 
sensitivity of fibroblasts to canonical Wnt ligands, sequential stimulation 
experiments were performed in which HC fibroblasts were incubated first 
with TGFβ (TGFβ priming) and then subsequently treated with Wnt-3a. 
TGFβ-primed fibroblasts showed a 3.1-fold increase in TOPFlash activity 
compared to fibroblasts treated with Wnt-3a alone (P<0.01) (Figure 6.4A). 
Interestingly, this was equivalent to the enhanced response to canonical Wnt 
signalling observed in SSc fibroblasts, which showed a 3.8-fold increase in 
TOPFlash activity compared to HC fibroblasts (P<0.05) (Figure 6.4B). 
Subsequently, the maximum increase in TOPFlash activity following TGFβ 
priming was investigated. While the effect of TGFβ priming on TOPFlash 
activity was observable within 2 hr by 1.6-fold, this was increased over time 
to 2.0-fold and 2.5-fold at 4 and 6 hr, respectively (Figure 6.4C). However, 
maximal effects were observed following 24 hr treatment and were sustained 
at 48 and 72 hr increased by 4.0-fold, 4.3-fold and 4.1-fold, respectively 
(Figure 6.4D). 
Therefore, the effect of 24 hr TGFβ priming upon AXIN2 expression was 
subsequently evaluated. As expected, Wnt-3a treatment increased AXIN2 
expression by 287.2% in contrast to the reduction to 48.0% following TGFβ 
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treatment (Figure 6.4E). In TGFβ-primed fibroblasts, Wnt-3a induced a 
247.1% increase in AXIN2 expression, which was comparable to that 
observed following treatment with Wnt-3a alone. (Figure 6.4E). This effect 
was confirmed at protein level where TGFβ-primed fibroblasts showed 
increased expression of AXIN2 comparable to that induced by Wnt-3a 
treatment alone (Figure 6.4F). Consistent with previous observations TGFβ 
treatment alone induced a reduction of AXIN2 both at RNA and protein 
levels (Figure 6.4E-F). 
In order to determine whether the increased canonical Wnt signalling 
observed in TGFβ-primed fibroblasts was a direct effect of an increase in 
nuclear β-catenin, nuclear localisation experiments were performed. 
Nuclear β-catenin was increased in TGFβ-primed fibroblasts treated with 
Wnt-3a; however, the levels were equivalent to TGFβ treatment alone 
(Figure 6.4G). These levels were much higher than those observed following 
Wnt-3a treatment alone (Figure 6.4G). Consistently, no depletion of β-
catenin in the cytosolic cellular fraction was observed (Figure 6.4G). In 
contrast, a concomitant reduction of SMAD3, a positive control for TGFβ-
induced activity, was evident in cytosolic fraction and was increased in the 
nuclear fraction for both (Figure 6.4G). 
To determine whether TGFβ-induced β-catenin nuclear localisation was 
dependent on the expression/secretion of canonical Wnt ligands and 
ultimately a consequence of increased Wnt-induced signalling, blockade of 
Wnt secretion was utilised. This was achieved using the inhibitor of Wnt 
Production-2 (IWP-2) to block the palmitoylation of intracellular Wnt proteins, 
thereby reducing their solubility and preventing their subsequent secretion. 
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Concurrent with previous data, TGFβ treatment did not significantly deplete 
the cytosolic fraction; however, a significant increase in nuclear β-catenin 
was observed and was unchanged in the presence of IWP-2 at 
concentrations of 200nM, 1.0 µM (5.0-fold excess) and also at 2 µM (10.0-
fold excess) (Figure 6.4H). 
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Figure 6.4 TGFβ priming of fibroblasts reproduces the increased 
canonical Wnt signalling response observed in SSc fibroblasts 
independent of Wnt secretion 
TGFβ-primed fibroblasts were compared against HC counterparts to 
determine whether TGFβ could reproduce the increased sensitivity observed 
in SSc fibroblasts. A) HC fibroblasts were transfected with the TOPFlash 
reporter and treated with (primed) or without TGFβ (5 ng/ml) for 24 hr, 
followed by Wnt-3a treatment (100 ng/ml) for 24 hr before TOPFlash activity 
was quantified by luciferase activity. B) The relative amplitude in canonical 
Wnt signalling activity between SSc and HC fibroblasts was determined by 
TOPFlash activity following Wnt-3a treatment for 24 hr. TOPFlash activity 
was measured relative to Wnt-3a-treated HC fibroblasts, set to 1-fold (100% 
activation). C-D) As in A, but TGFβ treatment was carried out for 2-72 hr 
prior to Wnt-3a treatment. E) Under the same experimental condition in A, 
the effects on AXIN2 expression, quantified by qRT-PCR. F) As in A, where 
Wnt-3a treatment was carried out for 72 hr prior to determination of AXIN2, 
α-SMA (+ve) and GAPDH (loading control) protein expression by Western 
blot. G) Cytosolic/nuclear localisation of β-catenin and SMAD3 (+ve) were 
determined by Western blot following 240 min TGFβ treatment. H) TGFβ-
mediated β-catenin nuclear localisation was determined following IWP-2-
mediated inhibition of Wnt secretion, incubated 1 hr prior to 240 min TGFβ 
treatment. Data shown as mean ± SEM, n=3-5; Mann-Whitney test for 
unpaired samples, *P=0.05, **P=0.01, ***P=0.001, ****P=0.0001. 
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6.5 AXIN2 silencing reproduces the increased canonical Wnt 
signalling response observed in TGFβ-primed 
fibroblasts 
Since TGFβ has a multitude of intracellular targets, to determine whether the 
observed downregulation of AXIN2 was sufficient to explain the increased 
responsiveness of fibroblasts to canonical Wnt-induced signalling AXIN2 
expression was downregulated by siRNA. 
First, control siRNA conjugated to AlexaFluor-488 was transfected into HC 
fibroblasts and used to determine the transfection efficiency by 
immunofluorescent visualisation across a 10-40 nM concentrations (Sup 
Figure 10.1). At an oligonucleotide concentration of 20nM, transfection 
efficiency was deemed to be optimal and was therefore utilised in all further 
transfection experiments (Figure 6.5A). 
Next, HC fibroblasts were transfected with either AXIN2-specific siRNA 
(siAXIN2) or scramble control oligonucleotide (SCR). A 48% reduction in 
AXIN2 expression was achieved in siAXIN2 compared to SCR fibroblasts 
(P<0.05) (Figure 6.5B). Similar results were also observed at protein level, 
where AXIN2 expression was significantly downregulated at 48 and 72 hr 
post-transfection, while the expression of AXIN1 remained unaffected 
(Figure 6.5C). 
Next, canonical Wnt signalling amplitude was evaluated in siAXIN2 
fibroblasts treated with Wnt-3a, and normalised relative to treated SCR 
fibroblasts. Wnt-3a treatment increased TOPFlash activity in siAXIN2 
fibroblasts 5.9-fold more than in SCR-treated fibroblasts (P<0.05) (Figure 
6.5D). 
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Of note, Wnt-3a treatment of untransfected HC fibroblasts induced an 
increase in TOPFlash activity equivalent to the level induced in SCR 
fibroblasts (Figure 6.5D). 
Parallel experiments determined whether a reduction in AXIN2 expression 
could modulate TOPFlash activity in response to TGFβ. In siAXIN2 
fibroblasts a 0.7-fold decrease in TOPFlash activity was observed compared 
to SCR controls; however, the response to TGFβ in siAXIN2 fibroblasts was 
similar to that observed in SCR fibroblasts decreased to 0.4-fold and 0.6-
fold, respectively (Figure 6.5E). 
Finally, to determine whether AXIN2 expression was involved in the 
regulation of TGFβ signalling activity, total TGFβ reporter activity was 
evaluated in siAXIN2 fibroblasts. While no spontaneous increase in TGFβ 
activity was observed in siAXIN2 fibroblasts, a 2.0-fold increase in TGFβ 
reporter activity was observed following Wnt-3a treatment, which was 
greater than the 1.4-fold increase observed in SCR fibroblasts (Figure 6.5F). 
- 153 - 
 
Figure 6.5 AXIN2 silencing reproduces the increased canonical Wnt 
signalling response observed in TGFβ-primed fibroblasts 
AXIN2 depletion was used to determine wether TGFβ-mediated AXIN2 
downregulation was sufficient for the increased canonical Wnt signalling 
amplitude observed in TGFβ-primed fibroblasts. A) HC fibroblasts were 
transfected with negative control siRNA coupled to AlexaFluor488 (green) 
and transfection efficiency was determined visually by immunofluorescence. 
B) HC fibroblasts were either transfected with scrambled (SCR) or AXIN2-
specific siRNA (siAXIN2) for 72 hr and AXIN2 mRNA expression was 
quantified by qRT-PCR or C) protein expression of AXIN1, AXIN2 and 
GAPDH (loading control) were determined following 48-72 hr transfection by 
Western blot. D) HC fibroblasts were transfected with TOPFlash reporter 24 
hr prior to transfection with AXIN2 or SCR siRNA for 72 hr. Subsequently, 
cells were treated with or without Wnt-3a for a further 24 hr and canonical 
signalling activation determined by luciferase activity relative to Wnt-3a-
treated SCR fibroblasts; set to 1-fold (100% activation). E) As in D, where 
Wnt-3a was substituted for TGFβ. TGFβ signalling activity was subsequently 
evaluated in HC fibroblasts by F) transfection with p3TP-Lux reporter (Total 
TGFβ activity) 24 hr prior to transfection with siAXIN2 or SCR siRNA for 72 
hr. Subsequently, cells were treated with or without Wnt-3a for a 24 hr and 
TGFβ signalling activity was evaluated by luciferase activity relative to SCR 
fibroblasts. Data shown as mean ± SEM, n=3-5; Mann-Whitney test for 
unpaired samples *P=0.05. 
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6.6 AXIN2 has a greater effect than AXIN1 upon canonical 
Wnt signalling amplitude 
AXIN1 shares 45% amino acid sequence homology to AXIN2 and is also 
important in the formation and function of the β-catenin destruction complex 
(Chia & Costantini 2005). However, functional studies have also 
demonstrated their activities may not be entirely redundant (Lammi et al. 
2004). Therefore the relative contribution of AXIN1, compared to AXIN2, 
towards the regulation of canonical Wnt signalling amplitude was 
investigated. 
First, the expression of AXIN1 in HC fibroblasts was examined following 
TGFβ treatment and was downregulated to 80.2% and 66.9% at 48 and 72 
hr, respectively (Figure 6.6A). This was significantly less than the TGFβ-
mediated downregulation of AXIN2, reduced to 60.7% as soon as 10 min 
(Figure 7.1B). Importantly, despite a slight downregulation at mRNA level, 
TGFβ treatment did not alter the protein expression of AXIN1 up to 72 hr 
later (Figure 6.6B). 
Despite this, parallel experiments were conducted to determine the relative 
role of AXIN1 expression in the regulation of canonical Wnt signalling 
amplitude. Here, HC fibroblasts were transfected with siRNA targeted 
against AXIN1 (siAXIN1) or SCR oligonucleotide. A significant 
downregulation of AXIN1 expression was observed in siAXIN1 fibroblasts 
compared to SCR (Figure 6.6C). Next, canonical signalling was then 
evaluated in siAXIN1 fibroblasts by TOPFlash activity. Following Wnt-3a 
treatement TOPFlash activity was increased by 1.9-fold in siAXIN1 
compared to Wnt-3a treated SCR fibroblasts (P<0.05) (Figure 6.6D). Overall, 
AXIN1 depletion displayed an increase in canonical Wnt activity that was 
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4.0-fold less than that observed in siAXIN2 fibroblasts (Figure 6.6D vs. 
Figure 6.5D). 
Similar experiments investigated whether a reduction in AXIN1 expression 
could modulate TOPFlash activity in response to TGFβ. Indeed, siAXIN1 
fibroblasts showed a 0.7-fold decrease in TOPFlash activity compared to 
SCR controls (Figure 6.6E). In the presence of TGFβ, both siAXIN1 and 
SCR fibroblasts showed no significant change in TOPFlash activity, 0.7-fold 
and 1.0-fold, respectively (Figure 6.6E). 
Next, to determine the effect of AXIN1 expression on the amplitude of the 
TGFβ signalling pathway, this was evaluated using the p3TP-lux reporter, 
which measured total TGFβ signalling activity. While in siAXIN1 fibroblasts 
basal TGFβ signalling activity was reduced by 0.3-fold, a 1.3-fold and 1.4-
fold increase was observed following TGFβ treatment in siAXIN1 and SCR 
fibroblasts, respectively (Figure 6.6F). 
- 156 - 
 
Figure 6.6 AXIN2 has a greater effect than AXIN1 upon canonical Wnt 
signalling amplitude 
The contribution of AXIN1 relative to AXIN2 in the regulation of canonical 
Wnt signalling was evaluated. A) HC fibroblasts were treated with TGFβ for 
24-48 hr and AXIN1 expression quantified by qRT-PCR or B) TGFβ treated 
for 48-72 hr prior to determination of AXIN1 and GAPDH (+ve) protein 
expression by Western blot. C) HC fibroblasts were transfected with 
scrambled (SCR) or AXIN1-specific siRNA (siAXIN1) for 72 hr and AXIN1, 
AXIN2 (-ve) and GAPDH (loading control) protein expression determined by 
Western blot. D) HC fibroblasts were transfected with TOPFlash reporter 24 
hr prior to transfection with siAXIN1 or SCR for 72 hr. Subsequently, cells 
were treated with or without Wnt-3a for 24 hr and canonical Wnt signalling 
activation was evaluated by TOPFlash activity, determined by luciferase 
activity relative to Wnt3-a-treated SCR fibroblasts; set to 1-fold (100% 
activation). Next, TGFβ activity was evaluated. E) As in D, where Wnt-3a 
was substituted for TGFβ. TGFβ signalling activity was subsequently 
evaluated in HC fibroblasts by F) transfection with p3TP-Lux reporter (Total 
TGFβ activity) 24 hr prior to transfection with siAXIN2 or SCR siRNA for 72 
hr. Subsequently, cells were treated with or without Wnt-3a for a 24 hr and 
TGFβ signalling activity was evaluated by luciferase activity relative to SCR 
fibroblasts. Data shown as mean ± SEM, n=3-5; Mann-Whitney test for 
unpaired samples *P=0.05. 
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6.7 Stabilisation of AXIN can inhibit the increased canonical 
signalling observed in TGFβ-primed fibroblasts 
As AXIN2 negatively regulated the amplitude of canonical Wnt signalling it 
was important to validate whether the increased canonical Wnt signalling 
response induced in TGFβ-primed fibroblasts was a specific effect of AXIN2 
downregulation. Therefore, the bioavailability of AXIN2 protein was 
increased in fibroblasts through the stabilisation of AXIN protein expression 
using a small molecule inhibitor, XAV-939, which has been shown to protect 
AXIN from proteasomal degradation (Huang et al. 2009). 
The ability of XAV-939 to protect AXIN2 protein from proteolytic degradation 
was evaluated. HC fibroblasts were treated with XAV-939 and a step-wise 
increase in the level of AXIN2 protein expressed was observed across a 
dose range of 0.3-10.0 µM (Figure 6.7A). Next, the concentration at which 
XAV-939 conferred protective activity in the presence of TGFβ was 
determined. The expression of AXIN2 remained stable in the presence of 
TGFβ when treated with XAV-939 across a dose range of 1.0-10.0 µM 
(Figure 6.7B). Consistent with the known role of AXIN2, in the presence of 
XAV-939, the Wnt-3a-induced increase in TOPFlash activity was by 0.6-fold, 
0.5-fold or 0.5-fold at 10.0, 3.0 and 1.0 µM of XAV-939, respectively (Figure 
6.7C). This validated the ability of XAV-939 to regulate the amplitude of 
canonical Wnt signalling through AXIN stabilisation. 
 
Subsequently, XAV-939 was used to determine the relative role of AXIN2 
downregulation towards the increased amplitude of canonical Wnt signalling 
observed in TGFβ primed fibroblasts or whether other TGFβ targets 
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mediated this activity. Consistent with previous data, Wnt-3a treatment of 
TGFβ-primed fibroblasts showed a 2.1-fold increase in TOPFlash activity 
compared to HC fibroblasts (P<0.05) (Figure 6.7C). This increase in TGFβ-
primed fibroblasts was reduced in the presence of XAV-939 and equivalent 
to the total Wnt-3a-induced activation observed in HC fibroblasts, reduced to 
to 0.9-fold, 0.9-fold or 1.0-fold at 10.0 µM, 3.0 µM and 1.0 µM, respectively 
(P<0.05) (Figure 6.7C). 
 
 
Figure 6.7 Stabilisation of AXIN can inhibit the increased amplitude of 
canonical signalling observed in TGFβ-primed fibroblasts 
A) In HC fibroblasts, AXIN stabilisation was determined following XAV-939 
treatment (1.0-10.0 µM for 24 hr and AXIN2 and GAPDH (loading control) 
protein expression were determined by Western blot. B) AXIN stability was 
evaluated in the presence of TGFβ treatment (5 ng/ml) and protein 
expression of AXIN2 and GAPDH (loading control) were determined by 
Western blot. C) To determine if AXIN stabilisation was sufficient to ablate 
the TGFβ-mediated increase in canonical Wnt signalling, HC fibroblasts 
were transfected with the TOPFlash reporter for 24 hr then treated with 
TGFβ (primed) or left untreated for 24 hr. Subsequently, fibroblasts were 
treated with or without XAV-939 (1.0-10.0 µM) 1 hr prior to Wnt-3a treatment 
(100ng/ml) for a further 24 hr prior to the determination of TOPFlash activity, 
quantified by luciferase activity. Data shown as mean ± SEM, n=3-5; Mann-
Whitney test for unpaired samples *P=0.05, ****P=0.0001. 
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6.8 DISCUSSION: Crosstalk between the TGFβ and 
Canonical Wnt signalling pathways 
Having previously demonstrated that SSc fibroblasts had an exaggerated 
canonical Wnt signalling response to canonical Wnt-3a treatment (Figure 
4.2D, E), a further series of experiments in different SSc and HC patients 
reconfirmed these observations (Figure 6.1A). Consistently, SSc fibroblasts 
had a reduced basal expression of AXIN2 and, following Wnt-3a treatment, a 
concomitant increase in canonical Wnt signalling (Figure 6.1B). These data 
indicated that explanted SSc fibroblasts, under basal conditions, do not 
display an autonomous increase in canonical Wnt signalling and instead 
imply that these fibroblasts are primed to respond to canonical Wnt agonist. 
This extends upon previous studies that support the role of differential Wnt 
ligand expression in the increased activation of the canonical Wnt signalling 
pathway (Akhmetshina et al., 2012; Beyer et al., 2012; Wei et al., 2012). 
Indeed, the increased canonical Wnt signalling activation consistently 
observed in SSc skin biopsies (nuclear β-catenin staining) may be as a 
consequence of both of these factors working in parallel. 
Due to the limited availability of samples from SSc patients, a direct 
comparison, between β-catenin translocation in SSc and HC fibroblasts, to 
determine the differential effects upon the kinetics and integrated density of 
fluorescence could not be performed. However, immunofluorescence data 
from HC fibroblasts showed a distinct nuclear β-catenin localisation following 
Wnt-3a treatment, which supported the methodology and analysis of 
TOPFlash reporter data (Figure 6.1C). This data also showed that while 
Wnt-induced β-catenin translocation localised around the nucleus, an en 
masse translocation was not observed, similar to other studies that also 
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showed an unremarkable translocation pattern in fibroblasts (Carthy et al. 
2011; Wei et al. 2012; Akhmetshina et al. 2012). Indeed it has long been 
know that β-catenin can interact with the cytoplasmic tails of cadherins and 
participate in cell adhesion processes, therefore, aside from a critical role in 
TCF/LEF-mediated transcriptional activation, β-catenin might also play a 
wider role in regulating other biological mechanisms (Ko et al., 2001; Luo & 
Lin 2004). 
 
In SSc, the link between TGFβ signalling in the activation and differentiation 
of fibroblasts is well described and its involvement in the pathogenesis of 
tissue fibrosis compelling (Varga & Pasche 2009). Of note was the fact that 
a key gene profiling study evaluating TGFβ responsive genes intrinsic to the 
dcSSc subset, did not display a distinct Wnt signalling profile in dcSSc 
patients dermal fibroblasts (Milano et al., 2008; Sargent et al., 2009). 
However, on further inspection of the supplementary data, two important 
negative regulators of Wnt signalling were significantly downregulated, 
namely AXIN2 and DKK-1, which could explain the reduced expression of 
AXIN2 in SSc fibroblasts observed previously (Figure 6.1B). Therefore, the 
effect of TGFβ signalling upon the expression of AXIN2 was evaluated by 
comparative analysis of SSc and HC fibroblasts. In support of the gene 
profiling study, TGFβ induced a significant downregulation of AXIN2 
expression in HC fibroblasts, which was equivalent to the basal levels 
expressed in SSc fibroblasts (Figure 6.2A, B). These data could support an 
autocrine or constitutive TGFβ signalling activity within explanted SSc 
fibroblasts. Additionally, TGFβ signalling has recently been described to 
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influence canonical Wnt signalling activation in fibroblasts, through 
downregulation of the Wnt antagonist DKK-1 (Akhmetshina et al., 2012). 
One important contrast with the previous study was a consistent absence of 
TOPFlash reporter induction in fibroblasts following TGFβ treatment (Figure 
6.2C). In support of our results, two seminal papers identified the 
mechanism by which the TGFβ pathway can influence canonical Wnt 
signalling amplitude. The homeobox twin (Xtwn) gene, similar to AXIN2, was 
identified as a direct Wnt-responsive target that was under the control of the 
LEF1 transcription factor in Xenopus (Laurent et al., 1997). Differential 
analysis of Xtwn and the TOPFlash reporter constructs found that the former 
was TGFβ responsive while the later was not (Labbe et al., 2000; Nishita et 
al., 2000). This was found to be dependent on the presence of SBEs, 
located in the Xtwn promoter that were absent in the TOPFlash reporter, but 
which could be made TGFβ-inducible by the inclusion of SBE upstream of 
the TCF/LEF consensus sequences (Labbe et al., 2000; Nishita et al., 2000). 
Labbe et al., also concluded that TGFβ-dependent activation of LEF1 target 
could be independent of β-catenin; however, reinterpreting these data, β-
catenin was essential as its loss significantly affected the induction of the 
promoter system by approximately 362% (Labbe et al., 2000). Together, 
these data indicate the critical nature of β-catenin in canonical (β-catenin-
mediated) Wnt signalling and the further augmentation that can result from 
the presence of SBEs within the promoter sequences of a subset of 
canonical target genes. 
Paradoxically, TGFβ, like Wnt-3a, induced β-catenin nuclear translocation in 
HC fibroblasts in contrast to the absence of TOPFlash activity (Figure 6.2C 
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Vs. D). Furthermore, this translocation was subsequently confirmed by β-
catenin immunofluorescence data (Figure 6.2E). Again, due to the lack of 
patient samples experiments could not be carried out to confirm whether the 
effects observed in HC fibroblasts were similar to SSc fibroblasts and this 
represents a limitation of the analysis. These conflicting data would need to 
be resolved and promoter analysis of genes known to be upregulated by 
canonical Wnt signalling would be a logical first step. Although AXIN2 is a 
direct Wnt-induced target other targets would need to be included due to the 
effect of TGFβ upon AXIN2 expression. Overall, whether TGFβ-induced 
nuclear β-catenin translocation takes part in TCF/LEF mediated canonical 
Wnt signalling is debatable. 
Like HC fibroblasts, TGFβ treatment also reduced AXIN2 expression levels 
in SSc fibroblasts (Figure 6.2A). Explanted fibroblasts from the TβIIΔk-fib 
transgenic model, which have a constitutive and fibroblast-specific activation 
of TGFβ signalling, do display increased activation of TGFβ signalling 
pathways; however, these fibroblasts were also refractory to further TGFβ 
treatment (Denton et al. 2003). Together, these data would indicate that 
explanted SSc patient fibroblasts are not refractory to TGFβ treatment and 
therefore constitutive TGFβ signalling might not be a characteristic. This 
adds to a body of evidence that is already conflicting on the role of autocrine 
TGFβ signalling within SSc fibroblasts (Desmoulière et al. 1993; Kubo et al. 
2002; Ihn et al. 2001; Gabbiani 2003; Asano et al. 2011; Ho et al. 2014). 
 
Since TGFβ was discovered to mediate the downregulation of AXIN2 
expression in HC fibroblasts in vitro, this was subsequently validated in vivo 
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using the TβRIIΔk-fib mouse model, described previously. This model 
displayed evidence of fibrosis through increased dermal thickness, loss of 
subcutaneous fat and increased collagen deposition, which were consistent 
with the literature (Figure 6.3A-C) (Denton et al. 2003). Specifically, Axin-2 
positive nuclei for were reduced in the dermal tissues of this model but the 
reduction was not absolute, which might be a consequence of the ECM 
(Figure 6.3D, E). The ECM regulated the distribution of cytokines, growth 
factors and angiogenic factors, as well as providing biochemical and 
biomechanical cues to the cells it contacts, including fibroblasts (Kim et al. 
2011). Consequently, the absence of complete Axin-2 repression could be 
as a result of spatiotemporal Wnt release from the ECM, which would either 
restore or increase Axin-2 expression at those sites. In fact, in the human 
TGFβ-primed fibroblast model, discussed later as a surrogate of the SSc 
fibroblast canonical Wnt signalling phenotype, AXIN2 expression could be 
restored following canonical Wnt treatment (Figure 6.4E, F). Nonetheless, 
the fact that more Axin-2 negative nuclei were present in this model 
ultimately supports the hypothesis that TGFβ signalling mediates the 
downregulation of AXIN2 expression in fibroblasts, which might also be 
important in the profibrotic activation of fibroblasts and hence the 
pathogenesis of tissue fibrosis. 
 
AXIN2 plays an essential role in regulating the activity of the canonical Wnt 
pathway; acting as a critical scaffold protein required for the formation of the 
β-catenin destruction complex, which is responsible for facilitating ubiquitin-
mediated β-catenin proteosomal degradation (Sakanaka et al., 1998; Salic et 
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al., 2000; Liu et al., 2002). Thus, the reduction of AXIN2 expression 
observed in SSc fibroblasts could facilitate their increased canonical Wnt 
signalling response through suboptimal destruction complex assembly and 
this might also be perpetuated by aberrant TGFβ signalling activity. 
Indeed, HC fibroblasts primed with TGFβ and subsequently treated with a 
canonical Wnt agonist could reproduce both the reduced expression of 
AXIN2 and the increased amplitude of canonical Wnt signalling observed of 
SSc fibroblasts (Figure 6.4A). The canonical Wnt signalling amplitude 
displayed by TGFβ-primed fibroblasts, following canonical Wnt agonist 
treatment, was equivalent to that of SSc fibroblasts in the absence of TGFβ-
priming (Figure 6.4A, B). Further analysis revealed that the TGFβ-mediated 
downregulation of AXIN2 might be a transient event as canonical Wnt 
signalling activity significantly upregulated its expression (Figure 6.4E, F). 
Therefore a mechanism must be in place to sustain the reduced AXIN2 
expression in SSc fibroblasts, which could involve autocrine/constitutive 
TGFβ signalling, a long-described if controversial characteristic of SSc 
fibroblasts (Desmoulière et al. 1993; Gabbiani 2003; Ho et al. 2014). 
Consistent with previous data, TGFβ induced nuclear translocation of β-
catenin and this was equivalent in TGFβ-primed fibroblasts (Figure 6.4G). 
Canonical Wnt treatment induced nuclear translocation that was on average 
less than that induced by TGFβ, which could indicate a reduced recombinant 
protein activity. In addition, the ability of TGFβ to induce β-catenin nuclear 
translocation could be attributed to an elevation in Wnt secretion; however, 
there are sparse protein data available to confirm this postulated activity 
(Chong et al., 2009). Opposing this hypothesis was the absence of 
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TOPFlash activation following TGFβ treatment, which would be predicted to 
be induced by the release of canonical Wnt ligands. To further examine this, 
Wnt secretion was blocked using a small molecule inhibitor, IWP-2, to 
inactivate porcupine (PORCN), which mediates the required parmitolylation 
of Wnts to facilitate their secretion (Gao & Hannoush 2014). Interestingly, 
TGFβ could still mediate β-catenin nuclear translocation independent of Wnt 
secretion (Figure 6.4H). 
These data indicate that the increased canonical Wnt signalling response in 
TGFβ-primed fibroblasts was not as a result of an increased nuclear 
translocation of β-catenin or caused by an increase in Wnt secretion. Indeed, 
canonical Wnt-3a treatment had a clear and consistent affect on TOPFlash 
reporter activity while TGFβ showed no activation, which would suggest that 
TGFβ- and Wnt-3a-induced signalling could utilise β-catenin in a divergent 
manner (discussed further on Page 232). Overall, these data further 
supported the hypothesis that TGFβ-primed fibroblasts, like SSc fibroblasts, 
have an increased responsiveness to canonical Wnt ligands. This increased 
responsiveness could be as a result of a downregulated AXIN2 expression 
and was therefore the subject of further evaluation in this study. 
 
As TGFβ signalling downregulated AXIN2 expression but also regulates a 
multitude of intracellular targets, siRNA-mediated AXIN2 downregulation 
was employed to determine whether this was sufficient to explain the 
increased responsiveness of TGFβ-primed fibroblasts to canonical Wnt-
induced signalling (Figure 6.1A). Following the depletion of AXIN2 
expression, the canonical Wnt signalling response was significantly 
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increased to levels that were equivalent to those observed in both the TGFβ-
primed fibroblast model and ultimately in SSc fibroblasts (Figure 6.5A-D; 
Figure 6.4A; Figure 6.1A). This was in further support of the hypothesis that 
the downregulation of AXIN2 was sufficient to reproduce the increased 
canonical Wnt signalling amplitude observe in SSc fibroblasts, independent 
of other TGFβ-mediated activities. 
In parallel, the absence of TOPFlash activity following TGFβ treatment was 
not affected by AXIN2 depletion activity (Figure 6.5E). 
Furthermore, AXIN2 depletion was also used to evaluate whether Wnt-
induced canonical Wnt signalling could affect total TGFβ signalling activity. 
This was performed due to the conflicting literature on role of AXIN in the 
regulation of TGFβ signalling activity. For example, AXIN expression can 
positively regulate TGFβ signalling, negatively regulate TGFβ signalling by 
destabilising SMAD3, but has also been observed to positively regulate 
TGFβ signalling by facilitating the ubiquitin-mediated degradation of SMAD7; 
an endogenous inhibitor of the TGFβ signalling pathway (Koinuma., 2003; 
Wei et al. 2006; Dao et al., 2007). Interestingly, AXIN2 depleted fibroblasts 
showed a 30% increase in total TGFβ activity, which suggested that the 
TGFβ-mediated downregulation of AXIN2 might also act to augment the 
Wnt-induced TGFβ signalling response (Figure 6.5F). In support of this, a 
previous study found that Wnt-3a could induce phosphorylation of SMAD3 in 
fibroblasts, which could be prevented by the pre-incubation with a 
neutralising anti-TGFβ1 antibody (Wei et al. 2012). However, as the TGFβ 
reporter assay was not as robust as the TOPFlash assay, more replicates 
would be required for this preliminary data to achieve significance. 
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Nevertheless, this represents another element of crosstalk between the Wnt 
and TGFβ pathways, where AXIN2 expression can act in a reciprocal 
manner. 
The increased canonical Wnt signalling amplitude in TGFβ-primed 
fibroblasts mediated by AXIN2 downregulation, could have also be as a 
result of an effect on AXIN1, which shares 45% amino acid sequence 
identity to AXIN2, and is also important in the formation and function of the 
β-catenin destruction complex (Chia & Costantini 2005). However, functional 
studies have demonstrated that their activities may not be entirely 
redundant. Therefore the relative contribution of AXIN1 to the increased 
canonical signalling amplitude inducible in TGFβ-primed fibroblasts was 
investigated. 
Notably, while TGFβ treatment affected the expression of AXIN1 at 
transcriptional level it was not observed at translational level (Figure 6.6A, 
B). This would support the supposition that AXIN2 is the more important 
dynamically regulated TGFβ-responsive target, which is supported by its 
downregulation in a previously discussed gene profiling study in dcSSc 
fibroblasts (Milano et al., 2008; Sargent et al., 2009). 
Despite this, the evaluation of the relative contribution AXIN1 in the 
regulation of canonical Wnt signalling amplitude was continued. The specific 
depletion of AXIN1 expression could regulate canonical Wnt signalling 
amplitude (Figure 6.6C, D); however, this increased amplitude was 4.0-fold 
lower compared with AXIN2 depletion experiments (Figure 6.6D Vs. Figure 
6.5D). These results suggest that in the TGFβ-primed fibroblast model, 
AXIN2 is dynamically regulated by TGFβ signalling and therefore plays an 
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critical role in regulating canonical Wnt signalling amplitude in preference to 
AXIN1. 
In addition, like AXIN2, the absence of TGFβ-inducible TOPFlash activity 
was not affected by AXIN1 depletion activity (Figure 6.6E). 
Finally, the requirement of AXIN1 expression in the regulation of TGFβ 
signalling activity was determined by total TGFβ reporter activity within 
siAXIN1 fibroblasts. Consistent with AXIN2 depletion, AXIN1 depletion had 
no additional effect on TGFβ signalling amplitude (Figure 6.6F Vs. 8.3A). 
These data supported the independent role of AXIN2 as the critical regulator 
of canonical Wnt signalling amplitude in response to TGFβ priming. 
 
As a reciprocal method to determine the necessity of TGFβ-mediated AXIN2 
downregulation for the increased canonical Wnt signalling amplification in 
fibroblasts, XAV939-mediated inhibition of AXIN proteosomal degradation 
was employed (Huang et al., 2009). Accordingly, at basal levels, XAV-939 
protected the expression of AXIN2, leading to an increase in expression 
(Figure 6.7A, B). As expected, XAV-939 inhibited the canonical Wnt 
signalling response in HC fibroblasts (Figure 6.7C). Moreover, the 
hyperactivation of canonical Wnt signalling observed in TGFβ-primed 
fibroblasts was inhibited by AXIN stabilisation and was restored to levels that 
were equivalent to activated HC fibroblasts (Figure 6.7C). This evidence 
suggested that AXIN2 is a critical mediator of canonical Wnt signalling 
hyperactivation, although other factors likely contribute to the complete 
inhibition of β-catenin-mediated activity. 
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Overall, this supports the hypothesis that TGFβ-induced downregulation of 
AXIN2 expression is a critical mechanism that regulates the increased 
canonical Wnt signalling amplitude observed in both the TGFβ-primed and 
AXIN2 depletion models, but this could not be subsequently confirmed in 
SSc fibroblasts due to limited availability (Figure 6.4A & Figure 6.5D, 
respectively). Furthermore, these data extend upon the previously discussed 
hypothesis, that the increased canonical Wnt signalling observed in 
fibroblasts resident in SSc patient skin goes beyond the differential 
expression of Wnt ligands (Akhmetshina et al., 2012; Beyer et al., 2012; Wei 
et al., 2012). Instead, these data strongly implied that increased Wnt/β-
catenin activation observed in SSc fibroblasts could also be a consequence 
of TGFβ-priming. Indeed, the increased canonical Wnt signalling activation 
that is consistently observed in SSc skin biopsies (by nuclear β-catenin 
staining) may be as a consequence of both of these factors working in 
parallel. 
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7 TGFβ-mediated regulation of AXIN2 
expression: Determining a mechanism 
The TGFβ-mediated downregulation of AXIN2 in HC fibroblasts was 
sufficient to reproduce an equivalent increase in canonical Wnt signalling 
response characteristic of SSc fibroblasts. However, the initial mechanism 
by which TGFβ induced this downregulation was subsequently investigated 
in a continuation of these experiments. Hence, the kinetics of AXIN2 
downregulation were determined alongside reciprocal TβRI blockade. 
Subsequent analysis of key TβR protein kinase signalling intermediates, in 
addition to ARE binding proteins, were evaluated for potential transcriptional 
and post-transcriptional effects upon AXIN2 expression, respectively. 
 
7.1 TGFβ-mediated downregulation of AXIN2 is initially 
mediated by mRNA degradation 
First the dose effect and subsequently the kinetics of TGFβ-mediated AXIN2 
downregulation were initially determined. TGFβ mediated a dose-dependent 
reduction in the AXIN2 expression by 87.8%, 46.8% and 51.3% at 1.0, 5.0 
(maximal effect) and 10 ng/ml, respectively (Figure 7.1A). This was 
subsequently found to be time-dependent as TGFβ mediated a reduction in 
AXIN2 expression to 60.7%, 54.5%, 45.7%, 41.1% and 38.0% at 10, 30, 60, 
120 and 240 min, respectively (P<0.05) (Figure 7.1B). Further, TGFβ-
mediated a longitudinal downregulation with transcriptional expression 
reduced to 33.3%, 39.6% and 38.7% at 24, 48 and 72 hr, respectively 
(P<0.05) (Figure 7.1C). 
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At protein level, TGFβ was able to reduce AXIN2 expression as soon as 2 hr 
following stimulation, which was reduced further by 4 and 6 hr (Figure 7.1D). 
Also, TGFβ showed a longitudinal repression of AXIN2 at a period of 48 and 
72 hr (Figure 7.1E). Interestingly, blockade of de novo protein synthesis 
achieved by cycloheximide treatment showed depletion of AXIN2 expression 
within 2 hr (Figure 7.1F). These data indicated that the expression of AXIN2 
protein was dynamically regulated and this could be achieved by either a 
transcriptional or post-transcriptional mechanism. 
While the intrinsic and TGFβ-mediated turnover of AXIN2 protein was a 
potential regulatory mechanism, the rapid downregulation of AXIN2 
expression with a 10 min period of TGFβ treatment suggested either an 
affect on transcription or an early post-transcriptional mechanism. Therefore, 
blockade of de novo transcription was used to determine the half-life of 
AXIN2 mRNA. These experiments showed that the half-life of AXIN2 mRNA 
was 109 min, whereas in the presence of TGFβ this decreased to 26 min, 
which equated to a 4.2-fold increase in the rate of mRNA decay (Figure 
7.1G) (P<0.01). This indicated that TGFβ could play a role in the regulation 
of mRNA stability. 
To determine whether TGFβ could regulate the transcription of AXIN2 in 
parallel to its effects on mRNA stability, the effect on the AXIN2 primary 
transcript was evaluated. Initially, TGFβ induced an increase in the 
expression of the AXIN2 primary transcript by 126.9% and 199.6% at 10 
(P<0.001) and 30 min (P<0.05), respectively (Figure 7.1H). At periods 
greater than this, TGFβ reduced AXIN2 primary transcript expression to 
82.9%, 55.8% or 49.4% at 60, 120 and 240 min, respectively (P<0.05) 
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(Figure 7.1H). This was in contrast to the mature transcript that was 
downregulated across the same time periods (Figure 7.1B). These data 
indicated that regulation of AXIN2 by TGFβ involved both mRNA decay and, 
at later time points, transcription. 
Additionally, the increase in the expression of a second messenger of TGFβ 
signalling, CTGF, was used as a positive control for TGFβ activity. In 
general, TGFβ showed a time-dependent increase in the expression of the 
CTGF mature transcript, an initial decrease in expression was observed at 
10 and 30 min of 43.2% and 71.4% that was significantly increased at 60, 
120 and 240 min by 151.1%, 434.8% and 456.1%, respectively (P<0.05) 
(Figure 7.1I). 
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Figure 7.1 TGFβ-mediated downregulation of AXIN2 is initially 
mediated by mRNA degradation 
The kinetics of TGFβ-mediated AXIN2 downregulation were initially 
determined in HC fibroblasts A) Fibroblasts were treated with TGFβ (1.0-
10.0 ng/ml) for 24 hr and AXIN2 mRNA was quantified by qRT-PCR. B) HC 
fibroblasts were treated with 5 ng/ml TGFβ (maximal effect) for 10-240 min 
or C) 24-72 hr and AXIN2 mRNA quantified by qRT-PCR. D) Protein 
expression of AXIN2, AXIN1 and GAPDH (loading control) following 2-6 hr 
TGFβ treatment or E) 24-72 hr treatment were determined by Western blot. 
F) AXIN2 protein turnover was determined by cycloheximide treatment (100 
ug/ml) for 2-6 hr and subsequent determination of AXIN2 and GAPDH 
(loading control) expression by Western blot. G) AXIN2 half-life was also 
evaluated by treatment with or without TGFβ for 10-120 minutes in the 
presence of actinomycin D (1 µg/ml) and AXIN2 expression was quantified 
by qRT-PCR. The transcriptional effects of TGFβ were determined by TGFβ 
treatment for 0-120 min and the effect on H) AXIN2 primary transcript, using 
primers spanning the intron-exon 3 boundary (see chapter 2.12), and I) 
CTGF mRNA expression (+ve) were quantified by qRT-PCR. Data shown as 
mean ± SEM, n=3-8; Mann-Whitney test for unpaired samples *P=0.05, 
**P=0.01, ***P=0.001. 
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7.2 TβRI kinase blockade prevents the TGFβ-mediated 
downregulation of AXIN2 
To determine whether the TGFβ-induced downregulation of AXIN2 was a 
direct effect of TβRI activation, experiments were performed in HC 
fibroblasts in the presence of the TβRI-kinase inhibitor, SD-208, which has 
been shown to selectively antagonise TβRI-induced signalling (Uhl 2004). 
Consistent with our previous data, TGFβ signalling reduced the expression 
of AXIN2 to 36.0% (P<0.05) at 24 hr. On the contrary, in the presence of SD-
208 AXIN2 expression remained at 94.0% of control levels following TGFβ 
treatment (Figure 7.2A). Similarly, the expression of DKK-1 was 
downregulated by TGFβ to 43.8% and partially prevented in the presence of 
SD-208, reduced to only 77.3% (P<0.05) (Figure 7.2B). As a positive control 
for the activity of SD-208, the TGFβ-induced expression of α-SMA and ET-1 
expression were evaluated as a known target of TβRI-induced signalling. As 
expected, inhibition of TβRI-induced signalling by SD-208 signalling 
prevented the 510% induction of α-SMA expression, reducing it to 97.7% 
compared to controls (P<0.05) (Figure 7.2C). Similarly, TβRI-induced ET-1 
expression was significantly inhibited reduced from 525.7% to 117.4% in the 
presence of SD-208 (Figure 7.2D). 
At protein level, HC fibroblasts treated with TGFβ showed a significant 
downregulation in the expression of AXIN2 and a concomitant increase in 
the expression of α-SMA at both 48 and 72 hr (Figure 7.2E). In line with 
mRNA data, the blockade of TβRI signalling prevented the TGFβ-induced 
downregulation of AXIN2 and also prevented the upregulation of α-SMA 
expression at both 48 and 72 hr (Figure 7.2E). 
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Figure 7.2 TβRI kinase blockade prevents the TGFβ-mediated 
downregulation of AXIN2 
HC fibroblasts were treated with the TβRI kinase inhibitor SD-208 (1 µM) for 
1 hr prior to 24 hr TGFβ treatment. The effect on A) AXIN2 mRNA 
expression as well as positive control genes B) DKK-1 C) α-SMA and D) ET-
1 were quantified by qRT-PCR. E) Following TGFβ treatment for 48 and 72 
hr, AXIN2 protein expression together with α-SMA (+ve) and GAPDH 
(loading control) were determined by Western blot. Data shown as mean ± 
SEM, n=3-4; Mann-Whitney test for unpaired samples *P=0.05. 
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7.3 TβRI kinase blockade can increase AXIN2 expression in 
SSc fibroblasts 
Next, preliminary data were obtained to investigate whether the decreased 
expression of AXIN2 in SSc fibroblasts could be a consequence of self-
activation of the TGFβ signalling pathway. 
Therefore, TβRI signalling was inhibited in SSc fibroblasts using the 
validated SD-208 inhibitor. The blockade of TβRI signalling by SD-208 
increased the expression of AXIN2 by 16.7% and 22.6% at 1.0 and 3.0 µM, 
respectively (P<0.05) (Figure 7.3A). Also, the expression of DKK-1 was 
increased by 37.0% and 72.7% at 1.0 and 3.0 µM, respectively (Figure 
7.3B). As positive controls, the expression of two known TGFβ-mediated 
profibrotic genes were evaluated. As anticipated, SD-208 inhibited α-SMA 
expression to 73.0% and 78.5% at 1.0 and 3.0 µM, respectively (Figure 
7.3C). Inhibition was also observed for COL1A1 expression, which was 
reduced to 53.5% and 58.2% at 1.0 and 3.0 µM, respectively (P<0.05) 
(Figure 7.3D). 
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Figure 7.3 TβRI kinase inhibition can increase AXIN2 expression in SSc 
fibroblasts 
Basal SSc patient fibroblasts were treated with the TβRI kinase inhibitor SD-
208 (1 or 3 µM) for 48 hr and the effect on A) AXIN2 mRNA expression as 
well as other TGFβ-responsive genes B) DKK-1 C) α-SMA and D) COL1A1 
were quantified by qRT-PCR. Data shown as mean ± SEM, n=4; Wilcoxon 
test for paired samples *P=0.05. 
 
7.4 SMAD3 does not mediate the TGFβ-induced 
downregulation of AXIN2 
In the TGFβ signalling pathway, the activation of TβRI recruits and 
phosphorylates two important signalling mediators SMAD2 and SMAD3, 
which are known to be critical to fibrotic gene activation in fibroblasts. 
However, as SMAD3 is a known transcriptional component, able to interact 
with those genes that contain SBE within their promoters and therefore 
might be have a functional role in the TGFβ-mediated downregulation of 
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AXIN2 expression. To test this hypothesis, SIS3, a selective inhibitor of 
SMAD3 phosphorylation, was used to prevent the activation of SMAD3 and 
any associated activities. 
First, the independent treatment of HC fibroblasts with SIS3 showed a dose-
dependent inhibition of AXIN2 expression, reduced to 62.1%, 80.0% and 
95.5% at 10.0, 3.0 and 1.0 µM, respectively (Figure 7.4A). However, light 
microscopy showed that at 10.0 µM SIS3 there was a significant alteration in 
cell morphology, which consistently lead to cell detachment and was 
therefore excluded from the dose series (data not shown). Next, the effects 
of SMAD3 inhibition on TGFβ-mediated gene expression was evaluated, 
specifically with respect to AXIN2 expression. 
Consistent with all other experiments, TGFβ-mediated a 41.8% 
downregulation of AXIN2 expression (Figure 7.4B). In the presence of SIS3 
there was no significant effect on the TGFβ-induced downregulation of 
AXIN2 expression, which remained downregulated by 46.7%, 41.7% and 
36.1% at 7.0, 6.0 and 5.0 µM, respectively (Figure 7.4B). As a positive 
control for the activity of the inhibitor, the expression of α-SMA, a SMAD3 
transcriptional target, was evaluated. Indeed, the TGFβ-induced 686.2% 
increase in α-SMA expression was inhibited in the presence of SIS3 to 
65.0% and 579.2% at 6.0 and 3.0 µM, respectively (Figure 7.4C). Similarly, 
α-SMA protein expression was significantly inhibited at doses of 7.0, 6.0 and 
5.0 µM SIS3 (Figure 7.4D). 
To validate the effects of SMAD3 inhibition, HC fibroblasts were transfected 
with siRNA targeted against SMAD3 (siSMAD3) or SCR oligonucleotide. In 
siSMAD3 fibroblasts, SMAD3 mRNA expression was reduced to 39.0% of 
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SCR controls (Figure 7.4E). Following TGFβ treatment, SMAD3 expression 
was reduced further to 17.1% in SCR fibroblasts, which was similar to the 
11.2% reduction observed in siSMAD3 fibroblasts (Figure 7.4E). 
Under the same experimental conditions, siSMAD3 fibroblasts showed a 
basal reduction of AXIN2 to 70.2% of the levels present in SCR controls 
(Figure 7.4F). Then in the presence of TGFβ, AXIN2 expression was 
reduced further to 46.4% in siSMAD3 fibroblasts, which was equivalent to 
the 49.0% expression observed in SCR controls (Figure 7.4F). Again, α-
SMA expression was used as a positive control for the inhibition of SMAD3 
activity. Indeed, α-SMA expression was relatively unchanged in siSMAD3 
fibroblasts at 92.9% of SCR controls (Figure 7.4G). Following TGFβ 
treatment, α-SMA expression was increased by 624.1% in siSMAD3 
fibroblasts; however, this was significantly reduced compared to the 
1007.2% increase observed in SCR controls (Figure 7.4G). 
 
The effect of SMAD3 reduction and the concomitant effect on the level of 
SMAD3 bioavailability were evaluated in relation to AXIN2 expression. At 
basal level, AXIN2 expression was reduced in siSMAD3 fibroblasts (Figure 
7.4H). TGFβ treatment induced a reduction in AXIN2 expression in SCR 
fibroblasts and was further reduced in siSMAD3 fibroblasts (Figure 7.4H). 
Like AXIN2, the expression of α-SMA was reduced at basal level in 
siSMAD3 fibroblasts compared to SCR controls (Figure 7.4H). In the 
presence of TGFβ, SCR fibroblasts showed a significant induction of α-SMA 
expression that was significantly reduced in siSMAD3 fibroblasts (Figure 
7.4H). 
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Figure 7.4 SMAD3 does not mediate the TGFβ-induced downregulation 
of AXIN2 
SMAD3 was evaluated for its potential to involvement in the TGFβ-meditated 
downregulation of AXIN2 expression in HC fibroblasts. A) The effect on 
basal AXIN2 expression and B) TGFβ-meditated AXIN2 downregulation 
were determined by SIS3 SMAD3 inhibitor treatment for 24 hr and 1 hr prior 
to 24 hr TGFβ treatment (5 ng/ml), respectively, where C) α-SMA expression 
served as a positive control, and all were quantified by qRT-PCR. D) 
Following 72 hr treatment with SIS3, α-SMA protein expression was 
determined by Western blot and served as a further control for SIS3 inhibitor 
activity. These effects were subsequently confirmed by SMAD3 siRNA 
(siSMAD3) gene silencing. HC fibroblasts were transfected with SMAD3 
siRNA (siSMAD3) or SCR oligonucleotide for 72 hr prior to TGFβ treatment 
for 24 hr and the effect on E) SMAD3, F) AXIN2 and G) α-SMA (+ve) 
expression were quantified by qRT-PCR. H) Under the same conditions, 
TGFβ treatment was extended to 72 hr and the protein expression of AXIN2, 
SMAD3, α-SMA (+ve) and GAPDH (loading control) were determined by 
Western blot. Data shown as mean ± SEM, n=3. 
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7.5 SMAD3 is required for the efficient activation of the 
canonical Wnt signalling response 
Although SMAD3 was not required for the TGFβ-mediated downregulation of 
AXIN2 expression (Figure 7.4A-H), inhibition experiments would suggest 
that SMAD3, like β-catenin, was required for Wnt-3a-induced canonical Wnt 
signalling activity, described later in this study (Figure 8.4A, B and E, F, 
respectively). Therefore it was determined whether Wnt-3a, like TGFβ, could 
lead to the phosphorylation (activation) of SMAD3, induce SMAD3 nuclear 
translocation and, subsequently, the consequence of SMAD3 depletion in 
relation to canonical Wnt signalling activity was determined. 
Included as a positive control, TGFβ caused a significant increase in SMAD3 
phosphorylation in HC fibroblasts by 30 min that returned to basal level by 
60 min (Figure 7.5A). Interestingly, Wnt-3a treatment also induced SMAD3 
phosphorylation, albeit to a lesser extent, at 30 min that again returned to 
basal level by 60 min (Figure 7.5A). 
Subsequently, Wnt-3a or TGFβ co-treatment with 5.0 µM of the SMAD3 
inhibitor SIS3 ablated the agonist-induced increases in SMAD3 
phosphorylation observed at 30 min (Figure 7.5B). 
Furthermore, Wnt-3a treatment also induced SMAD3 nuclear translocation 
by 360 min despite no change in the cytosolic fraction (Figure 7.5C). 
Similarly, TGFβ treatment increased SMAD3 nuclear localisation and this 
was greatest at 120 min and decreased over time up to 360 min (Figure 
7.5C). However, only TGFβ treatment showed a significant depletion of 
SMAD3 in the cytosolic cell fraction at 120, 240 and 360 min (Figure 7.5C). 
Finally, the effect of SMAD3 depletion on canonical Wnt signalling activation 
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was investigated. Expectedly, SMAD3 protein levels were reduced in 
siSMAD3 fibroblasts compared to SCR or untreated fibroblasts (Figure 
7.5D). Following Wnt-3a treatment, TOPFlash activity was increased by 
57.2-fold in SCR fibroblasts, which was equivalent to the treatment of 
untransfected controls (Figure 7.5E). Interestingly, Wnt-3a-induced 
TOPFlash activity in siSMAD3 fibroblasts was 27.2-fold less that SCR 
fibroblasts further, which further supported the potential role of SMAD3 
crosstalk with the canonical Wnt pathway (Figure 7.5E). 
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Figure 7.5 SMAD3 is required for the efficient activation of the 
canonical Wnt signalling response 
SMAD3 regulation of canonical Wnt signalling amplitude was evaluated in 
HC fibroblasts. A) Fibroblasts were treated with TGFβ or Wnt-3a for 30-60 
min and SMAD3 phosphorylation (activation) was determined by Western 
blot. B) Fibroblasts were treated with SMAD3 inhibitor SIS3 1 hr prior to 
TGFβ or Wnt-3a for 30 min and SMAD3 phosphorylation and GAPDH 
expression (loading control) were determined by Western blot. C) 
Cytosolic/nuclear localisation of SMAD3, HPRT (cytosolic marker) and 
Histone H3 (nuclear marker) were evaluated following TGFβ or Wnt-3a 
treatment for periods between 0-360 min and visualised by Western blot. D) 
Fibroblasts were transfected with SMAD3 siRNA (siSMAD3) or scrambled 
oligonucleotide (SCR) and SMAD3 and GAPDH (loading control) expression 
were determined by Western blot. E) Canonical signalling was determined 
by transfection of fibroblasts with the TOPFlash reporter for 24 hr and 
subsequently fibroblasts were transfected with siSMAD3 or SCR for 72 hr 
prior to treatment with Wnt-3a (100ng/ml) for 24 hr before TOPFlash activity 
was determined by luciferase activity. Data shown as mean ± SEM, n=3-4; 
Mann-Whitney test for unpaired samples *P=0.05, **P=0.01, ***P=0.001. 
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7.6 Additional downstream kinases of the TGFβ pathway are 
not involved the regulation of AXIN2 mRNA decay 
As SMAD3 was not involved in the TGFβ-mediated downregulation of AXIN2 
expression, alternative downstream mediators of the TGFβ signalling 
pathway were evaluated. MK-2206-mediated AKT1/2/3 inhibition had no 
effect on TGFβ-mediated AXIN2 downregulation despite a dose-dependent 
(0.3-10.0 µM) reduction in α-SMA expression (Figure 7.6A, B). Inhibitors 
targeted against PI3K (Wortmannin) and MEK1/2 (Selumetinib) also had no 
effect on TGFβ-mediated AXIN2 downregulation and showed no significant 
decrease in α-SMA expression (Figure 7.6C-F) 
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Figure 7.6 Additional downstream kinases of the TGFβ pathway are not 
involved in AXIN2 mRNA decay 
The activity of the inhibitors A-B) MK-2206 (AKT1/2/3), C-D) Selumetinib 
(MEK1/2) and E-F) Wortmannin (PI3K) were compared for their effect on 
AXIN2 and fibroblast activation marker α-SMA expression following HC 
fibroblasts inhibitor treatment (10-0.3 µM) 1 hr prior to 24 hr TGFβ treatment 
and quantified by qRT-PCR. Data shown as mean ± SEM, n=3-4; Mann-
Whitney test for unpaired samples *P=0.05, **P=0.01. 
 
 
- 186 - 
7.7 p38 could potentially regulate TGFβ-induced AXIN2 
downregulation 
Finally, the involvement of p38 MAP kinase in TGFβ-mediated 
downregulation of AXIN2 was investigated. HC fibroblasts were treated with 
the p38α/β inhibitor VX-702 in the presence and absence of TGFβ. While 
TGFβ induced the downregulation of AXIN2 expression to 45.9%, a partial 
restoration was observed in the presence of VX-702 where expression was 
increased to 69.0%, 67.7%, 58.8% and 50.0% at 10.0, 3.0, 1.0 and 0.3 µM, 
respectively (Figure 7.7A). 
Next, the activity of VX-702 was evaluated using a control gene panel. In this 
panel α-SMA expression was used as a control for TGFβ activity, DKK-1 
expression was used to evaluated the effect of inhibition on a second 
inhibitor of the canonical Wnt signalling pathway and c-MYC / CDKN2A were 
included as known p38-regulated gene targets. Indeed, the 578.4% 
induction in α-SMA expression by TGFβ was partially inhibited in the 
presence of VX-702 to 406.0%, 544.3%, 568.0% at concentrations of 10.0, 
3.0 and 1.0 µM, respectively (Figure 7.7B). The TGFβ-induced 
downregulation of DKK-1 to 28.8% was relatively unchanged in the presence 
of VX-702 and was expressed by 18.6%, 35.8%, 46.5%, or 46.2% at 10.0, 
3.0, 1.0 and 0.3 µM, respectively (Figure 7.7C). c-MYC expression was 
increased to 271.6% following TGFβ treatment and in the presence of VX-
702 showed inhibition to 192.2%, 158.2%, 201.6% and 200.3% at 10.0, 3.0, 
1.0 and 0.3 µM, respectively (Figure 7.7D). Finally, a potent inhibition of 
CDK2A expression was observed in the presence of VX-702, which was 
induced by 170.1% following TGFβ and inhibited to 63.4%, 75.6% or 81.3% 
and 74.6% at 10.0, 3.0, 1.0 and 0.3 µM, respectively (Figure 7.7E). 
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However, as the maximum effect of VX-702 inhibition was only 31%, a 
second p38 inhibitor, SB202190, was used to validate the role p38 in AXIN2 
expression. In contrast to the results presented in Figure 1.13A, the TGFβ-
induced downregulation of AXIN2 to 60.0% was not significantly affected in 
the presence of SB202190 and was expressed by 66.4%, 66.0%, 68.6% or 
63.8% at 10.0, 3.0, 1.0 and 0.3 µM, respectively (Figure 7.7F). Indeed, 
partial inhibition of the TGFβ-induced downregulation of AXIN2 expression 
was observed using VX-702 but was absent when using SB202190. 
Next, the activity of SB202190 was evaluated using the same gene panel 
used previously. Here, TGFβ induced a 1086.1% increase in α-SMA 
expression that was significantly inhibited in the presence of SB202190 by 
197.7%, 278.6%, 428.9% and 667.6% at 10.0, 3.0, 1.0 and 0.3 µM, 
respectively (Figure 7.7G). DKK-1 expression was reduced to 42.1% 
following TGFβ treatment and there was no significant change observed in 
the presence of SB202190, repressed by 37.4%, 39.6%, 50.6% or 47.4% 
expression at 10.0, 3.0, 1.0 and 0.3 µM, respectively (Figure 7.7H). 
However, the TGFβ-induced 415.4% increase in c-MYC expression was 
reduced to 186.5%, 199.5% and 271.2% at 10.0, 3.0, 1.0 and 0.3 µM 
SB202190, respectively (Figure 7.7I). Similarly, the TGFβ-induced 370.1% 
increase in CDK2A expression was reduced to 126.8%, 140.5%, 173.6% at 
10.0, 3.0, 1.0 and 0.3 µM SB202190, respectively (Figure 7.7J). 
- 188 - 
 
Figure 7.7 p38 could potentially regulate TGFβ-induced AXIN2 
downregulation 
The effect of p38 inhibition on TGFβ-mediated AXIN2 downregulation was 
determined in HC fibroblasts. p38 inhibitors (10-0.3 µM) were preincubated 1 
hr prior to TGFβ treatment for 24 hr. A-E) The activities of p38 inhibitor VX-
702 and F-J) SB202190 were compared for their effects upon AXIN2 
expression as well as positive control genes α-SMA, DKK-1, c-MYC and 
CDK2A, quantified by qRT-PCR. Data shown as mean ± SEM, n=3-5; Mann-
Whitney test for unpaired samples **P=0.01. 
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7.8 The AXIN2 transcript contains a TTP-1 ARE-binding 
protein sequence and TGFβ negatively regulates TTP-1 
expression 
As the investigation into the signalling intermediates responsible for the 
TGFβ-induced downregulation of AXIN2 were not conclusive, the post-
transcriptional mechanism by which TGFβ induced the 4.2-fold increase in 
AXIN2 mRNA degradation was explored further. While post-transcriptional 
regulation is complex, it is thought that the majority of eukaryotic mRNAs are 
degraded though the shortening of their poly(A)-tails, which in-turn initiates a 
deadenylation-dependent pathway that leads to the recruitment of the RNA-
degrading exosome complex (Houseley & Tollervey 2009). Therefore a 
bioinformatics approach was used to detect any 3’UTR AU-rich elements 
(ARE) binding sequences present within the AXIN2 transcript. Hence, AXIN2 
was found to harbour several ARE binding motifs that could potentially 
recruit the ARE-binding proteins TTP-1, HUR and AUF-1 (Figure 7.8A). 
Indeed, these predicted protein interactions could potentially regulate the 
stability of AXIN2 mRNA. 
In preliminary experiments, TGFβ-treated HC fibroblasts showed a 
downregulation of TTP-1 expression to 14.7%, 52.2% and 44.1% at 2, 4, 
and 6 hr, respectively (P<0.05) (Figure 7.8B). Further, TGFβ reduced TTP-1 
expression longitudinally to 65.3%, 58.6%, and 59.6% at 24, 48 and 72 hr, 
respectively (P<0.05) (Figure 7.8C). Next, the expression of HUR was 
unchanged in response to TGFβ at early time points of 2, 4 and 6 hr 
expressed by 111.3%, 113.3% and 126.4%, respectively (Figure 7.8D). 
Longitudinally, a trend toward decreased expression was observed 
expressed by 74.7% 74.5% and 87.2% at 24, 48 and 72 hr, respectively 
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(Figure 7.8E). 
AXIN2 expression served as a positive control and was downregulated by 
27.9%, 48.2% and 39.2% at 2, 4 and 6 hr, respectively (P<0.05) (Figure 
7.8F). Longitudinally, TGFβ downregulated the expression of AXIN2 by 
53.1%, 45.2% and 50.2% at 24, 48 and 72 hr, respectively (P<0.05) (Figure 
7.8G). The expression of AUF-1 was not included due to unreliable primer 
pairs (data not shown). 
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Figure 7.8 AXIN2 transcripts contain ARE-binding protein sequences 
and TGFβ negatively regulates TTP-1 expression 
A) Bioinformatics analysis of AXIN2 mRNA identified AU-rich element (ARE) 
binding motifs within the 3’UTR, predicted to bind RNA regulating proteins 
TTP-1 and HUR. TGFβ regulation of C) TTP-1 D-E) HUR and F-G) AXIN2 
(+ve) expression were determined in HC fibroblasts following TGFβ 
treatment for 2-72 hr and quantified by qRT-PCR. Data shown as mean ± 
SEM, n=4; Mann-Whitney test for unpaired samples *P=0.05. 
 
3’UTR Pentamer Sequence      
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7.9 Inhibition of TTP-1 potentially upregulates AXIN2 
expression 
As TGFβ negatively regulated TTP-1, the effect of basal TTP-1 depletion 
upon the expression of AXIN2 was evaluated. HC fibroblasts were therefore 
transfected with siRNA targeted against TTP-1 (siTPP-1) or SCR 
oligonucleotide. In siTTP-1 fibroblasts at 48 and 72 hr, TTP-1 expression 
was reduced to 41.9% and 35.7% (P<0.001), respectively (Figure 7.9A). 
Concomitantly, AXIN2 expression was increased by 162.1% (P<0.01) at 48 
hr, which was then reduced to 109.5% by 72 hr (Figure 7.9B). 
DKK-1 expression was used to evaluate the effect of TTP-1 expression on a 
second endogenous inhibitor of the canonical Wnt signalling pathway. 
Similarly, DKK-1 showed a 161.5% (P<0.01) increase in expression at 48 hr 
decreasing to 124.3% at 72 hr (Figure 7.9C). Finally, α-SMA expression 
served as a control for TGFβ activity and showed a minor increase in 
expression of 116.1% at 48hr and a reduced expression of 78.3% (P<0.05) 
at 72 hr (Figure 7.9D). 
At protein level, TTP-1 expression remained relatively unchanged compared 
to GAPDH loading controls (Figure 7.9E). Despite this, AXIN2 expression 
showed a significant upregulation in siTTP-1 fibroblasts compared to SCR 
controls at both 48 and 72 hr (Figure 7.9E). Similarly, DKK-1 expression was 
also increased in siTTP-1 fibroblasts compared to SCR controls at 48 hr and 
72 hr (Figure 7.9E). Finally, the expression of α-SMA and AXIN1 were used 
as negative controls. Both proteins showed no significant change expression 
in siTTP-1 fibroblasts compared to SCR fibroblasts at either time point 
(Figure 7.9E). 
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Following validation, a time-course was performed in order to evaluate 
whether reduced TTP-1 expression could significantly affect the TGFβ-
induced downregulation of AXIN2. As TGFβ regulated the stability of AXIN2 
within a period of 60 min (Figure 7.1G), expression was determined at 0-120 
min. In siTTP-1 fibroblasts, TTP-1 expression was reduced to 94.5% 
compared to SCR controls (Figure 7.9F). In the presence of TGFβ, TTP-1 
expression was increased in SCR fibroblasts by 210.5% at 30 min, and 
decreased over time to 173.2% at 60 min and 83.3% at 120 min (Figure 
7.9F). In contrast, siTTP-1 fibroblasts showed no increase in TTP-1 
expression, expressed by 72.1% at 30 min, 87.4% at 60 min and was 
significantly reduced to 26.7% at 120 min (Figure 7.9F). 
Despite the variable silencing of TTP-1 expression, the basal level of AXIN2 
was increased by 216.3% (P<0.05) in siTPP-1 compared to SCR fibroblasts 
(Figure 7.9G). This expression was reduced over time decrease to 140.7% 
(P<0.05), 156.4% (P<0.05) and 87.4% was observed at 30, 60 and 120 min, 
respectively (Figure 7.9G). TGFβ treatment of SCR fibroblasts reduced 
AXIN2 expression to 96.4% at 30 min, 95.5% at 60 min and more noticeably 
to 64.0% at 120 min in SCR fibroblasts (Figure 7.9G). 
The expression of COX2, a known TTP-1 regulated target, served as a 
positive control for TTP-1-mediated activity. As expected, siTPP-1 fibroblasts 
showed a significant increase in basal COX2 expression by 393.0%(P<0.05) 
compared to SCR controls and following TGFβ treatment this expression 
was reduced over time to 198.2%, 95.1% and 34.0% at 30, 60 and 120 min, 
respectively (Figure 7.9H). Similarly, TGFβ treatment downregulated COX2 
expression over time in SCR fibroblasts to 134.0%, 83.5% and 43.5% at 30, 
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60 and 120 min, respectively (Figure 7.9H). 
As a positive control for TGFβ signalling activity, the TGFβ-mediated 
expression of the early-intermediate gene CTGF was evaluated. At basal 
level, CTGF expression in siTTP-1 fibroblasts was similar to that of SCR 
fibroblasts at 90.4% (Figure 7.9I). In siTTP-1 fibroblasts, CTGF expression 
was increased to 78.7% at 30 min, 213.5% at 60 min and 539.7% at 120 min 
(P<0.05) (Figure 7.9I). This was similar to the TGFβ-induced expression 
observed in SCR fibroblasts, which increased by 232.5%, 280.0% and 
507.1% at 30, 60 and 120 min, respectively (P<0.05) (Figure 7.9I). 
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Figure 7.9 Inhibition of TTP-1 potentially upregulates AXIN2 expression 
The effect of TTP-1 downregulation on the expression of putative target 
AXIN2 was determined by treatment of HC fibroblasts with TTP-1 siRNA 
(siTTP-1) or SCR oligonucleotide for up to 72 hr. Basal expression of A) 
TTP-1 B) AXIN2 C) DKK-1 and D) α-SMA were quantified by qRT-PCR. E) 
Protein expressions of these genes were also determined by Western blot in 
addition to AXIN1 (-ve) and GAPDH (loading control). Subsequently, the 
effect of TTP-1 downregulation on TGFβ-responsive gene expression was 
determined by following the addition of TGFβ for 0-120 min and the 
expression of F) TTP-1 (+ve), putative target G) AXIN2 H) COX2 (+ve) and 
I) CTGF (+ve) were quantified by qRT-PCR. Data shown as mean ± SEM, 
n=3-5; Mann-Whitney test for unpaired samples *P=0.05, **P=0.01. 
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7.10 DISCUSSION: TGFβ-mediated regulation of AXIN2 
expression: Determining a mechanism 
Consistently in this study, it has been shown that TGFβ mediates the 
downregulation of AXIN2 expression and that this is sufficient to reproduce 
the increased canonical Wnt signalling response observed in SSc 
fibroblasts. However, the mechanism by which this downregulation was 
achieved was still unknown and was therefore investigated further. 
At a moderate dose of TGFβ, a rapid reduction in the expression of AXIN2 
was observable within 10 min and persisted for up to 72 hr (Figure 7.1A-C), 
which suggested that the expression of AXIN2 might be regulated at post-
transcriptional level and facilitate the dynamic regulation of AXIN2 protein 
expression (Figure 7.1F). This dynamic regulation was also reflected at 
translational level by a reduction as soon as 2 hr and up to 72 hr (Figure 
7.1D, E). In demonstration of the context dependent nature of this model, 
AXIN2 expression was not similarly effected by TGFβ treatment until 24 hr 
post-treatment in chondrocytes (Dao et al., 2007). 
Further supporting a post-transcriptional mechanism, transcriptional 
inhibition experiments revealed that TGFβ signalling influenced the half-life 
of AXIN2 mRNA by increasing the rate of mRNA decay by 4.2-fold (Figure 
7.1G). In contrast with the expression of the mature AXIN2 transcript, within 
0-60 min AXIN2 RNA destabilisation is one of the first events initiated 
following TGFβ treatment, while transcriptional regulation might play a more 
prominent role at later time points (Figure 7.1B Vs. H). Overall, these data 
provide a mechanistic insight into the processes involved the TGFβ-
mediated downregulation of AXIN2 expression, specifically attributable to 
dermal fibroblasts. 
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To supplement the mechanistic data, the effect of TGFβ receptor blockade 
was determined using the TβRI-kinase inhibitor SD-208, which has been 
shown to selectively antagonise TβRI-induced signalling and thereby inhibit 
profibrotic activity in lung fibroblasts (Kapoun et al., 2006). In the absence of 
TβRI activation, TGFβ treatment was unable to suppress AXIN2 mRNA and 
protein expression in addition to other TGFβ-regulated genes targets (Figure 
7.2A-E). This analysis also showed that inhibition of TGFβ-mediated DKK-1 
downregulation, a regulator of canonical Wnt singalling, was consistent with 
recent literature (Akhmetshina et al., 2012). This provides further evidence 
for the crosstalk between the TGFβ and Wnt signalling pathways, where 
TGFβ acts to downregulate at least two negative regulators critical for the 
control of canonical Wnt signalling. 
 
Utilising available SSc fibroblasts, similar TβRI-kinase inhibition experiments 
were performed, in the absence of TGFβ to evaluate whether SSc fibroblasts 
displayed phenotyptic changes consistent with the hypothesis of 
autocrine/constitutive TGFβ signalling activation within these fibroblasts. In 
support of this, blockade of TβRI signalling upregulated the expression of 
AXIN2/DKK1, which are both reproducibly downregulated following TGFβ 
treatment (Figure 7.3A, B). Again, consistent with the hypothesis a 
concomitant downregulation of α-SMA/COL1A1 expression was observed, 
which are known to be upregulated by TGFβ signalling (Figure 7.3C, D). 
Although confirmation at extended time points and protein expression would 
be required as a prior confirmations, these data would suggest that 
autocrine/constitutive activation of TGFβ signalling cannot be ruled out as a 
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characteristic of explanted dcSSc fibroblasts (Desmoulière et al. 1993; 
Gabbiani 2003; Ho et al. 2014). 
Overall, these data augment previous observations by demonstrating the 
potential regulation of the canonical Wnt signalling pathway through the 
aberrant activation of the TGFβ signalling pathway in SSc fibroblast, both of 
which could have important functions in SSc disease pathogenesis, 
including fibrosis. 
 
Following TβRI activation, SMAD3 is recruited and concomitantly 
phosphorylates SMAD2, two principal mediators of canonical TGFβ 
signalling. SMAD3 can act as a critical transcriptional component to directly 
activate immediate-early TGFβ-responsive genes, containing SBEs within 
their promoters, including α-SMA (Hu et al. 2003; Yang et al. 2003; Uemura 
et al. 2005). Therefore, SMAD3 activity/availability might have a role in the 
regulation of AXIN2 transcription, which follows on from the post-
transcriptional effect of TGFβ described previously. 
This hypothesis was evaluated using a selective SMAD3 phosphorylation 
inhibitor; SIS3, which was used to prevent SMAD3 
phosphorylation/activation and thereby prevent its mediation of downstream 
activities (Jinnin et al., 2006). In the absence of TGFβ treatment, SMAD3 
inhibition reduced the basal expression of AXIN2 (Figure 7.4A); however, 
showed no effect on the TGFβ-induced downregulation of AXIN2 expression 
in contrast to repression observed for α-SMA (Figure 7.4B-D). This is 
contrary to an observation in chondrocytes, which showed that eventual 
downregulation of AXIN by TGFβ signalling was SMAD3 dependent (Dao et 
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al., 2007). Subsequent evaluation using siRNA-mediated depletion of 
SMAD3 was consistent with effects described for the SIS3 inhibitor (Figure 
7.4H). These data indicate that while SMAD3 might be important for the 
steady-state expression of AXIN2; TGFβ-induced AXIN2 downregulation 
was independent of SMAD3 expression/activity and therefore mediated by 
an alternative mechanism in fibroblasts. 
Further evidence suggested that SMAD3, an essential component of the 
TGFβ signalling pathway, is also an important component of the canonical 
Wnt signalling pathway. Indeed, canonical Wnt-3a agonist treatment lead to 
the phosphorylation (activation) of SMAD3, which could be abolished by 
SMAD3 inhibitor co-treatment (Figure 7.5A, B). This was in agreement with a 
previous study that also showed Wnt-3a-induced phosphorylation of SMAD3 
(Wei et al. 2012). This was further supported by the canonical Wnt-induced 
nuclear translocation of SMAD3 (Figure 7.5C). Extending upon this 
observation, a more direct role for the participation of SMAD3 in canonical 
Wnt signalling pathway was indicated by the significant inhibition of the 
canonical Wnt signalling pathway in SMAD3 depleted fibroblasts (Figure 
7.5E). 
Suggestively, SMAD3 has been shown to directly interact with both AXIN 
and β-catenin in independent studies (Chia & Costantini 2005; Jian 2006; Liu 
et al. 2006; Tian et al. 2013). As discussed previously, due to the absence of 
SBEs within the promoter region of the TOPFlash reporter construct the 
reduction in canonical Wnt signalling in SMAD3 depleted fibroblasts was is 
suggestive of a direct effect on TCF/LEF transcriptional activity and not by 
SBE-mediated transactivation. 
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Therefore these observations could represent novel elements of crosstalk 
between the canonical Wnt the TGFβ signalling pathways within fibroblasts. 
In light of these data, it is possible that the previously observed increase in 
total TGFβ signalling activity following canonical Wnt treatment, that was 
increased further by canonical Wnt signalling hyperactivation, was as a 
result of a Wnt-induced increase in SMAD3 activity (Figure 6.5F), although 
further experiments would be required. 
 
As SMAD3 was not directly involved in the TGFβ-mediated downregulation 
of AXIN2 expression, additional downstream mediators of the TGFβ 
signalling pathway were henceforth evaluated. Preliminary analysis of 
several kinases including PI3K, MEK1 and AKT1/2/3 indicated that, having 
no effect on TGFβ-induced repression, they were unlikely to play a key role 
in the TGFβ-mediated transcriptional or post-transcriptional downregulation 
of AXIN2 (Figure 7.6A-F). 
Only the inhibition of p38 MAPK was found to have a partial inhibitory effect 
on TGFβ-mediated downregulation of AXIN2. This partial inhibition was 
achieved using the VX-702 p38 inhibitor (maximum of 31%), which showed 
a trend toward a dose effect and also showed an active inhibitory profile for 
both TGFβ- and p38-regulated genes (Figure 7.7A-E). In contrast, the use of 
a second p38 inhibitor, SB202190, showed no inhibition of TGFβ-mediated 
AXIN2 downregulation in contrast to its inhibitory activity upon other TGFβ- 
and p38-regulated genes (Figure 7.7F-J). 
As VX-702 only showed a partial of inhibition across a standard dose range, 
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this suggested the possibility that an off-target effect might be responsible 
for this activity. The second possibility was that the standard error present in 
the AXIN2 expression data for the SB202190 experimental series masks the 
VX-702-mediated partial inhibitory effect; however, analysis of each data 
individually revealed no such concealment (data not shown). A more 
intriguing hypothesis can be derived from the fact that VX-702 is known to 
have a 14-fold higher potency for the p38α isoform compared to p38β 
isoform. In contrast, the inhibition of p38 by SB202190 has not been 
described as being selective for a particular isoform. Therefore, one 
possibility might be that the p38 isoforms have opposing regulatory effects. 
The disparate roles of the p38 isoforms have been shown in the regulation of 
apoptosis in Jurkat cells (T-cells), where SB202190 induced apoptosis by 
inhibition of p38α/β; however, expression of the p38β isoform effectively 
rescued the phenotype while p38α expression showed a modest increase 
toward apoptotic activity (Nemoto et al., 1998). Therefore the balance 
between these two isoforms might have important consequences. 
Specifically, the p38α isoform may mediate the TGFβ-mediated 
downregulation of AXIN2 expression while the p38β isoform opposes p38α 
activity. Further support for utilisation of p38 in this specific pathway can be 
implied from its known role in the regulation of TTP-mediated RNA decay, 
discussed next (Brooks & Blackshear 2013). 
 
In parallel, the post-transcriptional mechanism by which TGFβ mediated the 
downregulation of AXIN2 was also investigated. Notably, the majority of 
eukaryotic mRNAs are degraded though the shortening of their poly(A)-tails, 
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which can initiate the recruitment of the RNA-degrading exosome complex 
through a deadenylation-dependent pathway (Houseley & Tollervey 2009). 
As this is known to be regulated by ARE harboured within the 3′UTR of 
many mRNAs, a bioinformatics analysis was performed on the AXIN2 
transcript and several ARE binding motifs were detected (Figure 7.8A). 
These motifs are known to recruit ARE-binding proteins including TTP-1, 
HUR and AUF-1, which could potentially regulate the stability of AXIN2 
mRNA (Figure 7.8A). Indeed, the mRNA and protein expression of several 
ARE containing mRNAs including COX2, TNF, c-MYC and CCND1 are 
known to be regulated by TTP-1-mediated destabilisation, in addition TTP-1 
expression has also been shown to be TGFβ responsive (Ogawa et al., 
2003; Marderosian et al., 2006; Kang et al., 2014; Blanco et al., 2014). 
Pertaining to the later observation, TGFβ treatment inhibited TTP-1 
expression in HC fibroblasts in contrast to these studies (Figure 7.8B, C) 
(Ogawa et al., 2003; Blanco et al., 2014). Despite this, the possibility 
remained that TGFβ might increase TTP-1 activity, which could then lead to 
the destabilisation of the AXIN2 transcript and the resulting TGFβ-mediated 
decrease in TTP-1 expression might act as a restorative negative regulatory 
mechanism. 
TTP-1 protein expression studies were impeded by the lack of a specific 
antibody, which apart from being highly non-specific also showed no change 
in expression following TGFβ treatment (data not shown), despite the 
previously observed downregulation at mRNA level. Interestingly, the TGFβ-
induced expression pattern for TTP-1 showed a similar profile to that of 
AXIN2 (Figure 7.8B, C Vs. F, G). Taking these data together with the 
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absence of reliable primers to detect AUF1 expression and the minimal 
effect of TGFβ upon HUR expression, only TTP-1 was subsequently carried 
forward for further investigation into the mechanism of TGFβ-mediated 
downregulation of AXIN2. 
Additionally, p38 is a known negative regulator of TTP-1 activity and, in 
tandem with ERK, has been shown to prevent TTP-1-mediated 
destabilisation of ARE containing mRNAs, which could potentially include 
AXIN2 (Figure 1.4) (Deleault, Skinner & Brooks 2008). This would be in 
contrast to the previous observation where p38 inhibition partially prevented 
TGFβ-mediated downregulation of AXIN2 (Figure 7.7A). However, as 
previously discussed, the potential for differential activities of p38 isoforms 
could account for this disparity. 
 
Initially, the effect of siRNA-mediated TTP-1 depletion upon the basal 
expression of AXIN2 was determined in HC fibroblasts. Indeed, in contrast to 
α-SMA, a temporal increase in the expression of both AXIN2 and DKK1, 
endogenous inhibitors of Wnt signalling, were observed at both 
transcriptional and translational level (Figure 7.9A-D). This supported the 
hypothesis that TTP-1 might regulate AXIN2 mRNA stability. 
As TGFβ-mediated destabilisation of the AXIN2 transcript most likely 
occurred within a 60 min window (Figure 7.1B Vs. H), a short TGFβ time-
course was performed in order to determine any differential effects on the 
kinetics of TGFβ-induced AXIN2 downregulation within TTP-1 depleted 
fibroblasts. On analysis of this data, one important shortcoming resided in 
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was the reproducibility of TTP-1 silencing, which was not achieved prior to 
TGFβ treatment in this experimental series (Figure 7.9F Vs. A). As a result, 
the possibility remained that the effects observed in TTP-1 silenced 
fibroblasts may be due to off-target effects. 
However, several effects that would have been predicted to occur in TTP-1 
depleted fibroblasts were observed. For example, COX2, a known TTP-1 
regulated gene, and AXIN2 expression were significantly increased in TTP-1 
depleted fibroblasts and showed a similar decrease in expression over time 
following TGFβ treatment (Figure 7.9G, H) (Kang et al., 2015). As CTGF 
expression was not affected in the same manner, this would have supported 
the specificity of the effect found for AXIN2 expression (Figure 7.9I). 
A further limitation was observed in subsequent evaluations of TTP-1 
expression. As discussed previously, the TGFβ-induced downregulation of 
TTP-1 expression is in contrast to the literature (Figure 7.8A, B) (Ogawa et 
al., 2003; Blanco et al., 2014). This result was difficult to confirm due to the 
lack of TTP-1 antibody specificity (data not shown); however, when a second 
TTP-1 antibody was utilised, no significant change in TTP-1 protein 
expression was found following TGFβ treatment (data not shown) and this 
was further confounded by the minute effect observed in TTP-1 silenced 
fibroblasts (Figure 7.9E). Therefore the reliability of the antibodies is in 
question. The potential involvement of TTP-1 activity in the regulation of 
AXIN2 expression still remains to be conclusively determined. To further 
evaluate the effect of TGFβ signalling upon TTP-1 activity, irrespective of 
expression, would require a complex series of biochemical experiments to 
validate the hypothesis given the unreliability of the antibodies. 
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Overall, these data indicate that TGFβ initially mediates AXIN2 
downregulation by increasing its rate of mRNA degradation. That this is 
required for the increased response of fibroblasts to canonical Wnt 
signalling, and equivalent to that observed in SSc fibroblasts. Preliminary 
evidence suggests that the basal repression of AXIN2 in SSc fibroblasts 
might be mediated by activation of the p38 signalling pathway, although this 
is not conclusive. In addition, the AXIN2 transcript contains an ARE at its 
3’UTR, which potentially regulates mRNA degradation through ARE binding 
protein-mediated destabilisation. 
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8 The consequence of canonical Wnt 
signalling hyperactivation upon profibrotic 
activation of fibroblasts 
Fibrosis is a fundamental hallmark of SSc. Patients with dcSSc have a 
higher extent of fibrotic involvement in both the skin and internal organs, 
which increases the risk of developing severe complications (Penn et al. 
2007). Further, the severity of the diffuse cutaneous disease is associated 
with the level of fibrotic skin involvement (Steen & Medsger, 2001). TGFβ 
signalling is fundamental in the pathogenesis of tissue fibrosis but more 
recently studies have shown overactivation of canonical Wnt signalling 
during fibrosis in SSc and in other fibrotic models (Bayle et al. 2007; Wei, et 
al. 2011; Yu et al. 2003; Ask et al. 2008; Varga & Pasche 2009). However, 
the nature of this activation is yet to be identified and the relative crosstalk 
with the TGFβ pathway is unclear. In this study it has been identified that 
TGFβ can increase the amplitude of the canonical Wnt signalling pathway 
through the downregulation of AXIN2 expression. Therefore the fibrotic 
consequences of increased canonical Wnt signalling pathway were 
evaluated in the both TGFβ-primed and AXIN2 depletion models of 
canonical Wnt signalling hyperactivation. Correspondingly, β-catenin was 
also evaluated due to its fundamental function as a downstream regulator of 
canonical Wnt signalling. 
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8.1 TGFβ priming does not significantly effect profibrotic 
fibroblast activation 
The TGFβ-primed model of canonical Wnt signalling hyperactivation was 
evaluated for its potential effects on profibrotic gene expression, 
myofibroblast generation and ECM contractile capacity. 
This was first evaluated in TGFβ-primed fibroblasts using two known 
markers of fibroblast activation α-SMA and COL1A1 expression. Indeed, HC 
fibroblasts treated with Wnt-3a showed a 136.3% (P<0.05) increase in α-
SMA expression in contrast to the 905.9% (P<0.01) increase in expression 
following TGFβ treatment (Figure 8.1A). When fibroblasts were primed with 
TGFβ and sequentially treated with Wnt-3a, α-SMA expression was 
increased to 1090.1% (P<0.05); however, this was not found to be 
statistically significant when compared to independent TGFβ treatment 
(Figure 8.1A). Similarly, COL1A1 expression was inhibited following Wnt-3a 
treatment, which was reduced to 87.8%, and this was in contrast to the 
308.4% (P<0.05) increase in expression by TGFβ (Figure 8.1B). In TGFβ-
primed fibroblasts, Wnt-3a treatment lead to a 294.4% (P<0.001) increase in 
COL1A1 expression that was equivalent to the expression in TGFβ treated 
fibroblasts (Figure 8.1B). 
In agreement with mRNA data, the expression of α-SMA protein was 
unchanged following treatment with Wnt-3a and this was in contrast to the 
significant upregulation following TGFβ treatment (Figure 8.1C). Further, 
TGFβ-primed fibroblasts that were subsequently treated with Wnt-3a were 
not significantly different from TGFβ-treated fibroblasts (Figure 8.1C). 
As a validation, fibroblast-mediated contraction of 3D collagen gels were 
- 208 - 
also used to evaluate profibrotic activity. 3D Collagen gels were seeded with 
HC fibroblasts, polymerised and floated in low-serum medium. In the 
presence of Wnt-3a medium, collagen gel contraction was not significantly 
different to control gels, 90.3% (Figure 8.1D). However, TGFβ treatment 
induced collagen gel contraction and reduced the gel area to 65.1%, which 
was equivalent to the contraction to 65.3% exhibited by Wnt-3a-treated 
TGFβ-primed fibroblasts, (Figure 8.1D). 
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Figure 8.1 TGFβ priming does not significantly effect profibrotic 
fibroblast activation 
TGFβ-primed canonical Wnt signalling hyperactivation was evaluated for 
significant profibrotic effects. A-B) HC fibroblasts were primed with TGFβ (5 
ng/ml) or left untreated for 24 hr, subsequently treated with Wnt-3a for 24 hr 
and the expression of α-SMA and COL1A1 were quantified by qRT-PCR. C) 
As in A, where Wnt-3a treatment was carried out for 72 hr and subsequenty 
fibroblast activation marker α-SMA and GAPDH (loading control) protein 
expression were determined by Western blot. D) Under the same condition 
as C, relative fibroblast-mediated 3D collagen gel contraction was quantified 
according to gel surface area. Data shown as mean ± SEM, n=3-5; Mann-
Whitney test for unpaired samples *P=0.05, **P=0.01. 
 
8.2 Increased canonical Wnt signalling in AXIN2 silenced 
fibroblasts has no effect on profibrotic activation 
Complementary to TGFβ-primed model, the AXIN2 depletion model of 
canonical Wnt signalling hyperactivation was subsequently evaluated for its 
potential effects on profibrotic gene expression, myofibroblast generation 
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and ECM contractile capacity. 
Here, AXIN2 expression severed as a positive control and was silenced to 
57.5% in siAXIN2 compared to SCR fibroblasts (Figure 8.2A). When treated 
with Wnt-3a, AXIN2 expression was increased by 167.7% in SCR fibroblasts 
and to 115.1% in siAXIN2 fibroblasts (Figure 8.2A). 
Next the effect on α-SMA and COL1A1 profibrotic gene expression was 
evaluated. Indeed, α-SMA expression showed no change in expression in 
siAXIN2 fibroblasts, 100.2% compared to SCR controls (Figure 8.2B). Wnt-
3a treatment also showed no significant change α-SMA expression in either 
SCR or siAXIN2 fibroblasts, expressed by 105.4% and 110.4%, respectively 
(Figure 8.2B). 
Interestingly, a 172.2% increase in COL1A1 expression was observed in 
siAXIN2 fibroblasts at basal level, compared to SCR controls (Figure 8.2C). 
Indeed, this was greater than the 137.8% induced by Wnt-3a in SCR 
fibroblasts; however, less than the 217.7% increase in Wnt-3a-treated 
siAXIN2 fibroblasts (Figure 8.2C). 
At protein level, the expression of AXIN2 was significantly downregulated in 
siAXIN2 compared to SCR fibroblasts (Figure 8.2D). Following Wnt-3a 
treatment, AXIN2 expression was upregulated in both siAXIN2 and SCR 
fibroblasts compared to controls, while α-SMA expression was unaffected 
throughout (Figure 8.2D). 
Like SCR fibroblasts, AXIN2 expression was upregulated following Wnt-3a 
treatment, but the increase was greater in SCR fibroblasts, in contrast to the 
unaffected expression of α-SMA (Figure 8.2D). 
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Next, the differentiation state of siAXIN2 fibroblasts was evaluated based on 
α-SMA stress fibril formation and quantified by the concomitant increase in 
the integrated density of fluorescence (IDF). At basal level, the IDF of 
siAXIN2 fibroblasts was reduced to 0.9-fold compared to SCR fibroblasts. In 
the presence of Wnt-3a, SCR fibroblasts the IDF was increased by 1.1-fold, 
but this was reduced to 0.8-fold in siAXIN2 fibroblasts (Figure 8.2E). As a 
positive control, normal myofibroblast differentiation was evaluated in an 
untransfected population of HC fibroblasts in response to treatment. HC 
fibroblasts treated with Wnt-3a or TGFβ increased the IDF by 1.7-fold and 
3.4-fold, respectively (Figure 8.2E). 
Finally, the effect of increased canonical Wnt signalling on collagen gel 
contraction was evaluated in the siAXIN2 model. Collagen gels were seeded 
with either siAXIN2 or SCR fibroblasts and under basal conditions there was 
no significant change in gel surface area, 99.1% of SCR gel area (Figure 
8.2F). In the presence of Wnt-3a, there was a trend toward increased 
collagen gel contraction with the gel area reduced to 88.7% and 88.3% in 
SCR and siAXIN2 fibroblasts, respectively (Figure 8.2F). 
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Figure 8.2 Increased canonical Wnt signalling in AXIN2 silenced 
fibroblasts has no effect on profibrotic activation 
The profibrotic effects of AXIN2 depletion-mediated canonical Wnt signalling 
hyperactivation were evaluated. HC fibroblasts were transfected with AXIN2 
(siAXIN2) or SCR siRNA for 72 hr. A) Following Wnt-3a treatment for 24 hr 
the expression of A) AXIN2 (+ve) and profibrotic genes B) α-SMA and C) 
COL1A1 were quantified by qRT-PCR. D) After 72 hr Wnt-3a treatment, the 
protein expression of AXIN2 (+ve), fibroblast activation marker α-SMA and 
GAPDH (loading control) were determined by Western blot. E) Myofibroblast 
counts were determined by the relative integrated density of fluorescence 
(IDF) from α-SMA positive staining of fibroblasts, under the same conditions 
as D, quantified using ImageJ. F) Relative fibroblast-mediated 3D collagen 
gel contraction was quantified according to gel surface area under the same 
condition as D. Data shown as mean ± SEM, n=2-4. 
 
8.3 AXIN2 does not regulate TGFβ-induced profibrotic 
fibroblast activation 
While TGFβ clearly regulates the amplitude of canonical signalling through 
the downregulation of AXIN2, it was possible that this downregulation 
facilitated the profibrotic activity of TGFβ. Therefore preliminary experiments 
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were performed to determine any differential profibrotic activities following 
AXIN2 depletion. 
First, the effect of AXIN2 expression on the amplitude of the TGFβ signalling 
pathway was evaluated using TGFβ-induced luciferase reporters. The p3TP-
lux reporter measured total TGFβ activity and SMAD-mediated activity was 
measured by pSBE-Luc activation. In siAXIN2 fibroblasts, total TGFβ activity 
showed no basal increase compared to SCR fibroblasts and in the presence 
of TGFβ, there was a 4.3-fold induction in siAXIN2 fibroblasts, which was 
equivalent to the 3.7-fold increase observed in SCR fibroblasts (Figure 
8.3A). Similarly, TGFβ-induced a 2.5-fold induction of SMAD-mediated 
TGFβ activity in siAXIN2 fibroblasts, which was also equivalent to the 2.7-
fold increase in TGFβ-treated SCR fibroblasts (Figure 8.3B). 
Despite this data, the profibrotic effects of TGFβ in siAXIN2 fibroblasts were 
evaluated. Consistently, α-SMA expression was unchanged at basal level in 
siAXIN2 fibroblasts compared to SCR fibroblasts (Figure 8.3C). Following 
TGFβ treatment, a significant increase in α-SMA expression was observed 
in siAXIN2 fibroblasts, although this was not significantly different to the level 
induced in SCR fibroblasts (Figure 8.3C). 
Next, myofibroblast differentiation was evaluated based on α-SMA stress 
fibril formation as quantified by the concomitant increase in the IDF. Indeed, 
no change in the IDF between siAXIN2 and SCR fibroblasts were observed 
(Figure 8.3D). Following treatment with TGFβ, a 1.8-fold increase in the IDF 
was observed in SCR fibroblasts, which was similar to the 1.7-fold increase 
in siAXIN2 fibroblasts (Figure 8.3D). As a positive control, untreated HC 
fibroblasts increased the IDF by 3.4-fold in response to TGFβ (Figure 8.3D). 
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Finally, 3D collagen gels were seeded with either siAXIN2 or SCR 
fibroblasts. Consistently, there was no significant change in collagen gel 
contraction in siAXIN2 fibroblasts, 97% of SCR fibroblasts gel area (Figure 
8.3E). TGFβ treatment induced a significant decrease in collagen gel area to 
59.0% (P<0.01) in SCR fibroblasts and a trend toward an increased 
contraction was observed in siAXIN2 fibroblasts, 51.6% (P<0.01) of SCR 
control gel area (Figure 8.3E). 
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Figure 8.3 AXIN2 does not regulate TGFβ-induced profibrotic fibroblast 
activation 
The contribution of reduced AXIN2 expression towards TGFβ signalling 
amplitude and TGFβ-mediated profibrotic activities were determined. HC 
fibroblasts were transfected with TGFβ reporters A) p3TP-Lux (Total activity) 
or B) pSBE-Luc (SMAD-mediated activity) 24 hr prior to transfection with 
AXIN2 or SCR siRNA for 72 hr. Fibroblasts were subsequently treated with 
TGFβ for a further 24 hr and TGFβ signalling activity was determined 
luciferase activity. C) As in A, where TGFβ treatment was for 72 hr and the 
protein expression of AXIN2 (+ve), fibroblast activation marker α-SMA and 
GAPDH (loading control) were determined by Western blot. D) Myofibroblast 
counts were determined by the relative integrated density of fluorescence 
(IDF) from α-SMA positive staining of fibroblasts, under the same conditions 
as in C, quantified using ImageJ. E) Relative fibroblast-mediated 3D 
collagen gel contraction was quantified according to gel surface area under 
the same condition as C. Data shown as mean ± SEM, n=3-4; Mann-
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8.4 β-catenin and SMAD3 are required for canonical Wnt 
signalling and basal α-SMA and COL1A1 expression 
Recently, in vivo fibroblast-specific β-catenin stabilisation has been shown to 
lead to fibrosis through characteristic hallmarks including dermal thickening, 
increased collagen expression and myofibroblast presence (Beyer et al. 
2012). However, in vitro canonical Wnt signalling hyperactivation in 
fibroblasts achieved using two independent models, TGFβ-priming and 
AXIN2 depletion (Figure 6.7 & Figure 7.1), have not supported these 
observations. Therefore the direct effect of modifying β-catenin activity was 
evaluated with respect to profibrotic gene expression using inhibitor studies. 
As a first measure to explore the putative activity of the β-catenin inhibitor 
FH535, canonical Wnt signalling activity was measured by AXIN2 
expression and TOPFlash activity, in the presence and absence of a β-
catenin inhibitor, FH535. Wnt-3a induced a 512.5% (P<0.05) increase in 
AXIN2 expression that was inhibited in the presence of FH535 to 146.2%, 
346.1% or 498.3% at 10.0, 3.0 and 1.0 µM, respectively (Figure 8.4A). 
Similarly, the Wnt-3a-induced 19.4-fold (P<0.01) increase in TOPFlash 
activity was inhibited to 7.0-fold, 7.5-fold or 10.6-fold at 10.0, 3.0 and 1.0 µM 
FH535, respectively (Figure 8.4B). 
Concomitantly, the FH535-mediated effects on the expression of both α-
SMA and COL1A1 were evaluated. Wnt-3a treatment induced α-SMA 
expression by 136.0% (P<0.05) and showed a dose-dependent inhibition to 
46.4%, 81.1%, and 107.9% at 10.0, 3.0 and 1.0 µM FH535, respectively 
(Figure 8.4C). Although Wnt-3a treatment did not induce COL1A1 
expression in the presence of FH535 a dose-dependent decrease in 
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expression was observed to 26.8%, 66.1%, and 89.7% at 10.0, 3.0 and 1.0 
µM, respectively (Figure 8.4D). 
In parallel, the effects exhibited by β-catenin inhibition were contrasted with 
those of SMAD3 inhibitor SIS3, which as a known regulator of fibrotic gene 
expression acted as a positive control. On evaluation of canonical Wnt 
signalling activity, Wnt-3a induced a 380.3% (P<0.05) increase in AXIN2 
expression that was inhibited to 130.0%, 306.3% or 343.3% at 5.0, 3.0 and 
1.0 µM SIS3, respectively (Figure 8.4E). Further, SIS3 also inhibited the 
17.4-fold (P<0.01) increase in Wnt-3a-induced TOPFlash activity to 1.1-fold, 
4.4-fold or 9.8-fold at 5.0, 3.0 and 1.0 µM, respectively (Figure 8.4F). 
The expression of both α-SMA and COL1A1 were concomitantly evaluated. 
Wnt-3a induced α-SMA expression by 194.3% and this was dose-
dependently inhibited in the presence of SIS3 to 28.7%, 155.3% and 192.5% 
at 5.0, 3.0 and 1.0 µM SIS3, respectively (Figure 8.4G). Wnt-3a treatment 
did not induce COL1A1 expression and while SIS3 treatment had no effect 
significant effect at 3.0 or 1.0 µM, expressed by 92.4% and 90.6%, 
respectively (Figure 8.4H), 5.0 µM SIS3 treatment lead to a 55.0% reduction 
in basal expression. 
Subsequently, the basal effects of β-catenin and SMAD3 inhibition were 
preliminarily evaluated independent of Wnt treatment. The expression of α-
SMA was significantly inhibited by 20.5% and 56.8% in the presence of 10.0 
µM FH535 and 3.0 µM of SIS3, respectively (P<0.01) (Figure 8.4I). This was 
also observed for COL1A1 expression which was inhibited by 54.5% 
(P<0.05) and 28.6% (P<0.01) at 10.0 µM FH535 and 3.0 µM of SIS3, 
respectively (Figure 8.4J). Protein expression of α-SMA also confirmed a 
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significant reduction following FH535 and SIS3 treatments (Figure 8.4K). 
Notably, the cell viability of fibroblasts co-treated with SIS3 and FH535 were 
evaluated by MTT assay under the same conditions. SIS3 showed no 
notable differences in cell viability in contrast to FH535, which showed a 
dose dependent increase across the 0.3-10.0 µM dose range (maximum of 
163.2% at 3.0 µM after 72 hr) at both 24-72 hr time points (Sup Figure 10.5). 
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Figure 8.4 β-catenin and SMAD3 are required for canonical Wnt 
signalling and basal α-SMA and COL1A1 expression 
The direct effect of inhibiting β-catenin (FH535) activity was evaluated 
against SMAD3 inhibition (SIS3) with respect to profibrotic gene expression 
and canonical Wnt signalling. HC fibroblasts were treated with FH535 (A-D) 
or SIS3 (E-H) inhibitors (0.3-10.0 µM) 1 hr prior to Wnt-3a (100 ng/ml) 
treatment for 24 hr. Canonical Wnt signalling was determined by A, E) 
AXIN2 expression, quantified by qRT-PCR or by B, F) TOPFlash reporter 
luciferase activity, transfected 24 hr prior to experimental start. Expression of 
profibrotic genes C, G) α-SMA and D, H) COL1A1, under the same 
conditions as A, were quantified by qRT-PCR. Additionally, HC fibroblasts 
were treated with FH535 (10.0 µM) and SIS3 (3.0 µM) for 24 hr and the 
basal expression of I) α-SMA and J) COL1A1 profibrotic genes were 
quantified by qRT-PCR. K) Basal protein expression of fibroblast activation 
marker α-SMA was determined following 72 hr inhibitor treatment by 
Western blot. Data shown as mean ± SEM, n=5; Mann-Whitney test for 
unpaired samples *P=0.05, **P=0.01. 
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8.5 β-catenin is required for the TGFβ-induced profibrotic 
activation of fibroblasts 
Like canonical Wnt signalling, TGFβ clearly induced the nuclear 
translocation of β-catenin and this was independent of Wnt secretion (Figure 
6.4H), it was possible that TGFβ-induced profibrotic activities might in part 
be regulated by β-catenin. Hence the consequence of β-catenin inhibition 
was evaluated upon profibrotic gene expression and ECM contractility were 
evaluated. 
HC fibroblasts were treated with TGFβ in the presence and absence of 
FH535 (0.3-10.0 µM). TGFβ-mediated the downregulation of AXIN2, 
included as a positive control, to 63.2% and in the presence of FH535, a 
dose dependent reduction was observed to 26.3%, 49.6% and 63.7% by 
10.0, 3.0 and 1.0 µM FH535, respectively (P<0.05) (Figure 8.5A). 
The expression of fibroblast activation marker α-SMA was similarly effected, 
increased by 1014.5% following TGFβ and reduced to 36.8%, 586.4% and 
926.6% in the presence of 10.0, 3.0 and 1.0 µM FH535, respectively 
(P<0.05) (Figure 8.5B). This was also observed for COL1A1 expression, 
which was induced by 371.9% following TGFβ and inhibited in the presence 
of FH535 to 85.7%, 256.7% and 291.0% at 10.0, 3.0 and 1.0 µM, 
respectively (P<0.05) (Figure 8.5C). 
In turn, this was confirmed by α-SMA protein expression, where the TGFβ-
mediated increase in expression was dose dependently decreased by 
FH535 across the dose series (Figure 8.5D). 
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Finally, the effect on fibroblast-mediated 3D collagen gel contraction was 
evaluated using 10.0 µM FH535, which showed the greatest effect on α-
SMA expression (Figure 8.5D). 
In the presence of FH535, contractile force was reduced and gel area was 
increased to 112.1% compared to basal controls (Figure 8.5E). TGFβ 
treatment induced gel contraction and reduced the gel area to 67.4% of 
controls. In contrast, this was partially prevented by co-treatment with 
FH535, where the gel area was reduced to only 88.5% (Figure 8.5E). 
Additionally, under the same conditions, FH535 mediated a dose-dependent 
increase in fibroblasts cell viability across the dose range of 0.3-10.0 µM 
(maximum of 215.4% at 3.0 µM following 72 hr) at both 24 hr and 72 hr time 
points (Sup Figure 10.4). 
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Figure 8.5 β-catenin is required for the TGFβ-induced profibrotic 
activation of fibroblasts 
To determine the function of of β-catenin in TGFβ-induced profibrotic 
activities, FH535-mediated of β-catenin inhibiton (FH535) was employed. HC 
fibroblasts were treated with the FH535 inhibitor (1.0, 3.0 and 10.0 µM) for 1 
hr prior to 24 hr TGFβ treatment and A) AXIN2 (+ve) expression, a canonical 
Wnt target, and B) α-SMA and C) COL1A1 profibrotic gene expression were 
determined by qRT-PCR. D) As in A, but following 72hr TGFβ treatment, the 
expression of fibroblast activation marker α-SMA and GAPDH (loading 
control) were determined by Western blot. E) Relative fibroblast-mediated 
3D collagen gel contraction was quantified according to gel surface area 
under the same condition as in D. Data shown as mean ± SEM, n=3-4; 
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8.6 β-catenin negatively regulates the profibrotic activation 
of fibroblasts 
Complementary to inhibitor studies, the function of β-catenin in regulating 
TGFβ-mediated profibrotic activity was subsequently evaluated by siRNA-
mediated β-catenin depletion in HC fibroblasts. 
β-catenin silenced fibroblasts (siβcat) showed a profound reduction in 
expression of β-catenin at 48 hr and this was decreased further by 72 hr 
compared to SCR fibroblasts (Figure 8.6A). This repression was 
reproducible and persisted for a minimum of 144 hr (Figure 8.6B). 
TGFβ treatment significantly increased the depleted levels of β-catenin 
present in siβcat fibroblasts equivalent to the basal levels present in SCR 
fibroblasts, while not affecting SCR fibroblasts levels (Figure 8.6B). TGFβ 
treatment also induced a profound increase in the expression of fibroblast 
activation marker α-SMA in siβcat fibroblasts, which was greater than that 
observed in SCR fibroblasts (Figure 8.6B). 
To confirm these data, 3D collagen gels were seeded with either siβcat or 
SCR fibroblasts. In resting siβcat fibroblasts, collagen gels showed evidence 
of gel contraction, reduced by 14.6% (P<0.05) compared to SCR fibroblast 
seeded gels (Figure 8.6C). Following TGFβ treatment, a significant increase 
in collagen gel contraction was observed in siβcat fibroblasts, which reduced 
gel area by 72.5% (P<0.05) in contrast to the 46.8% (P<0.01) reduction in 
SCR fibroblasts, compared untreated SCR controls (Figure 8.6C). 
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Figure 8.6 β-catenin negatively regulates the profibrotic activation of 
fibroblasts 
β-catenin expression was evaluated in the regulation of TGFβ-mediated 
profibrotic activity by siRNA-mediated gene silencing. HC fibroblasts were 
transfected with β-catenin siRNA (siβcat) or SCR oligonucleotide. A) β-
catenin and GAPDH (loading control) expression were determined by 
Western blot 48 and 72 hr post-transfection. B) At 72 hr post-transfection, 
fibroblasts were treated with TGFβ (5 ng/ml) for 72 hr and the expression of 
β-catenin (+ve), profibrotic marker α-SMA and GAPDH (loading control) 
were determined by Western blot. C) Relative fibroblast-mediated 3D 
collagen gel contraction was quantified according to gel surface area under 
the same condition as in B. Data shown as mean ± SEM, n=3-4; Mann-
Whitney test for unpaired samples *P=0.05, **P=0.01. 
 
 
8.7 DISCUSSION: The consequence of canonical Wnt 
signalling hyperactivation upon profibrotic activation of 
fibroblasts 
Extensive fibrosis can lead to the destruction of the tissue architecture and 
ultimately can lead the loss of organ function. While therapies that target 
immunological, vascular and fibrotic processes are required for the effective 
treatment of SSc, the development of novel anti-fibrotic treatments may be 
considered a priority given the morbidity and high risk of mortality associated 
with fibrosis. Although clinical trials are on-going, there are currently no 
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treatments available that can lead to the remission of fibrosis (Ong & 
Denton, 2010). Analogous to activation of the TGFβ pathway in fibroblasts, 
activation of the canonical Wnt/β-catenin signalling pathway has also been 
linked pathogenesis of tissue fibrosis (Wei et al., 2011; Beyer et al., 2012; 
Akhmetshina et al., 2012). Crosstalk between these two pathways is though 
to be significant and recently the TGFβ-mediated downregulation of DKK-1, 
a Wnt signalling antagonist, lead to a supposed canonical Wnt signalling-
mediated experimental fibrosis (Akhmetshina et al., 2012). 
Thus far, this study has elucidated a mechanism whereby canonical Wnt 
signalling can become hyperactivated in dermal fibroblasts through the 
TGFβ-mediated downregulation of AXIN2, a critical component of the 
canonical Wnt signalling pathway. However, in contrast to previous studies, 
canonical Wnt signalling hyperactivation in HC fibroblasts, mediated by 
TGFβ-priming, showed no evidence of increased fibrotic activity beyond that 
of TGFβ (Figure 8.1A-D). These data support the conventional consensus 
that TGFβ is a potent mediator of fibrotic activity, increasing profibrotic gene 
expression and facilitating a fibroblast-mediated increase in 3D collagen gel 
contractile force generation (Figure 8.1A-D) (Desmoulière et al. 1993; 
Gabbiani 2003; Ho et al. 2014). 
 
Using a complementary approach, hyperactivation of canonical Wnt 
signalling was achieved siRNA-mediated AXIN2 depletion in HC fibroblasts 
(Figure 8.2A, D). Overall, the data from the AXIN2 depletion model are 
equivalent to those derived form the TGFβ-primed model of canonical Wnt 
signalling hyperactivation, showing no increase in profibrotic gene 
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expression, myofibroblast presence or fibroblast-mediated 3D collagen gel 
contractile force generation (Figure 8.2A-F). While there was a trend towards 
a reduced myofibroblasts presence in AXIN2 silenced fibroblasts, it was not 
considered representative of the phenotype due to the lack of any effect 
upon α-SMA (mRNA/protein) expression or 3D collagen gels contractile 
force generation (Figure 8.2D-F). 
These data provide additional evidence for the absence of canonical Wnt-
induced fibrotic activity. This work extends upon the TGFβ-mediated and 
AXIN2 depletion models of canonical Wnt signalling hyperactivation, and 
increases the confidence that canonical Wnt signalling does not induce a 
fundamental increase in dermal fibroblast fibrotic activity. 
These independent methods of investigation are in agreement with a 
comprehensive study in pulmonary fibroblasts, which indicated that 
adenoviral overexpression of Wnt-3a or β-catenin was not sufficient to 
activate markers of fibroblast activation, including COL1A1, α-SMA, CTGF 
and TGFβ, and did not increase fibroblast-mediated 3D collagen gel 
contractile force (Lam et al. 2011). Instead canonical hyperactivation 
convincingly increased proliferation demonstrated by bromodeoxyuridine 
incorporation into newly synthesised DNA (Lam et al. 2011). Furthermore, 
an earlier study also found that β-catenin overexpression had a minimal 
effect on 3D collagen gel contraction, instead having a more profound effect 
on fibroblast motility (Poon et al. 2009). Evidently, studies on proliferation 
and migratory potential would be of significant interest for the completion of 
this study. 
Of interest, and secondary to the aforementioned hypothesis, was the 
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observation that AXIN2 depletion, by gene silencing or by TGFβ-priming, 
could be restored following canonical Wnt agonist treatment, which was also 
observed in the TGFβ-primed model of canonical signalling hyperactivation 
(Figure 8.2D Vs. Figure 6.4F). This indicated that the increased canonical 
Wnt signalling response in fibroblasts, as a result of AXIN2 depletion, could 
be a transient effect. A possible conclusion could be that where there is a 
high concentration of Wnt agonists an initial increase in canonical Wnt 
signalling might have a pronounced downstream consequence but, over 
time, the system compensates through the increased expression AXIN2. It is 
possible that temporal peaks in the concentrations of TGFβ and canonical 
agonists, regulated by the ECM, which might have important implications for 
fibroblast phenotype. 
 
In addition to the function of AXIN2 in the regulation of canonical Wnt 
signalling, previous studies have suggested that AXIN expression could act 
to enhance TGFβ signalling activity. Of note, in HEK293 cells AXIN 
expression has been described to promote TGFβ signalling activation by 
forming a complex with SMAD7 and Arkadia; a ubiquitin E3 ligase, which 
leads to the ubiquitin-mediated proteosomal degradation of the inhibitory 
SMAD7 protein (Wei et al. 2006). In an alternative model, AXIN expression 
in COS7 cells was found to be inhibitory, forming an inactivating complex 
with SMAD3 that was only abolished upon TβRI activation (Furuhashi et al. 
2001). Therefore the role of AXIN2 in regulating TGFβ signalling is uncertain 
and was evaluated using both SMAD- and non-SMAD-dependent TGFβ 
reporter constructs. 
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In conflict with both of the described models, TGFβ signalling potential was 
not modified by AXIN2 silencing in HC fibroblasts, consistent with this 
observation was the absence of a significant effect upon α-SMA expression, 
myofibroblasts presence or fibroblast-mediated 3D collagen gel contractile 
force generation (Figure 8.3A-E). These data indicate that AXIN2 does not 
regulate TGFβ signalling or its concomitant profibrotic activities, but instead 
is primarily involved in the regulation of canonical Wnt signalling pathway in 
dermal fibroblasts. 
One consequence of reduced AXIN2 expression would be suboptimal 
destruction complex assembly that results in a reduced ability to negatively 
regulate β-catenin-mediated activity. As well as nuclear β-catenin staining in 
SSc dermal tissue, in vivo, the stabilisation of β-catenin has been shown to 
lead to fibrosis including dermal thickening, increased collagen expression 
and myofibroblast count (Wei et al., 2011; Akhmetshina et al., 2012; Beyer 
et al., 2012). In this study, two independent models of canonical (β-catenin-
mediated) Wnt signalling hyperactivation, achieved by AXIN2 
downregulation/depletion, are not in agreement with these studies (Figure 
8.1 & Figure 8.2). Hence, the direct effect of β-catenin inhibition upon 
profibrotic gene expression and canonical Wnt signalling activity were 
initially determined using in FH535 (β-catenin) inhibitor experiments. 
As expected, FH535 co-treatment inhibited the Wnt-3a-induced induction of 
canonical Wnt signalling and therefore initially validated the activity of the 
inhibitor (Figure 8.4A-D). Although Wnt-3a did not induce COL1A1 or α-SMA 
profibrotic gene expression, FH535-mediated β-catenin inhibition reduced 
the expression of profibrotic genes below control levels thereby 
- 229 - 
demonstrating the potential requirement of β-catenin for the basal 
expression of both genes (Figure 8.4C, D). 
Included as a positive control, SMAD3 inhibition produced highly similar 
results to those produced by β-catenin inhibition, namely the negative 
regulation of the Wnt-3a-induced canonical signalling activity and a 
coinciding reduction in basal profibrotic gene expression (Figure 8.4E-H). 
The effect of SMAD3 inhibition on canonical Wnt signalling was supported 
by previous data, which demonstrated the requirement of SMAD3 for the 
efficient activation of the canonical Wnt signalling pathway (Figure 7.5E, F). 
Independent of canonical Wnt signalling, both β-catenin and SMAD3 
inhibitors consistently reduced the basal expression of α-SMA and COL1A1 
expression, further supporting the requirement for both SMAD3 and β-
catenin in the regulation of their basal expression (Figure 8.4I-K). 
Due to these similarities, it is possible that SMAD3 and β-catenin might 
function as part of a co-dependent mechanism where the affecting the 
activity of one will reciprocally affect the other. Suggestively, AXIN2 contains 
both SMAD3 and β-catenin binding domains and could potentially be an 
intersecting regulator of such a mechanism (Chia & Costantini 2005). 
Overall, these augment the view of canonical Wnt signalling activation and 
extend upon crosstalk between the TGFβ and canonical Wnt signalling 
pathways, in this instance intersecting through SMAD3. 
 
In addition to SMAD3 crosstalk with the TGFβ pathway, β-catenin was also 
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implicated in the regulation of the TGFβ signalling pathway. TGFβ signalling, 
like canonical Wnt signalling, induced the Wnt-independent nuclear 
translocation of β-catenin, despite hyperactivation of canonical (β-catenin) 
Wnt signalling not playing an important role in profibrotic activation thus far 
(Figure 6.4H). Therefore, the consequences of FH535-mediated β-catenin 
inhibition upon TGFβ-induced profibrotic activities were subsequently 
determined. 
Following FH535-mediated inhibition of β-catenin, TGFβ-induced profibrotic 
gene expression was dose-dependently inhibited and, in addition, a 
reduction in TGFβ-induced 3D collagen gel contractile force generation was 
also evident (Figure 8.5B-E). Indeed, independent FH535 inhibitor treatment 
also reduced the normal contractile force generated in 3D collagen gels 
containing resting HC fibroblasts (Figure 8.5E). These data would support 
the opinion of other studies that β-catenin is central to TGFβ-mediated 
profibrotic activity in fibroblasts (Akhmetshina et al., 2012; Beyer et al., 2012; 
Wei et al., 2012). However, those effects assumed to be mediated by β-
catenin inhibition, might act in tandem or as a direct result of inhibition of the 
PPAR pathway, a known alternative target of this inhibitor, which can 
similarly regulate TGFβ-responsive profibrotic gene targets (Handeli & 
Simon, 2008). 
 
To confirm the potential involvement of β-catenin in the regulation of TGFβ-
mediated profibrotic activity, further experiments were carried out in HC 
fibroblasts transfected with β-catenin siRNA (siβcat). In contrast to those 
obtained using the FH535-mediated inhibition, depletion of β-catenin 
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expression increased the TGFβ-induced expression of α-SMA as well as 3D 
collagen gel contractile force generation (Figure 8.6A-C). These data 
indicated that β-catenin can act as a negative regulator of the TGFβ 
signalling pathway, which conflicts with previous reports that have used β-
catenin blockade to inhibit experimental fibrosis (Henderson et al. 2010; Kim 
et al. 2011; Beyer et al. 2012). Instead these data could be used to indirectly 
support other studies, which have demonstrated, in contrast to fibrotic 
activity, an important function in proliferation and/or cell motility (Poon et al., 
2009; Lam et al. 2011). However, TGFβ acted to mediate the nuclear 
translocation of β-catenin despite the absence of β-catenin-mediated 
TOPFlash canonical Wnt signalling reporter activation (Figure 6.2C, D). One 
hypothesis could be that TGFβ-mediated β-catenin nuclear translocation is 
independent of canonical Wnt signalling, which is supported by a recent 
study that identified a β-catenin-dependent YAP1 and the TBX5 transcription 
factor complex that was important for the cell survival through the 
upregulation of antiapoptotic genes (Rosenbluh et al. 2012). 
Overall, as two independent models of canonical Wnt signalling 
hyperactivation were unable to significantly influence fibrotic activity in 
dermal fibroblasts it is likely that this is not the primary consequence. 
Evidently, evaluation of canonical Wnt signalling hyperactivation on 
proliferation, migration and cell survival of dermal fibroblasts would be of 
significant interest for the completion of this study. 
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9 Conclusion 
In SSc, activation of the Wnt/β-catenin signalling pathway, like TGFβ 
signalling, has been linked to the fibroblast-mediated pathogenesis of tissue 
fibrosis and the crosstalk between these pathways is considered to be 
significant. Extending upon this, explanted SSc fibroblasts displayed a clear 
and consistent differential increase in canonical Wnt signalling response 
compared to HCs, and also displayed a concomitant decrease in the basal 
expression of AXIN2, a critical regulator of this pathway. Suggestively, the 
mean concentration of SFRP4, a putative Wnt antagonist that is increased in 
SSc tissues, was higher in those patients positive for the Scl-70 
autoantibody, which is associated with the fibrotic diffuse-variant of SSc. 
Indeed, the increased SFRP4 expression observed could be attributable to 
the fibroblast lineage and its overexpression indicative of either TGFβ or Wnt 
signalling activation. Given that SFRP4 can potentially function as a Wnt 
antagonist, it could conceivably be involved in fibrosis through the regulation 
of the Wnt pathways; however, full-length recombinant SFRP4 protein did 
not have a measurable effect on Wnt- or even TGFβ-induced pathways. 
Likewise, expression of CAV-1, a TGFβ-regulated component of the 
caveolae endocytotic pathway, which can regulate cell surface receptor 
expression and is known to be downregulated in a subset of SSc fibroblasts, 
had no evident utility in profibrotic gene expression or canonical Wnt 
signalling activity characteristic of SSc fibroblasts in this study. 
Notably, this study identifies a new mechanism by which TGFβ mediates the 
increased canonical Wnt signalling response of fibroblasts to canonical Wnt 
activation without inducing a direct stimulatory effect. Specifically, TGFβ 
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mediated the downregulation of AXIN2, a critical component of the β-catenin 
destruction complex, which was sufficient to confer an increased canonical 
Wnt signalling amplitude equivalent to that observed in SSc fibroblasts. 
Primarily, this was due to the TGFβ-mediated increase in the rate of AXIN2 
mRNA decay, potentially regulated at its 3’UTR by ARE-binding proteins. 
Therefore the increased activation of canonical Wnt signalling observed in 
SSc skin-resident fibroblasts goes beyond the differential expression of 
secreted Wnt factors and indicates the importance of TGFβ crosstalk in 
relation to the intracellular expression of AXIN2. Additionally, SMAD3, a 
known mediator of TGFβ signalling was required for the efficient activation of 
canonical Wnt signalling but was independent of this mechanism. This 
suggests that the increased canonical Wnt/β-catenin signalling observed 
during fibrosis is a consequence of a TGFβ-primed environment and 
therefore the development of TGFβ-targeted therapies could potentially 
resolve the aberrant Wnt/β-catenin signalling observed during fibrosis. 
Indeed, therapies that target immunological, vascular and fibrotic processes 
are required for the effective treatment of SSc, although the development of 
novel anti-fibrotic treatments may be considered a priority given the high risk 
of mortality associated with fibrosis through internal organ involvement. 
However, this study provides evidence that the fundamental consequence of 
canonical Wnt signalling hyperactivation in dermal fibroblasts is independent 
of profibrotic activation in two independent models. Therefore further 
evaluation of processes associated with fibrosis, including proliferation, 
migration and cell survival, might resolve the anti-fibrotic outcomes observed 
for therapeutics targeting the Wnt/β-catenin pathway in models of 
experimental fibrosis. 
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10 Appendix 
 
Sup Figure 10.1 siRNA delivery into HC fibroblasts (24 hr) 
The AlexaFlour-488 containing oligonucleotide was transfected into HC 
fibroblasts across at concentrations of 10nM, 20nM and 40nM in the 
presence and absence of serum. The fluorescent intensity showed a step-
wise increase in concentration, which therefore indicated that siRNA 
transfection across this range could be employed. 
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Sup Figure 10.2. Plasmid DNA delivery into HC fibroblasts (24 hr) 
Transfection of the IRES-GFP plasmid was used to visualise transfection 
efficiency at 24 hr post-transfection. Transfection efficiency of HC fibroblasts 
was determined across with differential combinations of DNA:transfection 
reagent complexes. At a ratio of 1:1 and 1:2 showed poor transfection 
efficiency, while efficiency was significantly increased at ratio of 2:1 and 2:2 
and at 3:1 and 3:2, which then decreased at higher ratios of 4:1 and 4:2. 
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Sup Figure 10.3. Plasmid DNA delivery into HC fibroblasts (48 hr) 
48 hr post-transfection of HC fibroblasts with IRES-GFP plasmid. 
Transfection efficiency was determined across the differential combinations 
of DNA:transfection reagent complexes. Similar to visualisation at 24 hr, 
ratios of 1:1 and 1:2 showed poor transfection efficiency, while efficiency 
was significantly increased at ratio of 2:1 and 2:2 and at 3:1 and 3:2, which 
then decreased at higher ratios of 4:1 and 4:2. 
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Sup Figure 10.4. MTT fibroblast viability data for small-molecule 
inhibitors in the presence and absence of TGFβ 
HC fibroblasts were treated with TGFβ in the presence or absence of small 
molecule inhibitors A) FH-535 B) SIS3 and C) XAV-939 at 24 and 72 hr, 
respectively. MTT cell viability was quantified to determine adverse effects 
on fibroblast metabolic activity/proliferative potential. 
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Sup Figure 10.5. MTT fibroblast viability data for small-molecule 
inhibitors in the presence and absence of Wnt-3a 
HC fibroblasts were treated with Wnt-3a in the presence or absence of small 
molecule inhibitors A) FH-535 B) SIS3 and C) XAV-939 at 24 and 72 hr, 
respectively. MTT cell viability was quantified to determine adverse effects 
on fibroblast metabolic activity/proliferative potential. 
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